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Abstract 
Northern Pakistan, Khyber Pakhtunkhwa (KP) is low malaria endemic area 
characterised by seasonal transmission with predominantly vivax malaria. Migration of 
high number of Afghan Refugees in 1978 into KP led to concerns for an increase in 
malaria, as the malaria incidence in this group was reportedly high compared to the 
local Pakistani population. Considerable progress has been made in controlling malaria 
through operational research in the camps where the Afghan refugees reside. 
However, this process requires effective, repeatable active surveillance tools for 
monitoring malaria control as availability of accurate data is the major challenge at 
present. 
The aim of this PhD project was to generate current information on malaria infection 
rates through parasite prevalence and malaria exposure using antimalarial antibody 
responses.The project also investigated the risk factors of malaria and heterogeneity in 
the geographic distribution of malaria in the camps by using GIS data with serological 
responses and parasite prevalence data. As an ancillary objective the project aimed to 
determine the prevalence of G6PO deficiency in the study population. 
A cross-sectional survey was conducted in five Afghan refugee camps of KP between 
June and September in 2010. Blood samples were obtained on filter paper from 2526 
individuals and tested by rapid diagnostic test, paraSite species specific PCR and ElISA 
for antibody responses to Plasmodium vivax and Plasmodium falciparum. A 
questionnaire was administered to collect household and individual based information 
to determine the potential risk factors of malaria. 
Heterogeneity in malaria was observed between the studied camps based on 
seroprevalence, which ranged from 17%-45% for P. vivax and 3% to 11% for P. 
!alciparum. Variation in P. vivax infection prevalence was also detected between the 
camps, which ranged from 0.4-9% (ROT) and 5-15% (peR). Variation in the distribution 
of malaria was also found within the camp using spatial/GIS data with clear foci of 
infection identified in 4 of 5 camps. The results showed that as expected parasite 
based prevalence measures (ROT and peR) are significantly lower than serological 
measure of exposure. P. !alciparuminfection prevalence (ROT and PCR) and 
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seroprevalence was found to be extremely low with P. vivaxinfections predominant. 
Age seroprevalence changes were more pronounced for P. vivax than P. falciparum 
and seroconversion rate was strongly associated with parasite rate. 
Increasing age .and poorly built houses were associated with increasing risk, while 
staying in the same camp for the last 6 months and using measures to reducing vector 
biting such as repellents repellent, coils or insecticide spraying were associated with 
reduce risk of falciparum malaria. The risk of vivax malaria was observed to increase 
with increasing age, sharing house with cattle and having fever within 24 hours or two 
weeks and a reduction in the risk was seen in the individuals who reported use of 
Insecticide treated Bed Nets (ITN) night prior to surveyor used self protection 
measures from vector. The 563C-T polymorphism of G6PD gene was observed in only 2 
unrelated individuals out of 505 individuals tested (O.4%). In conclusion, both 
parasitological and serological measures were able to detect spatial variation in 
infection and exposure to malaria at the micro epidemiological level within the camp. 
This data will help to provide beneficial and up-to-date information to manage control 
activities in the study area. 
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Chapter 1. Introduc on 
1.1. Malaria 
Malaria is caused by protozoan parasites of the species Plasmodium, four main species 
can cause humans infection: P. falciparum,P. vivax, P.malariae and P. ovale. However, 
recently an additional simian species, P. knowlesi, has been shown to cause malaria in 
humans transmitted from primate species, which represents the only known animal 
reservoir of zoonotic human malaria (Singh et al., 2004).Mosquitoes of the Anopheles 
species are the natural vectors of malaria and 70 of 422 Anopheles species are known 
to transmit the parasite (Day et al., 1999). Malarial parasites can also be transmitted 
trans-placentally (Singh et al., 2003, Fischer, 2003, Valecha et al., 2007)and by 
innocultion of infected blood, as demonstrated by recorded cases of transfusion-
transmitted malaria (George, 1911, Mackintosh et al., 2004). 
Malaria is an ancient disease, which has persisted in mankind probably since humans 
existed. A French physician Charles Louis Alphonse Laveran first discovered malarial 
parasites in the blood of patients by microscopy in 1880. In 1899, Ronald Ross 
discovered that human malarial parasites were transmitted by anopheline mosquitoes 
(Cox, 2010). 
1.1.1. Life cycle 
The malaria parasite has a complex, multistage life cycle occurring within the vector 
mosquitoes and the vertebrate hosts. In the lifecycle of malaria parasite (Figure 1.1) 
humans are infected when bitten by a female infectious Anopheles mosquito, which 
injects a mean of about 15 haploid sporozoites (Rosenberg et al., 1990). It is the first 
encounter of the immune system with plasmodium but sporozoites are often injected 
in small numbers and remain in the blood stream for a short period. Hence sporozoites 
are considered less immunogenic (effective immunity to this stage is less evident) and 
do not cause disease symptoms in either immune or non-immune persons (Struik and 
Riley, 2004). Over 5-16 days (the exact time-frame depends on the malarial parasite 
species) the sporozoites replicate in the liver and are then released as merozoites 
capable of invading red blood cells (White, 2004). Red blood cells lack MHC receptors 
allowing the malarial parasite to evade the immune system in the absence of antigen-
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presenting MHC molecules. These asexual forms of the parasite in red blood cells 
undergo further reproduction in 1-3 days (depends on the species), releasing more 
merozoites as the red blood cell ruptures (Leggat, 2003). This is the stage of infection 
which leads to most symptoms of malaria (Dietz et al., 1974, Kitchen, 1949) and 
becomes detectable in blood by microscopy approximately 7-13 days after sporozoite 
inoculation (Eyles and Young, 1951). Some merozoites develop into male or female 
gametocytes, which mature while initially sequestered deep in the vasculature (P. 
!alciparum) and therefore are not detected in the blood samples. They first become 
visible on blood slides in a mature infectious form 11-19 days after the appearance of 
the asexual blood-stage parasites (Nedelman, 1989). Gametocytes may be taken up in 
a mosquito's blood meal, transmission requiring at least one male and one female 
gametocyte. In the mosquito gut, the infected human erythrocyte ruptures, freeing the 
gametocytes, which develop into mature male and female gametes that fuse to form 
diploid zygotes. The zygote further develops into motile ookinetes that penetrate into 
the mosquito stomach wall to form oocysts. These oocytes undergo meiosis, producing 
the haploidsporozoites which migrate to the salivary glands and the mosquito 
becomes infectious (Leggat, 2003). In P. vivax and P. ovale a dormant stage 
(hypnozoites) can persist in the liver and cause relapse by invading the bloodstream 
weeks or even years later (CDC, 2010). 
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1.2. Immune response to malaria 
Immunity to malaria is very complex (langhorne et al., 2008, Augustine et al., 2009), 
due to several antigenica"y diverse life cycle stages of malarial parasite (Greenwood et 
al., 2008). The malaria parasite (P. !alciparum), has more than 5,300 genes that express 
some 5,268 predicted proteins, about 2/3 (60%) are suggested to be unique to 
Plasmodium (different to proteins in other organisms) (Gardner et al., 2002, Gardner 
et al., 1998, Bowman et al., 1999). These specialized proteins are thought to help in 
the invasion and growth of parasite within multiple cell types of the invertebrate and 
vertebrate hosts and to evade host immune responses, and observed to be kept 
changing often (Florens et al., 2002, Greenwood et al., 2008). Immunity to malaria is 
widely perceived as transitory such that natural infection with malarial parasites leads 
to only a partial and short lived immunity such that individuals are not protected 
against new infections and prone to repeated malaria infections (Struik and Riley, 
2004). 
In African malaria endemic areas, children (especia"y non-exposed) are particularly 
vulnerable and are at high risk of dying from severe malaria (Crawley et al., 2010). In 
cases of severe pathology it has been observed that protective immunity 
quicklydevelopsand does not require boosting by re-infection (Struik and Riley, 2004). 
However, previously exposed individuals to malaria may still be susceptible to 
uncomplicated malaria (Augustine et 'al., 2009) until immune effector mechanisms 
become adept at controlling parasite growth usually after repeated exposure to 
infections (Struik and Riley, 2004). Asymptomatic infections are thought to persist 
throughout life even with repeated infections in cases when protective immunity to 
malaria is incomplete (Wipasa et al., 2010) although the parasite load is lower 
compared to freshly infected individuals (Struik and Riley, 2004, Oke" et al., 2012). 
A successful immune response against malaria require a number of inoculations a 
person receives or exposures to parasite and some intervals between these exposures 
(Struik and Riley, 2004). In general, acquisition of active immunity to malaria is slow 
and compounded by age, nutritional/health status and genetics of host. Both innate 
and adaptive immune responses as we" as environmental factors are believed to 
regulate host immune responses against malaria (Crawley et al., 2010). 
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1.2.1. Protec ve immunity against malaria 
Division of protec ve immunity against malaria on the basis of epidemiology: 
• Clinical immunity (A): Immunity to protect against severe malaria and to reduce 
malaria death risk in case of P. ja/ciparum (non-cerebral) acute attacks, can be 
obtained after one or two infections (Gupta et al., 1999) 
• Clinical immunity (B): An immune response to reduce the intenSity of clinical 
symptoms which requires frequent inoculations of malarial parasite (Trape and Rogier, 
1996, Carter and Mendis, 2002) 
• Antiparasitic immunity helps to clear parasite from an infected individual: is 
effective after many and frequent malaria infections (Struik and Riley, 2004). 
The immune system must be able to deal with each parasite species but also parasite 
strain each time an individual exposed (Jeffery, 1966, Mendis et al., 1991, Cheesman et 
al., 2010). In endemic areas, children born to immune mothers are protected against 
disease during their first half year of life by maternal antibodies and fetal hemoglobin 
(Amaratunga et al., 2011, Carter and Mendis, 2002). This innate passive immunity is 
followed by 1 or 2 years of increased susceptibility before acquisition of active 
immunity (Struik and Riley, 2004). It has been observed that people who lived in 
endemic areas previously and acquired immunity to malaria by repeated exposure are 
still vulnerable to uncomplicated malaria but resistant to severe malaria if they inhabit 
a non-endemic area from months or years (Struik and Riley, 2004). This finding 
suggests that protective immunity against uncomplicated malaria is short lived as 
compared tosevere malaria. 
In naturally acquired protective immunity against blood stage malaria antibodies play 
an essential part. They protect uninfected RBCs from entry of meroloites, block 
infected RBC cytoadherence to endothelial cells and increase phagocytosis by 
monocytes and macrophages (Beeson et al., 2008, Wipasa et al., 2002). However, it is 
commonly perceived that in the absence of reinfection antimalarial antibodies are 
short-lived whereby to maintain acquired immunity periodic reinfection is required 
(langhorne et al., 2008). One hypothesis is that B cell memory to malaria is defective 
or suboptimal (Struik and Riley, 2004). A study conducted in Thailand to investigate the 
induction and maintenance of B cell memory responses to malarial infection has 
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shown otherwise and demonstrated that B cell responses can be sustained for many 
years after infection (Wipasa et al., 2010). Another study found 50% antibody positive 
individuals against malaria in a cohort of Pakistanis and Indians in Bradford who could 
only have acquired antibodies 10-15 years previously, which indicates that antibody 
must have been synthesized from B cells, as IgG only lasts approximately one month in 
the serum following infection (Bruce-Chwatt et al., 1972). Antibodies to gametocytes 
(sexual blood stages of the parasite, infective to red blood cells and mosquitoes) are 
not correlated to protection from the disease and they decline with age. 
1.2.1.1. Malarial parasite life cycle stages and an body responses 
The immune system produces antibodies against each stage of the malarial parasite 
however the level of antibodies depends largely on the antigen load and the duration 
for which the immune system remains exposed to the antigen (Cook, 2010). Antibody 
responses against asexual pre-erythrocyte and asexual blood stage antigens 
accumulate with age (Smith et al., 1998, Rogier and Trape, 1993, Drakeley et al., 2006), 
whilst antibodies to gametocyte antigens studied to date do not show this pattern 
(Drakeley et al., 2006, Graves et al., 1988). 
Pre-erythrocyte and sexual stages of the malarial parasite are thought to be less 
immunogenic and effective immunity to these stages is less evident (Struik and Riley, 
2004). Immunity to non-pathogenic sporozoites inoculated by mosquito into human 
develops after a long exposure to intense malaria transmission. Anti-gametocytic 
antibodies readily develop with course of natural infection and have some impact on 
the transmission dynamics of the disease in certain endemic situations (Drakeley et al., 
2006, Graves et al., 1988). 
Generally, antibodies to asexual blood stage antigens are considered to be the most 
abundant antimalarial-antibodies due to large numbers of merozoites and continued 
exposure to antigens (Drakeley et al., 2006). An immuno-epidemiological study has 
shown a high seroprevalence against many blood stage antigens (e;g AMA-l or MSP2) 
as compared to pre-erythrocytic (lSA-l, CSP) and to sexual stage gametocyte (Pfs48/45 
and Pfs230) (Bousema et al., 2010b). In seroepidemiological studies the presence of 
antibodies, which represent exposure to malaria, is more important than the 
antibodies function in protecting against malaria. 
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Table 1.1 Level of protec ve immunity in di erent age group and endemicity 
Types of Protective immunity Geographicallocation(s) 
Malariatransmission And Age 
Stable • High in older age groups • Sub-Saharan Africa 
• Low in children under 5 
Unstable • Unreliable in older age • Europe and 
groups Mediterra nean 
• Absent in children under 5 • Asia and Western Pacific 
• North, Central &South 
America 
• Caribbean 
Epidemic • Low or absent in all age • Tropical Africa Highland 
groups • Central Asia 
• Caucuses Asia 
• Latin America 
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1.2.2. Pathogenesis 
Clinical malaria is characterized by nonspecific symptoms such as fever, headache, 
muscle pain, anorexia, nausea, weakness, cough, diarrhoea, abdominal pain, 
splenomegaly, hepatomegaly, heamolytic anaemia and less commonly respiratory 
distress. Except for severe anemia, complications such as cerebral malaria, 
hypoglycemia, metabolic acidosis, renal failure, and respiratory distress followed by 
coma and death are more common in severe P. jalciparuminfections than infections 
with other species of malaria(Anstey et al., 2009, Chen et al., 2000, Miller et al., 2002). 
However, infections with other species of malaria occasionally result in severe clinical 
symptoms similar to Plasmodium jalciparumspecies (Beg et al., 2002), as there are 
reported many cases of uncomplicated malaria than fatal cases. Although P. vivax 
infections usually cause similar symptoms to the other types of malaria mentioned 
above, they uniquely cause severe rigors (Crawley et al., 2010). 
Falciparum malaria can be severe in residents of all ages of areas with low or no 
malaria transmission (who have no immunity to malaria). In case of high transmission, 
severe malaria is mre common in young children (Snow et al., 1999, Snow and Marsh, 
2002) and pregnant women (Duffy and Fried, 1999, Cot and Deloron, 2003) (whose 
immunity is decreased by pregnancy, especially during the first and second trimester). 
Immunosuppressed individuals are at high risk of severe malaria (Grimwade et al., 
2004, Grimwade et al., 2003), for example HIV infection in pregnant women was 
observed to increase the risk of maternal death, miscarriage, stillbirth and neonatal 
death (Ticconi et al., 2003). 
Other Plasmodium species especially P. vivax (suggested to cause significant 
morbidity) are generally considered to be relatively benign and rarely life threatening 
compared to P. jalciparum (Kitchen, 1949). This view of malariologists remained over 
several decades but recently life-threatening illness with diagnosis of vivax malaria has 
been observed in endemic settings (Kochar et al., 2005, Anstey et al., 2009). For 
example, cases of severe P. vivax malaria have recently been reported among 
populations living in (sub) tropical countries including; Brazil (Lanca et al., 2012, 
Andrade et al., 2010), India (Kochar et al., 2010b, Kochar et al., 2010a), Indonesia 
(Barcus et al., 2007, Tjitra et al., 2008) and Pakistan (Shaikh et al., 2012). 
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1.2.2.1. Pathogenesis of Severe Malaria 
Several pathophysiological factors including parasite toxic factors such as 
glycosylphosphatidylinositol (GPI), cytoadherence, rosetting and sequestration, altered 
deformability and fragility of parasitized erythrocytes, endothelial activation and 
altered thrombostasis have been found to be involved in the development of severe 
malaria (Anstey et al., 2009, Chen et al., 2000, Miller et al., 2oo2). For invasion of P. 
jalciparumrequires attachment of merozoites to the host cells. In the process of 
attachment and invasion highly polymorphic proteins (to evade immune system) are 
involved: those, which help to invade the host cell examples, are AMA1, MSP1, MSP2, 
and erythrocytic binding antigen (EBA1). Another set of highly polymorphic protein 
namelyP. jalciparum erythrocyte membrane protein (PfEMP-1) mediates adhesion of 
infected red blood cells to host cells and sequestration of infected cells. 
Invasion and internalization leads to either sequestration (adherence of RBCs infected 
with malarial parasite to endothelium of capillaries and venules) or rosseting (binding 
of infected RBCs to uninfected RBCs), which may cause cerebral malaria, hemolysis and 
malarial complications during pregnancy. In falciparum malaria, sequestration of 
parasitised erythrocytes in the microcirculation and excessive release of 
proinflammatory cytokines has been implicated as the main cause of disease and 
. 
death (Planche and Krishna, 2005, Clark et al., 2006). Sequestration of erythrocytes 
containing mature forms of P. jalciparumin the microvasculature of vital organs is also 
a well established feature of fatal malaria in adults and its occurrence in children has 
been confirmed relatively recently (Taylor et al., 2004). 
Sequestration is thought to be mediated by interaction of parasite-derived molecules 
expressed on the surface of infected erythrocytes (highly polymorphic and clinically 
variant erythrocyte membrane protien1, e.g PfEMPI) (Magowan et al., 2000) and 
receptors expressed on the surface of the vascular endothelium, of which intercellular 
adhesion molecule I (ICAMI) is probably the most important within the brain (Turner 
et al., 1994). Tumour necrosis factor (TNF) a was thought to promote cytoadherence of 
erythrocytes and platelet thrombi within the cerebral microvasculature by up 
regulation of ICAM1 and other endothelial receptors (Armah et al., 2005, Turner et al., 
1994). 
30 
1.3. Epidemiology of Malaria 
1.3.1. World Malaria Burden 
Malaria is thought to be one of the main causes of morbidity and mortality worldwide, 
about 40% of the world's population lives in malaria transmission endemic areas. 
About 3.3 billion people were at risk of malaria (WHO, 2011a). Estimated malaria 
episodes 216 million, of which 81% (174 million cases) approximately occurred in 
Africa (WHO, 2010b). In 2010, the estimated malaria deaths recorded were 655 000 
(91% were in Africa) and more than 80% of these were of children under 5 years of age 
(Gallup and Sachs, 2010). 
1.3.2. Control 
Development of dichlorodiphenyltrichloroethane (DOT) in early 1900s, led to an 
eradication programme from 1955-1972. This was associated with significant reduction 
in transmission, burden of disease and in eliminating malaria from around 35-40 
countries (McKenzie, 2000) and large-scale control of malaria seemed achievable. 
However, in the late 1960's because of lower funding for malaria and a resurgence of 
transmission in the late 70s and 80s, the malaria eradication goal of the World Health 
Organization was switched to control (WHO., 2008b). The resistance of parasite to 
drugs and mosquito to insecticides is perceived to be one of the problems in malaria 
control (Toure et al., 2003). Over the past decade malaria funding increased 
significantly (Snow et al., 2008) and malaria control programs focussed on full-scale 
elimination and eradication of the parasite instead of management of the disease 
(Feachem and Sabot, 2008). 
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1.3.2.1. Malaria control strategies and interven ons 
There are two major levels of intervention used to control malaria: 
1) Vector control 
• long lasting insecticide-treated nets 
• Indoor residual spraying 
• larviciding (used in urban areas) 
2) Individual treatment with an malarial compounds (parasite control) 
• Intermittent presumptive treatment of malaria in infants, young children and 
those attending school 
• Intermittent presumptive treatment for pregnant women 
• Access to diagnosis and effective treatment for children with a fever 
First line of defence against malaria is to implement public health control measures to 
protect people living in malaria risk areas. The recommended control measures 
depend on the level of malaria risk in an area (Hay et al., 2008, Cohen et al., 2010). 
There is evidence that transmission has fallen further in Sub-Saharan Africa in the last 
few years (Gosling et al., 2008, Q'Meara et al., 2008a), although the cause is unclear. 
Possible reasons for the reported decrease are change in the environment, human 
behaviour and malaria control interventions. Malaria mortality rates have fallen by 
more than 25% since 2000, with the largest percentage reductions seen in the 
European (99%), American (55%), Western Pacific (42%) and African Regions 
(33%)(WHO., 2008c). 
In many of the temperate regions malaria has been successfully controlled and 
effectively eliminated (Sachs and Malaney, 2002). This has been achieved by standing 
water reduction, use of insecticides (DOT), changes in agricultural practices, 
industrialization and improved housing conditions being employed as control 
strategies (Greenwood and Mutabingwa, 2002). 
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Figure 1.3Reduc on in global distribu on of malaria endemic areas over the last century 
(Hay et al., 2004). 
The map shows global distribu on of malaria since preinterven on distribu on 
(1900) and the years 1946, 1965, 1975, 1992, 1994, and 2002, which illustrates range, 
changes through me. Areas of high and low risk were merged throughout to 
establish all-cause malaria transmission limits. The 1992 distribu on is excluded 
from the gure for clarity because it was so similar to that of 1994 (Hay et al., 2004). 
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1.3.2.2. Plasmodium /alciparum 
High levels of P. /alciparummalaria endemicity are common in Africa. Uniformly low 
endemic levels were recorded in Americas and Southeast Asia, but pockets of 
intermediate and very rarely high transmission remain (Hay et al. , 2009). 
The actual estimates of morbidity and mortality may vary due to unrecorded malarial 
deaths at home, misdiagnosis and unavailability of microscopes (Greenwood and 
Mutabingwa, 2002). In medium to high transmission settings it is estimated that 
nearly 4% of children die of malaria before the age of 5 (Hay et al., 2004, Gardner et 
al.,2002). 
c:::::J w at e r 
c:::::J f a lclprum free 
pfAPI<O. l % 
Figure 1.4The spa al distribu on of Plasmadium /alciparum malaria endemicity map in 2010 
globally (MAP,20B). 
This map is showing the age-standardised P. /alciparum Parasite Rate (PjPRz_1o)whichis 
es mated propor on of 2-10 year olds in the general popula on infected with P. /alciparum 
at anyone me, averaged over the 12 months of 2010(MAP,20B). 
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1.3.2.3. Plasmodium Vivax 
Plasmodium vivax is endemic in Asia, the Middle East and Western Pacific, with a lower 
prevalence in Central and South America. It causes more than 50% of all malaria cases 
outside Africa (Mendis et al., 2001, Sattabongkot et al., 2004). P. vivax invariably 
coexists with P. /alciparum (often equally prevalent) outside of Africa (Hay et al., 
2004). The estimated clinical infections each year by vivax malaria were recorded 72-
390 million (Mendis et al., 2001, Price et al., 2007). Vivax malaria is considered to be a 
benign infection, but it has a significant burden on morbidity and socio-economic 
status of endemic countries (Mendis et al., 2001). 
P. vivax is more challenging to eliminate than P. /alciparum and the relative proportion 
of P. vivax malaria often increases compared to P. /alciparum in areas of intensive 
control measures (Price et al., 2009). This relative increase in vivax malaria is due to 
relapse caused by the hypnozoites stage as well as the early appearance of 
gametocytes, the potential of greater transmission even at low parasite densities, and 
emerging drug-resistant of P. vivax in Asia, South America and Africa (Price et al., 2009, 
Baird, 2009). In many malaria-endemic countries, P. /alciparum andP. vivaxhas often 
been observed to be transmitted by the same vector species (Frances et al., 1996, 
Sattabongkot et al., 2004). 
In many malaria-endemic areas (e.g China and Korea) vivax is re-emerging after 
eradication and becoming a major problem (Chai, 1999, Sleigh et al., 199B). For 
example, in Sa Kaeo (Eastern Thailand province bordering Cambodia) the prevalence of 
P. vivax malaria increased from 20% in 1965 to 50% in 2002, this increase was 
attributed to changes in the composition and abundance of anopheline mosquito 
vectors (Sattabongkot et al., 2004). Similarly, in the late 1960s, USA eliminated malaria 
transmission (Sattabongkot et al., 2004), but re-introduction of P. vivax was recorded 
in Virginia in 2002, where susceptible mosquito vectors were present (2002, 
Sattabongkot et al., 2004). In these areas the re-introduction of P. vivax is mostly 
linked with the movement of people (travellers, immigrants or soldiers) from malaria-
endemic areas (Sattabongkot et al., 2004). 
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Figure 1.5 Vivax malaria risk de ned by PvAPI (MAP, 2009a). 
Transmission was de ned as: 
• Stable (red areas, where PvAPI was recorded greater or equal to 0.1 per 1,000 
people) 
• Unstable (pink areas, where PvAPI, was recorded less than 0.1 per 1,000) 
• No risk (grey areas) 
Annual case incidence data over the most recent four years was used. 
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1.3.2.3.1. Glucose 6Phosphate Dehydrogenase (G6PD) De ciency and its 
screening signi cance in vivax malaria 
In P. vivax infections even with effective treatment for acute episodes, one initial 
infection may lead up to 10 or more subsequent episodes due to its ability to form 
hypnozoites in the liver (leslie et al., 2004, leslie et al., 2008). These hypnozoites acts 
as a reservoir of infection in host and allow the disease to continue its transmission 
cycle, which are thought to reduce the efficiency of insecticide treated nets as a 
control tool. Infected persons may develop further episodes, even if they regularly use 
an ITN.The radical cure of vivax malaria, using primaquine or other anti-hynozoite 
drugs, cannot be recommended in the population unless the prevalence of known 
G6PD(leslie et al., 2004, leslie et al., 2008) due to prevalence of G6PDvariants with 
low enzyme activity(Bouma et al., 1995, Ali et al., 2005) in most endemic and formerly 
endemic countries such as the Mediterranean countries(Turan, 2006). In the presence 
of primaquine, G6PD deficiency can cause clinically significant and occasionally severe 
haemolytic anemia (Bouma et al., 1995, Chamchod and Beier, 2013, leslie et al., 2010). 
Glucose-6-phosphate dehydrogenase deficiency is an X-linked recessive hereditary 
defect caused by G6PDgene mutations, resulting in abnormally low levels of glucose-6-
phosphate dehydrogenase (G6PD) (Beutler, 1992). The G6PD gene is nearly 18.5kb in 
length with 1545 bp of coding region (which encodes 515 aminoacids) and consists of 
12 introns and 13 exons (Szabo et al., 1984, Trask et al., 1991). There are about 140 
mutations reported, most of which are point mutations resulting in non-synonomous 
amino acid substitutions. Secondary mutations may rarely be present in the cistrons 
(Town et al., 1992, Hirono et al., 2002). The more the non-synonymous mutations, the 
lower the severity of the disease (Cheng et al., 1999). 
G6PD is involved in the pentose phosphate pathway that provides reducing power to 
all cells in the form of NADPH (reduced form of nicotinamide adenine dinucleotide 
phosphate). NADPH helps cells to reduce oxidative stress that can be generated by 
several oxidant agents (Cappellini and Fiorelli, 2008). G6PD is especially important in 
red blood cell metabolism, as RBCs lack mitochondria and NADPH (of the pentose 
phosphate pathway) is their only way to protect against oxidative damage (luzzatto et 
al., 2001, Williams, 2006). 
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Neonatal jaundice and acute haemolytic anaemia,caused by an exogenous agent,are 
the most common clinical signs of G6PD deficiency(Luzzatto et al., 2001). Persistent 
neonatal jaundice, may lead to kernicterus, which is considered to be the most serious 
G6PD deficiency problem and can cause acute renal failure (Luzzatto et al., 2001). 
Most G6PD deficient individuals are asymptomatic. Due to the X-linked pattern of 
inheritance, mostly males are symptomatic patients, however female carriers can have 
comparatively less severe clinical symptoms and rarely develop severe acute 
haemolytic anaemia (Luzzatto et al., 2001, Williams, 2006, Rowe et al., 2002). 
Table 1.2Five clinical classes of G6PD de ciency depending on the severity of the clinical 
outcome 
Class Clinical Manisfestations 
I Severely deficient, chronic non-spherocytic haemolytic anaemia 
11 Severely deficient, acute haemolytic anaemia 
III Moderately deficient 
IV Normal activity 
V Increased activity 
There are several drugs other than antimalarials, suggested to be harmful to G6PD 
deficient individuals including, sulfonamides, thiazolesulfone, methylene blue, 
naphthalene (only when taken at at higher doses), analgesics and some non-sulfa 
antibiotics (nalidixic acid, nitrofurantion, and furazolidone) (Beutler, 1994). 
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1.3.2.3.2. G6PD de ciency and protec on against malaria 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency has been hypothesised 
considered to provide protection against as malaria, due to its extensive distribution in 
malaria-endemic populations. This hypothesis was supported by a haplotypic analysis 
of the mutant A- and Med alleles of the G6PD gene (Tishkoff et al., 2001). A case-
control study conducted in Afghan refugees in Pakistan has shown G6PD deficiency 
(Mediterranean type) to provide a Significant protection against vivax malaria infection 
whether measured by phenotype or genotype, indicating a possible evolutionary role 
for vivax malaria in the selective retention of the G6PD deficiency trait in human 
populations (Leslie et al., 2010).Other previous studies also provided evidence that 
G6PD deficiency is involved in the clinical protection against malaria in a range of 
different settings (Mockenhaupt et al., 2003, Ruwende et al., 1995, Mombo et al., 
2003). Moreover it has been suggested that the phagocytosis of ring-stage infected 
G6PD deficient RBCs is twice as high as compared to infected normal RBCs (Cappadoro 
et al., 1998). The reason for protection against malaria G6PD deficient was suggested 
the accelerated oxidative membrane damage in deficient cells was defense to the 
impaired anti-oxidant properties of these cells(Ayi et al., 2004, Williams, 2006). 
Many studies to date described the protection against malaria to be related to 
structural and functional genes of RBC membranes. For instance, negativity of duffy 
blood antigen encoded by FY gene is protective against P. vivax malaria. Similarly, the 
Glycophorin C deficiency (Gerbich negativity) provides protection against EBA-140-
mediated invasion by P. /alciparum parasites (Thompson et al., 2001). CR1 (RBC 
complement receptor 1) deficient red blood cells infected with P. /alciprum are shown 
to have reduced ability form rosettes (Cockburn et al., 2004). Southeast Asian 
ovalocytosis is also proposed to confer resistance to invasion by a subset of virulent P. 
/a/ciparum parasites and increase adhesion of P. /alciparum-infectedovalocytes to 
CD36 (Cortes et al., 2005). 
Haemoglobinopathies such as Alpha Thalassaemia have been proposed to provide 
preferential protection against severe malarial anaemia and also possibly related to 
reduced surface-expression of CR1 (Wambua et al., 2006, Cockburn et al., 2004). 
Similarly, HbC homozygotes are shown to give greatest degree of malarial protection, 
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possibly due reduced surface expression of PfEMP1 in HbC homozygotes 
(Mockenhaupt et al., 2004, Fairhurst et al., 2005). Hbs homozygotes, on the 
otherhand, are possibly responsible for accelerated removal of ring-stage infected 
HbAS red blood cells through improved opsono-phagocytosisand reportedly improve 
acquisition of malaria-specific immunity in HbAS children (Ayi et al., 2004, Marsh et al., 
1989). Similalry, reduced invasion of HbAE red blood cells (HbE homozygotes) by P. 
!alciparum parasites is also demonstrated by in-vitro studies (Chotivanich et al., 2002). 
1.3.2.3.3. Epidemiology 
An estimated 400 million people worldwide carry a mutated G6PDgene associated 
with G6PD deficiency. Highest prevalence is reported in Africa, southern Europe, the 
Middle East, Southeast Asia, the Central and Southern Pacific islands and recently from 
North and South America and in parts of Northern Europe (Frank, 2005, Howes et al., 
2012). Several allelic polymorphs of the gene usually occur simultaneously in areas 
with high prevalence of G6PD deficiency (Cappellini et al., 1996, Martinez di 
Montemuros et al., 1997). There are however, some exceptions for instance G6PDA-
type is prevalent in about 90% of the tropical regions of Africa. This type is also 
common in the Americans and in areas with people of African origin such as West 
Indies. 
The second most widely distributed variant of the disorder is the Mediterranean type 
which is prevalent in the Mediterranean countries (Luzzatto et al., 2001) and some 
Middle Eastern countries including Israel (most common in Kurdish Jews) (Kurdi-Haidar 
et al., 1990, Karimi et al., 2003, Oppenheim et al., 1993), India and Indonesia. G6PD A-
and G6PDMediterranean are sympatric in several countries along the Persian Gulf 
(Bayoumi et al., 1996). Seattle and Union variants have been reported in Southern 
Italy, Sardinia (Fiorelli et al., 1989, De Vita et al., 1989), Greece, the Canary Islands 
(Cabrera et al., 1996), Algeria, Germany, and Ireland. G6PD Union was also reported in 
China and Vanuatu Archipelago (Ganczakowski et al., 1995). 
Few studies have described the prevalence of G6PD deficiency in Afghanis, whichvaries 
between 2.9 (Tajiks) to 15.8% (Pathans) (Bouma et al 1995).Some studies have also 
focused on mandatory testing for G6PD deficiency before administering anti-malarials 
[e.g. primaquin] in Afghanis. Inspite of high occurrence of G6PD deficiency. in the 
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Afghani as compared to other ethnic groups in Pakistan, very limited data is available 
about the molecular characterization of G6PD deficiency. Therefore, the present study 
aimed to identify the G6PD variants in the Afghani population. This will help to provide 
additional information on G6PD deficiency in Afghanis and help malaria control 
programmes in the population. 
1.4. Malaria endemicity classi ca on 
Levels of malaria transmission vary widely both between and within endemic settings 
(Hay et al., 2000), due to heterogeneity (Variation in the risk of malaria between areas 
in endemic regions) in transmission malaria endemicity has been variously classified: 
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Table 1.3 Malaria endemicity based division of transmission areas into classes 
Transmission areas categorized classically on basis of Characteristics of the three categories of malaria transmission (Carter and Recent classification of malaria 
endemicity (Pampana, 1969) Mendis, 2002) endemicity (Hay et al., 2008) 
-
Categories Transmission Parasite Type of Geographical location Transmission EIR Categories pfPR2-9 
characteristics prevalence malaria characteristics 
Hypoendemic Intermitten <10% Stable Sub-Saharan Africa Perennial or Regular, Intense stable >40% 
transmiSSion, malaria seasonal;regularcontact low to very endemic 
unstable, epidemic between vectors high 
prone andhuman hosts 
Mesoendemic Lower transmission, 10-49% Unstable Europe (not endemic Perennial or seasonal; Irregular, Moderate 5-40% 
regular seasonal malaria presently) and irregular contact low to stable 
transmission Mediterranean, Asia between vectors medium endemic 
Hyperendemic Intense transmission, 50-75% and Western Pacific, andhuman hosts 
no transmission in North (not endemic 
dry season presently), Central, 
SouthAmerica and 
Caribbean 
Holoendemic Perennial >75% EpidemiC Highland areas of Very variable, subject Rising Unstable <5% 
transmission, little malaria tropical Africa;Central to sudden and rapid suddenly, endemic 
seasonality, high Asia and Caucuses;Asia change low to 
parasitemia level and Latin America medium 
(severe anaemia) 
- -
_._._-
-
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1.5. Measuring malaria transmission 
Epidemiological patterns and malaria transmission intensity are used to estimate the 
burden of malaria and to improve strategic interventions for control and elimination 
{Noor et al., 2011, Cook, 2010}. For control programmes it is essential to have regular 
assessment of malaria transmission intensity to understand the dynamics of malaria 
transmission in a population, to perceive the magnitude of the problem and help to 
define when and where the greatest risk occurs and so it leads to the development of 
appropriate control strategies {Kelly-Hope and McKenzie, 2009}. 
There is need to establish a regular/periodic epidemiological surveillance system to 
estimate accurately malaria burden by using epidemiological tools, improve diagnosis 
and proper treatment for controlling or elimination of malaria. There are a number of 
methods for quantifying malaria transmission and evaluating the impact of control 
measures. The following are some commonly used measures of transmission intensity. 
1.S.1. Biological measures 
1.S.1.1. Entomological inocula on rate 
A gold standard measure of malaria transmission is the Entomological Inoculation Rate 
{EIR}, which is the mean number of infectious bites received per person per period of 
time most commonly a year. EIR is the number of infectious bites per person per unit 
time, commonly expressed per year. It is the product of the human biting rate and the 
sporozoite rate:The human biting rate {Ma} is the number of vectors biting an 
individual over a fixed period of time. 'M'is equal to the number of Anopheles per 
person and 'a'is the average number of persons bitten by one Anopheles in one day. 
The sporozoite rate {S} is the fraction of infectious Anopheles {with sporozoites in their 
salivary glands} present and biting {Shaukat et al., 2010}.EIR mainly dependent on 
proximity of households to larval habitat, domestic animals, human avoidance and 
defensive behaviour and individual attractiveness, depending mainly on odour or 
infection status. 
Entomological inoculation rate {EIR} is extremely useful and one of the major indices of 
malaria transmission. EIR values are used to assess the effect of indoor residual 
spraying {IRS}, insecticide treated bed nets (ITNs), and source reduction (SR) on malaria 
transmission to evaluating malaria control programmes (Shaukat et al., 2010). EIR 
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works with the calculation of the parasite-infected mosquito pool and its tendency to 
transmit infectious parasites to the human population. Therefore EIR is considered to 
be the most direct measurement to assess the impact of vector control programmes. 
Although EIR is the gold standard measure of MTI it has some limitations. For example, 
where sporozoite infection rate is low (Iow transmission areas) distribution of 
mosquitoes is very heterogeneous and variations occur in the transmission probability 
from mosquitoes to humans. Therefore extensive sampling may be needed to 
surmount the above mentioned limitations which will be very time consuming (Smith 
et al., 2004). Therefore this index is less useful and lacks precision in low transmission 
settings simply because it is difficult to find and quantify infected mosquitoes. 
EIR data provided by different areas is also not standardized due to use of different 
protocol for mosquitoes capture, (light, chemical and human landing captures), 
differences in mosquito infectivity determination methods and seasonal variations, so 
comparison over different regions is thought to be unreliable. EIR is also not 
considered as a tool to 'measure heterogeneity in MTI amongst specific areas or 
household because it is generated for large areas. 
However, EIR is commonly used in some African countries, Kenya, Burkina Faso, 
Gambia and Tanzania, where MTI is reported high and where well established research 
labs are available but data is scarce for other African countries (Kelly-Hope and 
McKenzie, 2009). 
As the present study was conducted in an area that has been reported as low malaria 
endemic it was most interested in the use of tools which are useful for low 
transmission. 
1.5.1.2. Prevalence of parasite 
The prevalence of infection is an estimate of the proportion of parasite positive people 
in an area and is the most frequently used measure of malaria endemicity. It is an 
indirect indicator of transmission intensity and hence the force of infection in a given 
setting and most commonly measured by ROT, microscopy and peR (Beier et al., 1999). 
Prevalence of infection is suggested to be the direct reflection of inoculations, 
immunity, and treatment effectiveness in humans as people can be treated based on 
their microscopy results (individual benefit) (Shaukat et al., 2010). 
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However, prevalence is not always considered to be a very sensitive outcome measure 
for measuring transmission especially when parasite densities are low and difficult to 
detect. Additionally, incidence of infection is difficult to measure directly due to the 
frequency of super infection and the difficulty of distinguishing these from existing 
infections even using sensitive molecular methods and cohort studies (Conway, 2007). 
Parasite prevalence data only represents a point measurement of endemicity and can 
be affected by season, levels of immunity and antimalarial drugs (Cook, 2010). Another 
major problem with the parasite rate data is the lack of standardization (skills can vary 
by laboratory) of techniques by different groups (Hay and Snow, 2006). 
1.5.2. Epidemiological measures 
1.5.2.1. Incidence data 
The incidence of clinical disease episodes can be used as an indicator of morbidity and 
transmission, which is useful for policy makers and clinicians. However, in areas where 
asymptomatic parasitaemia is common transmission intensity will be underestimated, 
on the other hand high transmission may be incorrectly concluded due to over 
diagnosis of malaria because of its non-specific symptoms (the symptoms can 
resemble other common diseases e.g. fever) (Chandler et al., 2006, Chandler et al., 
2008, Reyburn et al., 2004). The extent to which rates of uncomplicated episodes 
reflect transmission intensity is also uncertain, particularly comparing between 
different sites which have experienced different transmission intensities for a period of 
time and therefore have different immunity levels (O'Meara et al., 2008b). There is 
some evidence that rates of severe malaria are worst in areas of medium or low 
transmission, raising concerns about reducing transmission (Snow et al., 1997). 
It is also though that in low transmission areas the population will be less immune, 
meaning the number of infections that become symptomatic malaria cases will most 
likely to be high will be more common (Wickramarachchi et al., 2006, Wipasa et al., 
2010). On the contrary, several studies conducted in low endemic areas including the 
Solomon Islands (Harris et al., 2010), Colombia (Cucunuba et al., 2008), Amazon region 
of Brazil (Suarez-Mutis et al., 2007), Peru (Roper et al., 2000) and Principe (lee et al., 
2010) have reported asymptomatic (sub-microscopic) infections of malaria. 
Hospital records can be used to estimate transmission but these are highly unreliable, 
since there is a risk of losing information when large numbers of cases occurring in the 
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community are not referred to hospital (Tasanor et al., 2006). Transmission can be 
underestimated and go undiagnosed due to less usage of health facility, depending on 
use of traditional healers, the distance to and standard of care offered by the health 
facility (Chandler et al., 2008, Yousif EI-Safi Himeidan et al., 2005, Cibulskis et al., 2007, 
Chilundo et al., 2004, Tasanor et al., 2006). Additionally, false positive malaria cases 
may arise from clinical suspicion by nurses in resource poor settings lacking 
microscopes and/or expert microscopists (Font et al., 2001). Furthermore, nurses may 
not be properly trained for reporting (Kunimitsu, 2009). 
Another way, to collect incidence data is active case detection (ACD) or active infection 
detection, which is usually, used by the researcherduring eradication and post-
eradication control efforts. WHO defines Active Case Detection as lithe survey 
conducted by surveillance agents to visit every locality in a defined area at regular 
intervals (usually monthly during the transmission season), to detect fever cases (to 
test for malaria each suspected person so discovered) by visiting individual house, and 
treat if positive" (Sanders et al., 2012). When properly carried out, ACD is an unbiased 
(by health seeking behaviour) estimate of incidence rate and will be suitable in those 
areas where access to health facilities or treatment seeking behaviour reduces contact 
with the health system. On contrary, it is an unreliable parameter for measuring 
malaria incidencewhen carried out haphazardly. Most Often lOOs of slides are taken 
from a malaria negative person on the basis of which all are declared "negative". It can 
therefore underestimate the incidence of malaria. Additionally, in the post eradication 
era, ACD is an expensive method and can only be done by research teams. 
To assess difference in exposure between areas spleen rates are sometimes used 
(Senn et al., 2010) which is the proportion of children 2-9 years of age with a palpable 
spleen and is an indirect way of measuring impact of malaria on the spleen. There are 
some disadvantages related with this measure including variability in the skill of 
examiners and the occurance of many causes of splenomegaly. It onlyrepresents a 
point prevalence which can change rapidly with time (Shaukat et al., 2010). 
WHO utilizes the primary healthcare facilities baseline data currently to construct the 
epidemiological malaria profile of a country by case reporting (Kunimitsu, 2009). Since 
malaria reporting may have errors,the national surveillance systems may vary in 
reporting malaria and quality (Breman and Holloway, 2007). The accuracy of diagnosis 
and reporting is crucial in order to improve malaria surveillance and achieve malaria 
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elimination (Kunimitsu, 2009) since misreporting and miscounting of malaria may 
result in underestimation or overestimation ofthe actual malaria burden. 
1.5.2.2. Use of serological markers 
Sero-prevalence data (ie the prevalence of antibodies to specific pathogens or their 
antigens) has been used to measure Dengue fever (Egger et al., 2008, Ferguson et al., 
1999), Chagas disease (Feliciangeli et al., 2003), and measles transmission (Hardelid et 
al., 2008). In 1970's the same approach was applied to estimate malaria transmission 
(Mattews et al., 1970). Researchers had used antimalarial antibody responses to 
measure malaria transmission intensity, to evaluate the effectiveness of control 
measures, detecting latent foci, to estimate the burden of malaria and to diagnose 
different species (Corran et al., 2007). Serology was also used to confirm malaria 
eradication in Mauritius (Franks et al., 2003) and Greece (Bruce-Chwatt et al., 1975)'. 
The serological approach also enables measurement and interpretation of slight 
changes in age-stratified sero-prevalence because of its high sensitivity (Drakeley et al., 
2005). 
Previous studies have proven that serology is a valuable tool for assessing malarial 
transmission intensity and correlates with EIR and parasite rates(Cook et al; 20~0, 
Corran et al; 2007). It has some advantages in that as antimalarial antibodies persist 
longer in contrast to Iifespan/density of vector or the half-life of discrete parasite 
infection. Therefore, sero-prevalence has been suggested to be more accurate as 
compared to the above mentioned conventional measures of malaria endemicity 
(Corran et al., 2007) especially in low endemic areas (Bousema et al., 2010c). 
Serology has also been used to measure recent transmission changes and is 
particularly suitable for estimating current force of infection at very low levels of 
transmission (Druilhe et al., 1986) as the traditional methods based on finding cases or 
infectious mosquitoes was considered less sensitive at low levels of intensity (Bousema 
et al., 2010c). Another advantage of serology over above-mentioned measures of MTI, 
suggested was its ability to identify focal malarial transmission in small geographical 
areas by integration with household level geographical information system (GIS) in 
order to allow specific targeting by control measures (Cook et al., 2011). 
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Figure 1.6 Hypothe cal gure showing sensi vity of the three tools (EIR, PR and serological 
markers of exposure) with decreasing or increasing malaria endemicity adapted from 
(maIERA Consulta ve Group on Diagnoses and Diagnos cs, 2011). 
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1.6. Malaria diagnosis & detec on of infec on 
1.6.1. Microscopy 
Microscopy is a widely used method for detection of infection and measuring 
prevalence of parasite which is relatively quick, cheap and easy to do as compared to 
molecular techniques (PCR). Microscopic detection of malaria is the current 
recommended gold standard for its low cost, allowing speciation and detection but it 
has also some limitations like other diagnostic techniques. One of the problems is that, 
this method is less sensitive in areas of low transmission because of low overall 
prevalence and a greater prevalence of Iow-density infections in the population. Since 
high parasitemia level is crucial in low transmission areas it will require enough fields 
to read by microscopy, which will be timing consuming and will be difficult to 
implement in large scale, population-based studies (Rodulfo et al., 2007). Additionally, 
this procedure requires considerable training of the microscopists to obtain the 
necessary skills(Corran et al., 2007). 
1.6.2. Polymerase chain reac on (peR) 
low-density infections are thought to be important in maintaining malaria 
transmission in low endemic areas as well as contributing to the maintenance of 
acquired immunity (Shekalaghe et al., 2009). It has been observed that the prevalence 
of malaria parasite infection is higher than that estimated by evaluation of blood using 
microscope due to presence of these sub-microscopic infections in a population. 
Therefore it is essential to quantify sub-microscopic infections in a population to 
understand transmission dynamics for successful decrease in parasite transmission 
(Okell et al., 2oo9).Many epidemiological studies consistently provided evidence of 
prevalence of low-level infection detected through PCR (Okell et al., 2009) because of 
its higher sensitivity than microscopy for low-density infections (Snounou et al., 1993a, 
Okell et al., 2009, Musalika, 2010). 
PCR was also used to compare the sensitivity and specificity of other non-microscopic 
methods due to excellent sensitivity and identification to the species level (Mikhai/ et 
al., 2011). Currently however, PCR is an impractical routine method in cases of acute 
malaria diagnosis because of the time involved and the technical expertise required. In 
addition, the PCR based detection cannot differentiate between new infection and 
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recrudescence. Another major drawback is that PCR based detection is expensive as 
compared to other methods for example microscopy, ROT and serology. 
Most of PCR-based assays for diagnostic purposes multicopy target genes like 18S 
subunit rRNA gene or single stranded rRNA (Gunderson et al., 1987, Kawamoto et al., 
1996, Singh et al., 1999, Snounou et al., 1993b). Targeting these genes is useful in 
identifying Plasmodium species from clinical samples (on filter papers or from slides) 
that are commonly producing low parasite DNA content or in cases of low parastemia 
(Coleman et al., 2006). The completion of sequencing of the P. /alciparum genome has 
highlighted many multigene families e.g. var,rif and stevor genes. The potential of 
these genes for diagnostic purposes needs to be tested (Gardner et al., 2002). 
Conventional nested PCRs are highly sensitive and specific. The most commonly used 
diagnostic method developed bySnounou and colleagues (Snounou et al., 1993b) uses 
SU 18s rRNA nested primers that can differentiate between 4 Plasmodium species Le 
P. /alciparum, P. vivax, P. malariaeand P. ovale. However, these nested PCRs require 
long running periods and there is a high contamination risk. Molecular advancements 
such as real-time PCR, has been shown to be rapid, highly sensitive and specific, and 
have low risk of contamination due absence of post-PCR handling. Real-time methods 
also provide a simultaneous means to quantitate the parasite content. Most of real-
time assays target the SU 18s RNA (Andrews et al., 2005, Elsayed et al., 2006, Hermsen 
et al., 2001, Vo et al., 2007). The greatest disadvantage of real-time PCR is use of 
expensive consumables. However, Veron et al., (2009) were able to develop a cost 
effective duplex real-time PCR to detect Plasmodium /alciparum and Plasmodium vivax 
in the same tube (Veron et al., 2009). 
Loop-mediated isothermal amplification (LAMP) is a simple, rapid and sensitive 
method with high specificity. LAMP uses Bst DNA polymerase and a set of four primers 
that bind to six distinct regions of the target gene that produce a specific double 
hairpin DNA template. The target gene is amplified isothermally for about one hour. 
The amplified products can be achieved, either by visually comparing the turbidity of 
magnesium pyrophosphate (a byproduct of DNA synthesis) or by real-time detection 
through real-time turbidimeter (Notomi et al., 2000, Nagamine et al., 2001, Mori et al., 
2001). 
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LAMP has been found useful in malaria detection in the field settings since other 
commonly used methods like microscopy suffers from low sensitivity in cases of low 
parastemia and performance of inexperienced personnel (Sirichaisinthop et al., 2011). 
The specificity and sensitivity of this method is shown to be comparable with that of 
nested peR (Han et al., 2007). However, there are others that report instances of false 
positives and false negatives by this method. LAMP is prone to errors for visual of 
interpretation of turbidity to test positivity are subject to individual variation in 
interpretation (Paris et al., 2007). 
1.6.3. Rapid diagnos c tests (ROTs) 
An increasingly common method to assess prevalence of infection is rapid diagnostic 
tests (ROT).These are lateral flow immunochromatographic devices that detect protein 
(antigen most commonly histidine rich protein-II (HRP-2) for P. falciparum and lactose 
dehydrogenase (pLDH) for other plasmodium species) derived from the blood stage of 
malaria parasites in blood samples (Ochola et al., 2006). Recently a variety of rapid 
diagnostic tests (ROTs) have been developed which are easy to perform, require less 
labour and do not need electricity or specific equipment to run (Wongsrichanalai et al., 
1999). 
For better malaria case management accurate diagnosis was suggested fundamental, 
whether based on microscopy or ROTs. WHO recommended the antigen-detecting 
rapid diagnostic tests (ROTs) very essential for malaria diagnosis in areas where good 
quality microscopy is scarce. Increase in ROTs use has been observed over the past few 
years for diagnosis and active field studies. 
However, previous studies reported that ROTs sensitivity decreases with lower 
parasitaemia, making these tests unsuitable for individuals with low numbers of 
parasites (Moody, 2002). On contrary, recent (2008-2011) WHO summary report on 
ROT performance showed an overall improvement in their performance. Several ROTs 
detected malaria at low parasite densities (200 parasites/ill), had low false positive 
rates, showed stability at tropical temperatures, were easy to use, and could detect 
bothP. falciparumand P. vivax(WHO, 20llb).Sensitivity of ROT test is highly dependent 
on the endemicity of malaria, the parasite density in the target population, differences 
in transmission levels and also differences in immunity levels that affect the parasite 
density. For example, in low transmission areas; parasite densities will be lower, 
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resulting in lower sensitivity of the ROT. To maintain sensitivity of ROT, heat stability in 
the field (transport and storage of ROTs) was considered vital (Mikhail et al., 2011), 
especially in areas with high temperatures as compared to areas where temperatures 
rarely rise above 30°C. 
Despite sensitivity, another drawback reported for ROT use was persistence of 
antigens, in particular histidine rich protein 11 (HRP-2), in the blood circulation of the 
patient after parasite clearance, generating false-positive results when microscopy is 
used as a reference test (Kyabayinze et al., 2008, Tjitra et al., 1999, Moody, 2002). 
However, other reports stated that the problem is not antigen persistence but the 
limitations of microscopy, which misses parasite in a sub-set of the patient population 
(Bell and Peeling, 2006). It has also been known that in some South American areas, 
parasite did not express HRP2, which suggested that HRP2-detecting tests sensitivity 
would be reduced in such areas. So in these areas pLDH (P. /alciparum)has been 
suggested to be the more effective way to diagnose falciparum malaria (WHO, 2011b). 
Similarly, genetic variations in HRP proteins can result in variable sensitivities by their 
ROTs (Kumar et al., 2013). Complete deletion of HRP2 and HRP3 genes in P. /alciparum 
has also been reported leading to false negative results by these antigen based ROTs 
(Kumar et al., 2012, Gamboa et al., 2010, Houze et al., 2011). 
1.6.4. Measuring an -malarial an body responses 
Sero-epidemiological studies require an ideal malarial antibody detection test that is 
specific, simple, rapid, easily interpretable and high-throughput (serological surveys to 
detect and estimate malaria transmission require large sample size). Moreover, the 
assay should be cost-effective to enable widespread standardized use. 
CFT (Compliment fixation test) was one of the initial widely used tests to detect 
malarial antibodies in malaria-infected individuals, as blood slides to detect current 
infections in case of low parasitemia were found to be less sensitive (Thomson, 1918). 
The principal of the complement fixation test is based on antigen-antibody complex of 
interest and an indicator system competition for complement. CFT was simple, 
convenient, rapid, had minimal demand for reagents and a variety of the test's 
antigens were readily available. However, because of its major drawbacks including its 
labour-intensive method, requirement for large antigen quantities and high level of 
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false positives reported from some studies, the technique was abandoned and 
replaced by IHA (haem-agglutination test) (Wilson et al., 1975). 
IHA was a common method for detecting malarial antibodies since 1960s, based on the 
principal of cross-linking between antibodies and insoluble antigen to produce blood 
cells clumping (agglutination). These clumps can be measured by eye (Meuwissen et 
al., 1974). This method was suggested to be simple and had the added advantage that 
multiple samples could be tested simultaneously by using micro-titre plates. However, 
the technique became obsolete due to its non-reproducible results(Meuwissen et al., 
1972}, standardization difficulties(Bray and el-Nahal, 1966, Lobel et al., 1973}, 
dependency on high concentrations of antibody, reliance on visual examination and 
low sensitivity (Voller et al., 1974). 
Over the years tests used for sero-epidemiological studies have evolved and are 
meeting some or most of the above mentioned criteria. Some of the commonly used 
methods are described below. 
1.6.4.1. Immuno uorescence an body test (lFAT) 
From 1960s onwards the IFAT was one of the widely used serological technique, as it 
gives results in a few hours and can even be performed with filter paper blood spots 
and where the antibody is eluted later, which is good for field studies. In this 
technique, antigen (typically whole parasitized red blood cells) is fixed to glass slide, 
which is incubated with serum after which a secondary antibody coupled with a 
fluorescent compound is added which binds to antigen coupled antibodies. A 
specialized microscope is used to visualize the fluorescence. Plasmodium eldi (Simian 
malaria), were initially widely used as an antigen source for IFAT (Voller and Draper, 
1982), these were consequently found to be less sensitive in detecting human 
infections (Draper et al., 1972b, Draper et al., 1972a). Originally infected individuals 
were used as an isolation source for P. vivaxand P. falciparum antigen, this was later 
replaced by P. falciparum culture. 
IFAT was widely used for many years and it is still in use in certain areas (e,g China) 
(Domarle et al., 2006, Silvie et al., 2002, Zheng et al., 2008). Some previous studies 
suggested that IFAT displayed higher sensitivity (ability to detect antibodies at a lower 
concentration) compared to the IHA method (Draper et al., 1972b, Meuwissen, 1974, 
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Meuwissen et al., 1974). IFAT has also been found to detect higher titres of antibodies 
than eFT especially at peak infection (Schindler and Voller, 1967). 
Drawbacks to using IFAT 
There have been reports of cross reactivity of several P. /alciparum homologues with 
other plasmodium infecting species particularly rodent infecting species (Brahimi et al., 
2001, Ray et al., 1994, Doolan et al., 1996, del Portillo et al., 1991). The method is 
difficult to standardize (based on visual examination) and vulnerable to user error and 
bias (differences between users, microscopes and laboratories). Morover it is a time-
consuming process and inter-study comparison are difficult to make due to a wide 
variety of protocols and reagents in use. Although cultured antigens are available, 
differences among results were found between different batches of antigens and 
different storage conditions (Manawadu and Voller, 1978) 
1.6.4.2. Enzyme-linked immunosorbent assay (ELlSA) 
Enzyme-linked immunosorbent assay (ELlSA) uses antibodies to detect proteins and 
immunogens. The ElISA technique was conceptualized and developed by two Swedish 
scientists Peter Perlmann and Eva Engvall Engvall who published their first paper on 
the technique in 1971. Voller et al. in 1975 used the first ELlSAs to detect malarial 
antibodies in both P. /alciparumand P. vivax parasite-positive individuals by using 
antigen obtained from P. knowlesi (Voller et al., 1975). 
The technique, involves the coating of antigens (most often a single recombinant 
protein) on to high-binding micro-titre plates. The serum of interest is incubated in the 
plate, following blocking of non-specific sites. Bound antibodies are then detected with 
a secondary antibody that is linked with an enzyme. The final step involves the 
addition of an enzymatic substrate that is then converted if there is bound enzyme 
present in the well, resulting in colour change or fluorescence measurable by a 
spectrophotometer. 
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Advantages 
This method is regularly used to investigate humoural responses to malarial antigens in 
several seroepidemiological studies to look at endemicity of malaria (Drakeley and 
Cook, 2009). It is a high throughput and easily standardisable (Drakeley and Cook, 
2009)method which is relatively cheap and easy to perform. Italso generates objective 
results. Commercially available ElISA components and recombinant proteins help to 
compare results from different laboratories (Esposito et al., 1990). 
1.6.4.3. Protein micro-array 
Protein micro-array is a miniaturized assay system to detect antibodies to many 
antigens simultaneously. This is the most recent addition to the antibody detection 
techniques and is similar to the ElISA but recombinant proteins are bound to a 
microscope slide in nanogram quantities. Potentially arrays can screen hundreds of 
antigens simultaneously and have a greater dynamic range of antibody level detection 
than ElISA. limited data are available on their use for sero-epidemiology (Doolan et 
al., 2008, Gray et al., 2007). Protein microarray is not yet a very common method and 
it is not routinely used for assessing transmission intensity due to its high cost. 
1.6.4.4. Luminex uorescent assay 
High-throughput multiplex assays implemented in Luminex fluorescent microsphere-
based technology are preferred for their quick and cost effective screening using 
minimum sample quantities (Giavedoni, 2OOS, Nolan and Mandy, 2006, van der Heyde 
et al., 2007). Each color-coded microsphere set (out of 100 distinct sets) can be coated 
with analyte-specific capture antibody for the molecule of interest, allowing 
simultaneous detection and quantitiation of reporter signals by Luminex analyzer. The 
method has been shown to have similar or higher sensitivity compared to ElISA (van 
der Heyde et al., 2007, Elshal and McCoy, 2006). The assay has been utilized for 
detection of about 1S vaccine candidates simultaneously in P. !alciparum (Ambrosino 
et al., 2010). 
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1.7. Basic factors that in uence prevalence of malaria parasites 
within a popula on 
1.7.1.1. Vector related factors that in uence malaria prevalence 
High sporozoite rate and number of infectious bites are greatly influenced by the 
lifespan of the mosquitoes and mosquito density, which may lead to high transmission 
intensity (Paul et al., 2004, Protopopoff et al., 2009). The spread and survival of the 
malaria vectors are highly temperature, rainfall and humidity dependent (Adimi et al., 
2010). 
Temperature: Studies have shown that optimal larval development (optimum 
temperature range was suggested 25°C-30°C), stable malaria transmission, longevity 
and feeding frequency of a mosquito are all temperature sensitive (Warrell, 2002) .. 
laboratory based observation had shown that larval mortality increases when water 
temperature fell below 18°C (Bayoh and Lindsay, 2004). In a study conducted in the 
Kenyan highlands had shown a small larval survival rate was at low temperatures 
(Koenraadt et al., 2006), while the adult indoor mosquitoes could survive with 
temperatures 2 to 3 degrees higher (Garnham, 1945, Protopopoff et al., 2009, Vincke 
et al., 1946). Moreover speed of development of the parasite within the mosquito was 
found also temperature-dependent (Warrell, 2002). 
Rainfall: In most settings rainfall provides breeding sites for mosquito larvae, though 
larvae can also be flushed away and killed by heavy rain showers (Paaijmans et al., 
2007). This is generally accepted that an increase in humidity may be leading to an 
increase in adult mosquitoes longevity and consequently the vectorial capacity 
(Warrell,2002). 
AI tude: A study to rank malaria risk factors in African highlands, suggested 1800-
2000 meters as the upper limit at which malaria transmission could occur (Protopopoff 
et al., 2009, Warrell, 2002). Previously the upper limit of malaria in Pakistan was 
suggested to be 1,500 metres but recent malaria limit maps have shown malaria 
endemicity in areas between 1500 and 2000 meters (Baluchistan and KP) (MAP, 2013). 
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Topography: The distribution of hills, valleys, plateaus, rivers, streams, swamps, 
vegetation and poor drainage affects the spatial distribution of breeding sites 
(Minakawa et al., 2005), irrigation and swamp drainage for cultivation, can create new 
habitats for malaria vectors (Protopopoff et al., 2009).One of the reasons for the 
epidemic of malaria in afghan refugee camp in Khyber Pakhtun Khawa (KP), Pakistan 
was the borrow pits that were dugout for taking mud for building households, which 
may have been extra habitats for larvae breeding (leslie et al., 2009). In the Kenyan 
highland,most of the breeding habitats of the malaria vector in the hilly highlands were 
observed in the bottom of the valley, as the hillside gradients offer efficient drainage 
(Minakawa et al., 2004). 
Household and sodo-economic: Previous studies have shown that a variety of factors 
related to household construction such as type of roof, walls, window glazing, open 
eaves, no separate kitchen, also increase potential to shelter mosquitoes and thus 
increase malaria transmission (Gamage-Mendis et al., 1991). For example, it is a 
common observation among the Southeast Asian countries that living in poorly built 
houses (presence of eaves in the room, thatched roof and non glazed windows) 
compared to well constructed ones leads to an increase in human-mosquito contact 
(Butraporn et al., 1986, Oemijati, 1992, Arasu, 1992, Sornmani,.1992). 
Other important factors apart from the above mentioned which can effect 
transmission of malaria in an area include; vector species e.g., zoophilic mosquitos 
which have particular preference for biting animals over humans (Bruce-Chwatt, 1960) 
(in Pakistan most of malaria vector speCies are zoophilic), climatic suitability for vector 
breeding and survival (Craig et al., 1999), as well as whether there are control 
measures in place (Malikul, 1988). 
1.7.1.2. Human related factors that in uence malaria prevalence 
Population immunity (which is the ability to supress malaria infections) is thought to 
be dependent on exposure (Bodker et al., 2006), health status and malnutrition 
(Shankar, 2000). Similarly, pregnant women were found more susceptible to malaria 
during pregnancy than non-pregnant women. Plasmodium /alciparum, which 
sequesters in the placenta, causes the greatest disease, contributing significantly to 
maternal and infant mortality (Menendez, 1995). Moreover, the most vulnerable 
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group is HIV patients (with no or little immunity against the disease) who might 
enhance malaria transmission and malaria parasite biomass (Protopopoff et al., 2009). 
Emergence of antimalarial drug resistance is a huge problem for malaria control 
strategies, which may play an essential part in the spread of malaria to new areas and 
in the incidence and severity of outbreaks (Bloland, 2001). Indeed, one of the main 
reasons suggested for resurgence of malaria in several countries was the emergence 
and spread of drug-resistant parasites (Bodker, 2000, Trape, 2001). This may lead to 
progressive build-up of the gametocyte pool in the human reservoir, contributing to 
increase of transmission (Protopopoff et al., 2009). In South Asian countries, the 
practice of self-medication (Oemijati, 1992, Arasu, 1992, Fungladda and Sornmani, 
1986, Fungladda W, 1991), variety of health-care seeking practices and non-
compliance with the prescribed full course of therapy have also been suggested as the 
cause of occurrence of drug resistance (Fungladda and Sornmani, 1986). 
Population migration (Martens and Hall, 2000), reduced access to health systems, poor 
quality of health services, and socio-economic pressure as population growth (Hay et 
al., 2004) favourable for malaria outbreaks. Previous studies in Thailand and in the 
Philippines had suggested periodic population movements into potential transmission 
sites in endemic areas was the most important risk factor of increasing transmission 
(Fungladda et al., 1987, Sornmani et al., 1983). Population movement is also 
associated with the spread of drug resistance parasite strains to areas previously free 
of drug resistance{Bloland, 2001). In Thailand population movement has been 
suggested as the main reason of the rapid spread of chloroquine-resistant P. 
/alciparum strains{Pinichopongse S, 1983). 
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1.8. Malaria in Asia 
The epidemiology of malaria in Asia differs from that of Sub-Saharan Africa where the 
disease has comparatively higher transmission levels. Although, the transmission is 
comparatively lower in Asia, the increased burden of the disease has implication for 
economic activity. 
In Southeast Asia, malaria is a major public health issue where 10 out of 11 countries in 
the region are malaria endemic. The region contains approximately 40% of the global 
malaria risk population. Maldives is the only country in the region, which is malaria-
free of indigenous transmission since 1984. Countries such as Bhutan, Nepal and Sri 
Lanka have experienced a sharp decrease in the number of reported cases since. The 
main factor that contributing to malaria transmission in this region is forest associated 
malaria,accounting for about 40% of total malaria cases and about 60% of the total P. 
/alciparumin the region (WHO, 2012b). Change in topography, due to construction and 
urbanization projects, may give way to malaria susceptible environments. Political 
unrest and natural disasters resulting in destruction and mass migrations may be 
another mode of exposing non-immune populations to the disease in endemic areas 
thus raising concerns of outbreaks. In 2010, in Pakistan post-flood surveys reported 
approximately 300,000 suspected malaria cases, including confirmed cases of the 
severe falciparum malaria. The number was above the average annual levels reported 
(WHO, 2010a). In previous decade (2000-2010), the SEA Region malaria incidence was 
approx 2.30-3.08 million with around 2400-7000 annual deaths. The highest annual 
incidence and malaria deaths were reported from India followed by Myanmar and 
Indonesia, whereas the lowest were reported from Bhutan and Sri Lanka followed by 
Nepal. The P. /alciprum prevalence in the regions was estimated to be 45% - 61%. Sri 
Lanka, Bhutan, North Korea and Thailand showed significant reduction in malaria 
morbidity. The increase in the proportion of P. /alciparumin the region may be the 
result of rising trend of drug resistance, suppressing P. vivax incidence by assumptive 
treatment of all cases with chloroquine, and the use of monovalent ROT (for P. 
falciparumonly). On the other hand, the increase might simply be due to the increased 
case detection in the countries especially in Indonesia, Myanmar, Bangladesh and India 
(WHO,2012b). 
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In Iran, before the implementation of the successful malaria control programme after 
1951, about 60% of the total population was living in malaria endemic areas (Edrissian, 
2006). Now in Iran, malaria high prevalence has been observed only in the south-east 
(areas that bordering Afghanistan and Pakistan) contributing 90% of the total cases in 
the country, with an API 3.6 per 1,000 (Masoumi Asl, 2001, Reza and Taghi, 2011). In 
Afghanistan, the parasite transmission is seasonal and reported higher in the east of 
the country bordering Pakistan where the slide positivity reaches 30%. Eighty percent 
of these cases are P. vivax(Leslie et al., 2012). 
In China, the annual reported incidence in 2009 was 14,098. Both P. vivax and P. 
!alciparum are prevalent, although the disease is more concentrated around the 
southeastern belt neighbouring Vietnam, Laos and Myanmar. Falciparum malaria was 
endemic in 15 provinces in the 1950s. The malaria control programme in 1955 was 
successful in eliminating malaria in the central provinces. By 1998, falciprum malaria 
was endemic only in the two southern most provinces of Yunnan and Hainan. Hainan 
accounted for 46% of the annual P. !alciparumcases(lin et al., 2009, Xiao et al., 2012, 
CDC,2012a). 
According to WHO, RBM Highlights Report of 2000-2001 approximately 30% of the 
Central Asian population live in malaria risk areas. In Tajikistan, the disease is endemic 
in the southern part bordering Afghanistan. However, epidemics have been reported 
from the central, western and northern regions of the country. Epidemic situations 
have been assumed in Uzbekistan and are becoming prevalent in Turkmenistan 
spreading along the western border along Iran. In Turkey about 23% of the population 
live in high risk malaria regions with approximately28 million people living in regions at 
high risk of epidemics (RBM, 2001). 
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1.9. Malaria in Pakistan 
Pakistan is a low malaria endemic country, where malaria is prevalent in areas below 
an elevation of 5000feetbefore 1950 (Bouma, 1996b) but now the limits of malaria 
prevalence extended to higher altitudes (Map, 2009b)and particularly associated with 
rice growing regions (Rowland et al., 2002a, Rowland et al., 2002b). The major 
Anopheline vectors observed in Pakistan are An. culici/acies andAn. Stephensi, with 
two species of Plasmodium: P. fa/ciparumandP. vivax. The main features of both 
vectors are their strong preferences for animals (zoophily), particularly cattle and to 
rest indoor (endophily). Their preferences to feed on animal blood and their short life 
span make them poor vectors in theory (Bouma, 1996b). In Pakistan the major malaria 
vectors are highly zoophilic, and Afghan refugees and local residents prefer to keep 
their cattle in the courtyard where they sleep in the summer. Therefore conditions 
forsuccessful passive zoo prophylaxis in Pakistan seem highly conducive. However, 
SOTA& MOGI (1989) mathematical model has predicted that introduction of cattle can 
lead to increased vector densitiesas result increased human biting rates, which can 
lead to greater malaria transmission (Bouma et al., 1995). 
Transmission of malaria is seasonal and occurs mainly after the July-August monsoon 
season (Rowland et al., 2000). There are usually two peaks of vivax malaria in a year; 
one in spring (early April), which may be new transmission or may be relapses from the 
previous year and the second in summer (September), which is new transmission 
(Rowland et al., 1997a, Bouma et al., 1996a). Previous studies suggest a single peak of 
falciparum malaria after the summer peak of P. vivax(Rowland et al., 1997a, Rowland 
et al., 1997a}. The peak transmission of both species of malaria in Pakistan is suggested 
to occur in October-November (Rowland et al., 2002 b, Bouma et al., 1996a). The key 
risk factors to enhance or prolong the transmission season in Pakistan are high rainfall 
in autumn or above-average temperatures in November-December (Bouma et al., 
1996a). 
Pakistan is one of the malaria endemic countries in South Asia and major epidemics 
were recorded in the past, the most devastating outbreak of malaria occurred before 
the Pakistani independence in 1908 with over 300,000 deaths in an estimated 
population of 20 million (de Zulueta et al., 1980), while the last epidemic was recorded 
in the mid-1970s (de Zulueta et al., 1980). Malaria in Pakistan has shown long term 
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periodic cycles, where many areas are prone to epidemics(RolI back Malaria NWFP 
Pakistan, Rowland, 1999a). Resurgence of malaria is a growing public health concern 
for many countries including Pakistan due to migration, deforestation, urbanization 
and changes in human host's immune suppression. 
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Figure 1.7 Annual Parasi c Incidence (API) of malaria in Pakistan by district (Govt of Pakistan 
Ministry of Health Web Site, 2006). 
The map shows district level API per 1000 popula on of malaria in Pakistan for the 
year 2004. The data is passive (clinical). Individual maps of P. /a/ciparum and P. 
vivaxes mated limits are given below. 
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P. /alciparum 
P. vivax 
D Water 
o P. /alclprum free 
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Figure l.SEs mated limits of Plasmodium /alciparum(MAP, 2010) and Plasmodium vivax 
malaria (MAP, 2009b)transmission. 
In the maps above risk-free areas are shown in light grey. Ught pink areas represent unstable 
malaria transmission. Red coloured areas represent stable malaria transmission. Annual case 
incidence data over the most recent four years was used. Annual case incidence district level 
data over the most recent four years was used. 
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· 1.9.1. Malaria control in Pakistan 
Pakistan initiated a Malaria control programme in 1950 which became an eradication 
programme in 1960 (Asif, 2008). However, due to epidemics of malaria in the 
seventies, the Programme strategy was reversed back to malaria control with the 
programme being decentralized and integrated into the Primary Health Care 
infrastructure in 1975 in line with WHO strategic policy (Roll back Malaria NWFP 
Pakistan). The program aims to effectively control malaria to improve the health status 
of the population and had a five year plan to reduce malaria burden 50% by the year 
2010 to achieve the WHO global RBM target (As if, 2008). 
According to WHO, although Pakistani malaria control programmes are well 
established, it is still one of the major health problems of the country, mainly because 
of the lack of skilled staff, forexample nationwide monitored Rural Health Centres 
lacked staff to run the Malaria Control programme. In addition, there are funding 
shortages, lack of health infrastructure, widespread poverty, few qualified doctors and 
poor data monitoring. Although malaria is the fourth most common medical condition 
after diarrhoea, ARI [acute respiratory infection] and tuberculosis, its control is 
hampered by the availability of accurate data at the moment whereby there is a need 
to strengthen the existing surveillance system (lRIN., February 2006). ITNs/LlINs were 
adopted in 2008 and distributed free of charge as recommended by WHO. IRS as a 
malaria control strategy was adopted in 1961; however, DOT is not used for IRS at 
present due to resistance. IPT (Intermittent Preventive Treatment) for malaria 
prevention during pregnancy is not in use (WHO, 2012a). 
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Table 1.4 WHO recommended case management policies in Pakistan adapted from (WHO, 
2012a). 
Case management Implementaion Year adopted 
(Yes/No) 
Patients of all ages should receive diagnostic test - -
RDTs used at community level no 
ACT (Free for all ages in public sector) yes 2009 
Pre-referral treatment with recommended medicines yes 2009 
Oral artemisinin-based monotherapies are not yes 2009 
registered 
Table 1.5 Pakistan an malarial policy and recommended an malarial drugs (WHO, 2012a). 
Antimalarial policy Medicine Year 
adopted 
First-line treatment of unconfirmed Chloroquine -
malaria 
First-line treatment of P.ja/ciparum Artisu nate+Su Ifadoxi ne- 2007 
pyrimethamine 
Treatment failure of P. ja/ciparum Quinine -
Treatment of severe malaria Artemether; Artisunate;Quinine 2007 
Treatment of P. vivax Chloroquine +Primaquine(14d) 2007 
The recommended malaria treatment for Afghan refugee is standard three-day 
chloroquine treatment (25 mg/kg) for first episodes and extended five-day 
treatment(40 mg/kg) for recrudescent infections, based on the assumption that afive-
day course would more likely achieve a cure (Haward et al., 2011).To reduce the risk of 
haemolysis (G6PD deficiency) and enhance adherence to treatment a 5-day course of 
PO for vivax malaria is used commonly in South Asia. In Pakistan and India studies have 
shown that the 5-day PO course is ineffective at reducing relapse rates and a recent 
review concludes that 5-day PO is no better than chloroquine alone at radical cure. 14-
day course of PO is only recommended where the G6PD status of the individual is 
known (leslie et al., 2008). 
local vivax malaria treatment policy is to treat with chloroquine alone while falciparum 
malaria is treated with sulfadoxine-pyrimethamine and artesunate. Patients are more 
likely to start with self-treatment at home as this allows them to minimize 
expenditure. In Pakistan, most of the patients in rural areas administer anti-malarial 
drugs without laboratory confirmation with preference of injectable forms. 
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1.9.2. Khyber Pakhtunkhawa (KP) 
Khyber Pakhtunkhawa (KP) formerly called North West Frontier Province (NWFP) 
. consists of 24 districts; the total population is 17.744 million with an annual growth 
rate of 2.82% (Census of Pakistan, 1998). Kp is among the areas of the highest latitude 
where malaria transmission occurs (Bouma, 1996b). 
In KP, falciparum malaria is particularly unstable and fluctuates markedly from year to 
year due to climatic variations and malaria outbreaks which have been reported in the 
past {Bouma, 1996b).P. /alciparum transmission season starts in the summer monsoon 
(July) when the temeperature and humidity is suaitable and remain until the end of the 
year when the temperature falls below the critical value (December) {Bouma, 
1996b).P. vivax has usually two peaks of transmission in the year, one is its early 
transmission period during the wet months of spring due to its lower temperature 
requirement (probably facilitated by true relapses) and the other is with the P. 
/alciparum (monsoon) (Bouma, 1996b). 
Malaria remains a public health problem in all districts of KP but 2 geographical 
clusters lie in the northeast (Malakand, Buner, Shangla, and dir) and the south west 
(Kohat, lakki Marwat, Bannu, Tank, Dera Ismail Khan) were previously recorded at high 
risk of malaria, defined by number of slides confirmed positive by peripheral blood 
smear, annual parasite incidence (API) and number of cases of 
Plasmodium/alciparum(Asif, 2008). Especially small part in the South (e.g D.I.Khan that 
border border Punjab to the South) is notorious for epidemics in the past.ln KP more 
than 50% of the rural health centres have no trained staff to run malaria control 
programmes (Asif, 2008, Govt of Pakistan Ministry of Health Web Site, 2006). 
Although, Pakistan and KP had committed to follow the Roll Back Malaria Standards 
they have been unable to implement these changes due to lack of investment in 
capacity development and infrastructure (As if, 2008). 
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Figure 1.9Malaria in NWFP recorded by Afghan Refugees Health Programme (ARHP) 1990-
1997 (Rowland et al., 2002 b). 
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1.9.3. Malaria in Afghan Refugee Camps 
Migration of refugees from one country to another can affect the distribution and 
incidence of malaria and may stimulate outbreaks if the new environment is suitable 
for transmission, e.g refugee camps on the Pakistan-Afghanistan and Thailand-Burma 
borders(Rowland et al., 2002b, Rowland and Nosten, 2001). About 3 million (nearly 
one fifth) of the Afghan population migrated to Pakistan in 1978 due to the Russian 
invasion (Rowland et al., 2002b, Rowland et al., 2002a). 
The refugees were settled in 245 camps in KP, 60 in Baluchistan and 12 in Punjab 
(Suleman, 1988). Most of their shelters were huts and tents, many of which were 
established in areas known to be capable of supporting mosquito breeding (Suleman, 
1988). As the refugees were non-immune at the arrival due to successful malaria 
control programme in Afghanistan before the Russian war, malaria became a 
significant health threat on arrival of the refugees to KP(Suleman, 1988). Several 
epidemics were recorded among refugees in the 1990's. Over 150000 cases were 
being diagnosed and treated each year by the combined health services of the UNHCR, 
the government of Pakistan and NGO (Rowland, 1999a, Rowland and Nosten, 2001). 
The number of cases has declined due to control measures taking effect (Rowland et 
al.,2002b). 
In the early 1990s, after the fall of the Soviet-backed regime about half the refugees 
were able to return home to safe areas however due to consequent terrorist incidents 
in the US and the invasion of Afghanistan, the number of Afghanis entering Pakistan 
increased dramatically resulting in a restoration of the former size of the refugee 
population (Rowland and Nosten, 2001). As health services scale downdue to refugees 
repatriating to Afghanistan, there is a risk that it will re-emerge. 
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Figure 1.10Cases of malaria recorded by the malaria control programmes (MCP)of the 
Pakistan Ministry of Health (for Pakistanis), the NW FP Department of Health (for Pakistanis) 
andAfghan Refugees Health Programme (ARHP) (NWFP, Punjab& Baluchistan) reproduced 
from (Rowland et al., 2002 b). 
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1.9.3.1. Malaria control in KPand in Afghan refugees 
In Kp malaria control has relied mainly on the vector control by using insecticide 
residual spray. From the late 1950s to 1970s 75% wettable powdered DOT was usedat 
1-2 g/m2 often in two rounds/year. Due to wide spread DOT resistance in both vector 
species repoted in the country, malathion (an organophosphate, 50% wettable 
powder) was introduced as an alternative. Malathion has been the mainstay of malaria 
control in Pakistan for morethan 20 years. It was used at adelivery dosage of 2 g/m2 
from 1976 to 1977 in double round and then in 1978 a single round was used in July 
and August. In 1983-1984 limited quantities of fenitrothion (Bouma, 1996b). However, 
the failure of malathion to reduce malaria substantially in refugee villages of North-
West Frontier Province was reported during early 19905 (Rowland et aI., 1994). 
In 1991 a major malaria epidemic was recorded in refugees and malaria burden 
increased from 11,200 cases in 1981 to 118,000 cases in 1991 (Rowland et aI., 2002 b). 
However, over the following decade incidence in the refugee camps fell 25% because 
of control activities, and by 1997 the burden fell to 26,856 cases per year (Rowland et 
aI., 2002 b). The main control measures operated in Afghan refugee camps included, 
IRS and ITN (Rowland et aI., 2002 b, Rowland et aI., 2000, Rowland et aI., 1997b). 
Malaria control in the Afghan refugee villages was supported by a vertical control 
program implemented by the NGO HealthNet-TPO and funded by UNHCR, which also 
provides free quality assured microscopy and treatment services for all residents. Due 
to the contribution of NGOs, increased awareness of malaria as a public health 
problem and operational research considerable progress has been made in controlling 
malaria among Afghan refugees but this progress still demands robust and active 
surveillance tools for monitoring the pre-eliminating process to intensify and 
coordinate global malaria control, WHO and its partner RBM partnership. 
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Chapter 2. Aims and objec yes 
2.1. Aims of the Project 
The aim of this study is to generate current information on malaria infection through 
parasite prevalence and malaria exposure using antimalarial antibody responses in five 
refugee camps in Khyber Pakhtunkhwa (KP) province of Pakistan formerly called North 
. West Frontier Province (NWFP). The study also aimed to characterise the risk factors 
for exposure and infection to both P. !alciparum andP. vivax malaria to assist decision-
makers in better targeting malaria intervention and control efforts. Additionally by 
combining GIS data with measures of exposure and infection, the study designed 
aimed to map potential foci of infection and exposure to malaria to aid malaria control 
programmes. 
2.1.1. Sped C objec yes 
1. To describe age seroprevalence of malarial antibodies for both P. 
!alciparumand P. vivax. 
2. To identify behavioural and residential risk factors for malaria using prevalence 
of infection and seroprevalence as an outcome variable. 
3. To examine spatial distribution of malaria infection and exposure to identify 
areas of high and low malaria transmission. 
2.1.2. Secondary objec yes 
1. To measure incidence of carriage of P. !alciparum andP. vivaxdetected by peR 
and how that is relatedto clinical epidemiology and seroepidemiology. 
2. To determine the incidence of G6PD deficiency mutations in the study 
population. 
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2.2. Results chapters according to objec yes 
Chapter 4 Assessment of malaria exposure and infec on in Afghan 
refugee camps 
low endemic areas are suitable for malaria elimination but accurate data on the 
proportion of malaria cases and population at risk are essential for the design and 
implementation of new interventions. In low endemic areas, the commonly used 
methods including, EIR, parasite rate and incidence data have been observed to be less 
sensitive. Therefore, all these three tools, serological markers to assess malaria 
exposure and ROT and PCR to determine prevalence of infection were used together to 
get complete information about the prevalence of infection and exposure to malaria in 
the study area. Since malaria endemicity in study area has been reported very low, it 
was expected to be difficult to assess malaria transmission intensity and evaluate 
burden of the disease by using only infection data or exposure data. 
Polymerase chain reaction (PCR) was used for more sensitive detection of parasite for 
assessing prevalence of Iow-density malarial infection as ROT was expected to miss a 
substantial proportion of malaria infections due to lack of sensitivity at low parasitemia 
expected in this low endemic area (Hay et al., 2008, Yekutiel, 1960). It is essential to 
take into account the extent of the population submicroscopic parasitemia acting as a 
reservoir for malaria transmission (Okell et al., 2009, Okell et al., 2012, Roper et al., 
1996, Schneider et al., 2007, Snounou et al., 1993a). PCR results were also used to 
examine the effect of parasite carriage on seropositivity and also to assess the relative 
sensitivity and specificity of ROT. Prevalence of infection measured by PCR and ROT 
was used to establish present transmission patterns in the area. 
Every Afghan refugee camp has its own basic health unit (BHU) that maintains detailed 
health records (including malaria) of each family within the camp. Recently a 
significant decrease in malaria prevalence among the refugee camps has been 
reported from several health facilities (BHU) due to malaria control activities especially 
the distribution of ITN being supported by International Rescue Committee {IRC)and 
Health Net International (HNI) (Rowland and Nosten, 2001). It is uncertain whether 
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these reported changes represent a genuine reduction in disease burden or whether 
they reflect changing in recording practices and presentation. This apparent decline 
has had a great impact on the implementation of new malaria control activities so 
needs to be investigated. This study was designed to provide information of sero-
epidemiology of malaria in the camps that could be used to monitor changes in 
transmission over time and space. So the current data on the malaria burden at 
population level will help to accurately update malaria situation as routine health 
facility data (BHU) remain limited due to deficiencies in the data collection and 
variations in the health services utilization as large percentage of refugees treat 
malaria at home. 
Chapter SToiden fy behavioural and residen al risk factors of malaria 
exposure and infec on in the studied camps 
The distribution of malaria risk and its burden are unequal within the population 
(Greenwood, 1989, Woolhouse et aI., 1997, Carter et aI., 2000), which vary from village 
to village (Ye et aI., 2007, Ramachandran, 2010). Previously malaria transmission has 
been observed to be dependent on the social and behavioural characteristics of 
individuals (Moore· et aI., 2004, Osorio et aI., 2004, Joshi et aI., 2006), and socio-
economic conditions of the household (Ramachandran, 2010).Therefore, it is 
important to take into account human behaviour, socio cultural and economic context 
for successful control and elimination of malaria at community level (Williams and 
Jones, 2004, Opiyo et aI., 2007). Therefore, this study also aimed to provide 
information about socio-economic and behavioural risk factors of malaria, such as 
travelling outside of camp, seeking malaria treatment, ITN use and IRSand to assess its 
relationship with infection and exposure to malaria in order to improve prevention and 
control strategies in the area. 
Chapter 6 Spa al distribu on of malaria infec on and exposure to 
iden fy hot spots of malaria within the camp 
Heterogeneity in infection and exposure to malaria disease was determined within the 
camps by measuring the spatial distribtution of the disease. To achieve this aim, 
household level GIS data was combined with infection data and serological responses 
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to map potential 'hot spots' of high malaria exposure and infection. Geographic 
information systems (GIS) data integrated with malaria data may provide a quick 
display of malaria transmission. Malaria mapping has become increasingly common 
throughout the worldover the past decade for assisting malaria control and elimination 
in malaria-prone countries to provide specific spatial information of the disease (Map, 
2013, EMRO, 2013, WHO, 2011a). 
Chapter 7 Prevalence and molecular characteriza on of G6PD de ciency in Afghan 
refugees in KP, Pakistan 
Plasmodium vivax is the dominant species (70-90% of cases) in the study area 
(Rowland et al., 1994, Rowland, 1999a, Rowland and Nosten, 2001)due to its ability of 
formation of hypnozoites in the liver and so means that one initial infection can cause 
up to 10 or more subsequent episodes even after effective treatment for acute 
episodes (leslie et al., 2008, leslie et al., 2004). The liver stage hypnozoites act as a 
reservoir of the disease that may help the disease to continue its transmission cycle 
and may reduce the protective efficacy of commonly used preventative measures 
(insecticide treated bed nets) (leslie et al., 2010, leslie et al., 2008). 
The radical cure for latent stage vivax malaria is primaquine but the high prevalence of 
GGPD deficiency and the lack of G6PD testing facilities among the studied population 
prevent its use. InGGPD deficiency primaquine triggers an acute hemolytic reaction 
(Bouma, 1995, AIi et al., 2005). Prevalence of GGPD deficiency in Afghans has been 
observed in several studies ranging from 2 to 10%. Due to occurrence of GGPD 
deficiency in the study population, the study also focused on the prevalence and its 
molecular characterization. Since GGPD testing is not readily available, anti-relapse 
therapy cannot be made widely accessible to most populations at risk of vivax malaria. 
75 
Chapter Three 
Materials and Methods 
76 
Chapter 3. Materials and methods 
3.1. Study Area 
This study was conducted in five Afghan refugee camps in two districts, Mardan and 
Peshawar of Khyber Pakhtunkhwa (KP) province. Three of the camps; Baghicha (camp 
2), Kagan (camp 4), and Jalala camps (camp 3) are located in the Mardan district 
whereas Adizai (camp 1) is located in Peshawar district and Zangal Patai (camp 5) is 
located in theMalakand agency (tribal area). Afghan refugees have been resident for 
more than 30 years in these different camps. The area is classified as malaria endemic 
and is characterised by seasonal transmission occurring from June to November 
(Rowland et al., 2002b). The primary malaria vectors are Anopheles stephensi and A. 
Culicijacies. Malaria is caused by two species P. vivax and P. /alciparum but 
predominantly due to P. vivax (:::85%-95% cases) in the studied population (Leslie et al., 
2009). The camps are situated in an area which is a well irrigated agricultural plain 
where sugarcane, wheat and rice are the main crops except for Zangal Patai camp 
(Table 1.1). House compounds are predominantly constructed from mud and stones 
separated by a high perimeter wall (Leslie et al., 2009). If animals are owned it is 
common practice to keep cattle, water buffalos and other domestic animals at night in 
the owners' compounds. Therefore, almost all sources of mosquito blood meals and 
indoor resting sites are situated within the camps (Rowland et al., 2001). 
3.1.1. Health infrastructure 
The province has a developing health system and the refugees most commonly use the 
Basic Health Units (BHU) run by United Nation High Commissioner for Refugees 
(UNHCR) and non-governmental organizations (NGO) (Rowland and Nosten, 2001, 
Rowland et al., 2002 b). These BHUs provide free primary health care services to the 
population of the camps. Malaria diagnosis is available at BHU level and above (NGOs 
main offices which are working in Afghan refugee camps), where control program 
provides free quality-assured microscopy for fever cases diagnosed parasite positive by 
BHU(Rowland et al., 2002 b). Use of rapid diagnostic tests is infrequent and has not yet 
been widely implemented,possibly due to high cost. Malaria treatment is free for all 
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residents of the Afghan refugee camps. local malaria treatment policy for P. vivax is 
treatment with chloroquine alone with standard 14 day course (leslie et al., 2008, 
leslie et al., 2007, leslie et al., 2004), while falciparum malaria (now constituting less 
than 5% of annual cases) is treated with sulfadoxine-pyrimethamine and artesunate 
(28 days) (Leslie et al., 2009). All BHUs in the selected camps were also included in the 
study to obtain historical data of malaria cases (appendix ll). 
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Afghanistan 
Baluchistan 
Figure 3.1Map (A) showing Pakistan its neighbouring countries and KP and map (B) showing 
loca on of studied camps in KP. 
Map (A) is the map of Pakistan, showing the four provinces (KP, Punjab, Baluchistan and 
Sindh), provincially administered tribal areas, federally administered tribal areas and 
neighbouring countries (India, Iran, China and Afghanistan). The highlighted red coloured 
area is KP bordering Afghanistan. Map (B) showing the geographical posi on of each studied 
camp in rela on to each other and main towns (ci es). The white square shaped symbols are 
the camps while the red small circles are Mardan (main city of district Mardan) and 
Peshawar (capital of KP). Adezai camp is labelled as camp 1, Baghicha camp as camp 2, 
Jalala camp as camp 3, Kagan camp as camp 4 and Zangal patai camp as camp S. 
79 
Table 3.1 Environmental characteristics of the refugee camps in the survey 
camps 
Characteristics Adezai (camp 1) 8aghicha (camp 2) Jalala (camp 3) Kagan (camp 4) Zangal patai (camp 5) 
Average altitude 314 312 376 312 477 
(meters) 
Land type Sandy and marshy Marginal and marshy Sandy area Soil and good for agriculture Hilly 
Agriculture Rice, sugarcane and Rice, sugarcane and Sugarcane and corn Rice, sugarcane and wheat Sugarcane and corn 
wheat (inside camp) wheat (adjoining (outside camp) (adjoining rice irrigation) (outside camp) 
camp) 
Occupation Business and labour Agriculture, jobs and Business and keeping sheep Agriculture, jobs and Bu~nessandlabour 
business and goats (some of them are business 
nomads) 
Predominant House Rocks and mud Bricks and mud Bricks and mud Mud Rocks and mud 
construction 
Camp sited Water logged /Along Water logged /Far Dry sandy waste land/At a Water logged /Small water Dry rocky waste land or 
on/location with the river away from river, height from river channels for irrigation scrub/At a height from 
water bodies water canal 
Recent Flooding 2010 No· The river beside the camps 2009 No 
was flooded but the houses 
are on the height were safe 
Surveyed During transmission Before transmission During transmission season Before transmission season During transmission 
season (August). season (2nd week of (August). After flood (last week of June) season (September). 
Half camp before July before rainy After flood 
and half after flood season). 
likely mosquito Marshes, water pits Irrigation water and Irrigation water Rice paddy and Irrigation Streams 
breeding sites Rice paddy water 
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Figure 3.2 An open drainage in a street of camp 4 
Figure 3.3 Rice eld in the vicinity of camp 4 
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3.2. Study Design 
3.2.1. Cross-sec onal Survey 
A systematic cross-sectional malariometric survey was conducted in each of the five 
camps, between 24th J~ne and 19th of September 2010. The BHU of each camp 
maintains good records of malaria history of all households and population size of the 
camp, where previously each family has a health card issued by BHU. The BHU of each 
camp was approached to obtain the sketch map of the camp and a recent household 
list made by BHU polio campaign team. 
Selected households for the study were visited by a team of 3 surveyors (already 
trained and briefed for the survey) from the BHU. In each case the household head was 
identified and if consent was obtained, questionnaire was administered and a finger 
prick blood sample was taken from three members ofthe household, one from each of 
the three age groups 1-5, 6-20 and >20 years. The household head{s) or primary 
caretaker(s) was interviewed to assess household wealth indices and about use of anti-
malarial measures including the use of ITNs, IRS, coils, sprays, recent treatment of 
family members with anti-malarial drugs{detailed questionnaire is given in appendix 
1). 
3.2.2. Sample Size 
The desired sample size for this study was calculated based on antibody 
seroconversion rates by using maximum likelihood estimations. Previously published 
surveys (Orakeley et al., 2005) were used to derive a model of the dependence of the 
confidence interval of A (SCR) on sample size. This model estimates sample sizes by 
assuming that confidence intervals scale with the number of positive individuals 
sampled (i.e. it becomes more accurate the greater the number of seropositive 
individuals identified). It fits a logarithmic function to the measured SO values to 
calculate sample size as the number of samples that need to be tested (n) to generate 
sufficient sero-positive samples at different values of SCR and therefore transmission 
intensity to give the required confidence limits (as % relative standard deviation or 
%RSO) (Or P H Corran personal communication). For this study a sample size of 500 
individuals per camp was required to define a sero conversion rate (A) of 0.01 with a 
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residual standard deviation (RSD) less than 25%. The required sample was 167 
compounds assuming 3 individuals per compound (Le. 500/3), however 200 
households were surveyed to allow for refusal or absence at the time of survey. 
Table 3.2: Number of samples (n) that need to be tested to generate the required number of 
seroposi ve samples, for a given rela ve standard devia on, at each level of transmission 
%RSD 
desired 
5 
10 
15 
20 
25 
30 
No A (yr 
seroposi ve (approx. EIR) 
samples ' 
required 
522 
305 
178 
104 
61 
36 
0.001 
(0.002) 
N 
18471 
10790 
6303 
3681 
2150 
1256 
0.005 
(0.035) 
5147 
3006 
1756 
1026 
599 
350 
3191 
1864 
1089 
636 
0.05 
(3) 
1187 
693 
405 
237 
138 
81 
0.1 
(11) 
802 
469 
274 
160 
93 
55 
0.15 
(24) 
642 
375 
219 
128 
75 
44 
0.2 
(41) 
550 
321 
188 
110 
64 
37 
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3.2.3. Sampling procedure 
3.2.3.1. Selec on of Compounds 
The pre-numbered list of households prepared by polio campaign team of the BHU 
was used to select households for the study. The first sampled house was chosen by 
taking a random number by using acomputer generated randomized number list and 
further, houses were selected systematically in the sequence moving up by one 
sampling interval each time; for example if number 4 was randomly generated then 
the 4th, 8th, 12th, 16th etc houses on the list were selected. The same procedure was 
repeated by moving systematically street by street until the entire camp was covered. 
Households who refused or who were uncontactable were excluded and not 
substituted or replaced as this was allowed for in the sample size calculation. The 
number of people from each age group in each selected household, household size 
and the number of households in a compound (household from a compound with 
more than one) were collected in the database to weight the data. 
3.2.3.2. Selec on of Households: In case more than one households in a 
compound 
Most of the compounds selected comprised of a group of households. In this case all 
households in a compound were numbered and then one household was randomly 
selected based on computer generated randomized number list(detailed procedure is 
given in appendix 17). 
The following de ni on of household was used;A household is a family with one head 
of the household and sharing one kitchen. In Afghan culture there is a joint family 
system, in which families of two or more brothers live together in one compound, 
sharing a kitchen and having one household head (typically the elder brother or their 
father). The number of households per compound ranged from 1-6 in refugees camps. 
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3.2.3.3. Sampling within houses 
For each camp three randomly selected individuals were chosen from each of the 
selected households. All members of a household were numbered using computer 
randomized tables and then one from each of the three age groups 1-5, 6-20 and >21 
years were randomly sampled. These numbers have been selected to generate a 
calculated sample size of at least 500 individuals per camp (detailed procedure is given 
in appendix 18). 
3.2.4. Sample Collec on 
A finger prick blood sample was taken from all consenting members of the household. 
Blood samples were collected as three blood spots on filter paper (Whatman,3MM) 
which has previously been shown to be a suitable source of antibodies for serological 
and molecular diagnosis in epidemiological surveys (Corran et aI., 2008). 
3.2.4.1. Rapid Diagnos c Test (ROT) 
All study subjects were screened to determine infection status using CareStart 3-line Pf 
(HRPII) Pan (pLDH) combo rapid diagnostic test (CareStart™ Malaria RapydTest). The 
CSPfPan test was suggested the most appropriate for this P. vivDxpredominant region 
and was found to be the most sensitive of the ROTs compared which was not unduly 
affected by heat (Mikhail et aI., 2011) (personal communication with authur).51l1 of 
blood sample was taken in the pipette provided by the company and then the blood 
was released into the sample well. The ROT was left for 20 minutes to develop as 
suggested by the manufacturer. All malaria positive cases were referred to the nearest 
health facility for full evaluation and appropriate treatment of their illness. 
3.2.5. Sample Storage 
Filter paper blood spot (FPBS) samples from the camps were dried and stored i.n self-
sealing plastic bags. Individual bagged FPBS were combined into sets and stored within 
two further successive plastic bags, the inner most of which contained approximately 
3g self-indicating silica desiccant gel. The bags were regularly checked to confirm that 
the status of the desiccant and was replaced as necessary (Corran et aI., 2008). FPBS 
were stored at 4°C in the Department of Zoology at Peshawar University, Pakistan and 
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after completion of survey the samples were shipped to the London School of Hygiene 
and Tropical Medicine and stored at -80°C for long term storage. 
3.3. Ethical approval 
Ethics approval for the study was granted by both Peshawar University (local Ethics 
committee) and the LSHTM ethics committee (copies of both ethics clearance are 
attached in appendices 19 and 20 respectively). 
3.4. Laboratory Methods 
3.4.1. Serology 
3.4.1.1. Se lee on of an gen 
As this study was conducted in a low transmission area, populationimmune responses 
were also expected to be low. To detect a low level of exposure, immunogenic blood 
stage antigens (AMA-l and MSP-119) were chosen as antibody responses can be 
detected and measured following very few infections (Drakeley et al., 2005, Corran et 
al., 2007, Bousema et al., 2010c, Cook, 2010, Cook et al., 2010). Pre-erythrocytic stage 
antigens (CSP and lSA) are relatively less immunogenic due to less abundance (or 
expression) of antigen and a shorter duration of exposure to host immune 
system(Cook, 2010). Studies have shown that measuring MSP-119 responses may be 
more suitable for areas of very high transmission as prevalence of anti-AMA-1 
antibodies approaches 100% very early in life. As MSP-119 is less immunogenic antigen 
compared to AMA-1, antibody responses may be more informative about malaria 
exposure in areas of very low transmission(Drakeley et al., 2005, Orlandi-Pradines et 
al., 2006, Bousema et al., 2010c, Cook, 2010). 
It is evident from some studies that MSP-2 is a highly polymorphic antigen (Franks et 
al., 2003, Hoffmann et al., 2001). Measuring antibody responses against just one 
variant can therefore lead to an underestimation of seroprevalence rates as other 
variants circulating in the community of interest will not be detected using EUSA. This 
makes it a less ideal choice for sero-epidemiological studies (Corran et al., 2007). 
86 
3.4.1.2. Produc on of MSP119·GST using E.coli 
P. vivax MSP-119 recombinant antigenwas prepared using the reagents, media and 
culture plates (LB-Amp plates) as detailed in appendix 15. To grow E.coli, the surface of 
the frozen glycerol stock was scraped with a sterile loop and streaked onto a LB-Amp 
plate. The plate was incubated at 37°C overnight.A single colony was then selected and 
streaked onto an LB-Amp plate and incubated overnight at 37°C. 
Small scale culture: 10ml LB-Amp medium was dispensed into a sterile tube. A single 
colony was picked off from a LB-Amp plate with a pipette, the tip was ejected into the 
sterile universal and incubated in a shaking incubator overnight. 
Large scale culture produc on: 500 ml LB-Amp medium was dispensed into each of 
two sterile flasks (2 litres). 5 ml of small-scale culture was added to each flask and 
shaken in a shaking incubator at 35°C for about 6 hours. IPTG stock of 0.5 ml (final 
concentration 0.1 mM) was added to each culture and was shaken for a further 30 min 
at 35°C. Flasks were maintained overnight at 4°C. The following day half of the 
supernatant was discarded and the cells re-suspended by swirling. Each flask was 
poured into a 500 ml centrifuge tube, which was centrifuged (Sorvall RB50) at 4°C and 
5000 rpm for 15 min and the supernatant discarded. The cell pellets were resuspended 
in PBS and transferred to 50 ml centrifuge tubes. This was washed with PBS and 100 J..lI 
was taken as a 'whole cell' sample which was frozen at -20°C. 
Cell suspensions were cooled in an ice bath then sonicated for 5 min in 30 sec bursts 
with 20 sec intervals inbetween, whilst cooling on ice. 1/20th volume of 20% Triton X-
100 was added and mixed for 1h on a rolling mixer at 4°C. 100 ~I of sample was taken 
as 'sonicate', which was frozen at -20°C. The cells were distributed into 2 x 50 ml high-
speed sterile centrifuge tubes then spun at 10,000 rpm for 20 min to pellet cell debris. 
The supernatant was removed into a 50 ml conical graduated centrifuge tube then 
100~1 of supernatant was taken and frozen. The pellet was re-suspended in PBS and 
100J..lI of sample as 'pellet' was and frozen at -20°C. 
Recovery of GST fusion partner by GSH-agarose chromotography 
Prepara on of GSH-agarose: 3 rnl of glutathione-Sepharose 4B was aliquotted into a 
SO ml conical centrifuge tube which was made up to 50ml with PBS. This was rotated 
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on roller stirrer for 2 min and centrifuged at 1000 rpm for 5 minutes. Supernatant was 
carefully decanted and 5 ml PBS was added per 2 ml of original sepharose stock. This 
was gently swirled to resuspend. 
A nity puri ca on of GST-fusion protein (centrifuge method): 
5 ml of washed GSH-sepharose suspension was added to the sonicated supernatant 
from the previous step. The mixture was incubated on a roller mixer at 4°C for an hour 
and then centrifuged at 1000 rpm for 5 min. The supernatant obtained was saved and 
a 100 III sample kept for SOS PAGE as 'Flow through'. The tube was topped up with 
PBS, rolled for 2 min and then centrifuged twice with the supernatant discarded each 
time. The pellet was suspended in an equal volume of PBS then transferred to 15 ml 
conical centrifuge tube, centrifuged and the supernatant discarded. GSH elution 
buffer was added to the washed sepharose-GST-fusion protein and rotated for 1 hr. 
The supernatant was transferred to a bijou and 2.5 ml of GSH elution buffer added and 
mixed for at least 1 hr. This was centrifuged and added supernatant to first elute and 
removed an aliquot (1001l1) for PAGE. The rest of the eluate was dialysed against PBS 
at 4°C and frozen at -20°e. 
Con rma on of product: SOS PAGE was performed on 10 III of each aliquot (Sill of 
crude sonicate and Sui of pellet), this was stained and the products molecular weight 
was confirmed (19.GST has M"'40 k, GST alone "'29K, single EGF domains "'3SK). 
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3.4.1.3. Titra on of An gens 
To assess optimal EUSA coating concentration of the antigen, GOOj..d of a 1/50 dilution 
of the antigen was prepared in coating buffer (the preparation procedure for buffers 
used is detailed in appendix IG). 100j.d of coating buffer was added to columns 2-12 
and rows 1-4 of an Immulon 4 HBX flat bottom plate (Thermo Scientific), wells Al to 01 
were left empty. 150I.d of diluted antigen (1/50 in coating buffer) was added to wells 
Al to 01 and then with multichannel pipette 50111 of diluted antigen from column 1 
was transferred to column 2 and mixed well. 50111 of diluted antigen was transferred 
from column 2 to column 3, mixed and transferred to column 4 and so on to column 
12. 50111 was discarded from column 12 and the plate was incubated overnight to 
enable binding of the antigen to the plate. 
After overnight incubation, the plate was washed 3 times with PBS/Tween (0.05%), 
and then 150j..l! of blocking buffer (1% skimmed milk in PBS/Tween 0.05%) was added 
to each well and incubated at room temperature for 3 hours. The plate was then 
washed 3 times and 100111 of 1/1000 dilution of positive control (diluted in blocking 
buffer) was added to each well and the plate was incubated overnight at 4°c' 
The following morning the plate was washed 5 times with PBS/Tween (0.05%) and 50111 
of diluted horseradish peroxidase-conjugated rabbit anti-human IgG (Oako #P0214,) 
diluted 1/5000 in PBST, was added to each well, then the plate was incubated for 3 
hours at room temperature. After washing a further 5 times, 100111 of OPO (SigmaFast 
OPD tablets, Sigma) substrate solution was added and left at room temperature in the 
dark for 15 minutes for the assay to develop. The reaction was stopped by adding 25111 
per well of 2M H2S04 and the plate was read at a wavelength of 492nm in ElISA reader 
to get raw data (OOs). 
The data was transferred to an Excel spreadsheet, and then OOs were plotted against 
the antigen dilution on a log scale. A coating concentration was chosen, which 
corresponded to a dilution just below where the curve was saturated. In the graph 
below, the 1/4000 dilution was chosen for this antigen, as this corresponds to a 
concentration where the entire plate surface is coated with antigen and no more will 
bind (Figure 3.2). 
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saturates 
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3.4.1.4. Recons tu on of Dried Bloodspots for ELlSA 
Antibodies were eluted from FPBS using methods previously described (Corran et al., 
2008). Briefly, using the leather hole punch, a bloodspot disc of 3.Smm was cut from 
the middle of the filter paper sample. The bloodspot was placed into a well of a 96 
deep well plate (Costar O.Sml V well bottom assay block) using tweezers, and the 
sample identity number was recorded {ID} on the plate plan. 280 ml of the 
Reconstitution buffer (sodium azide 19 per 1 litre PBS!Tween) was added to each well. 
The assumption is that a 3.Smm disc holds ~2.8ul of whole blood which constitutes a 
1:100 dilution of blood equating to a 1:200 dilution of sera, assuming a haematocrit 
content of ~SO%. 
Table 3.3 Filter paper recons tu on based on size of cu er spot 
Diameter (mm) Amount of blood (~.d) Volume to reconstitute 
Consequently, the deep-well plates were sealed with a mat and placed on a plate 
shaker overnight rocking. The following day if samples were successfully eluted, the 
filter paper circles appear white and the solution appears pink/red. Samples where the 
circle was still red and the solution pale were deemed as not eluted and were rejected. 
Plates were sealed and stored at 4°C for up to 1 month or at -20°C for long-term 
storage. 
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3.4.1.5. ELlSA 
ElISA was used to detect specific antibodies against P. vivaxand P. /a/ciprum malaria to 
estimate exposure and transmission intensity in the study area. The ElISA protocol was 
run over a 3 day period to allow the testing of a large numbers of samples during each 
run. Details of the preparation of specific reagents are given in appendix 16. 
A er iden ca on of the op mal an gen concentra on 96 well ElISA plates 
(Immulon 4) were marked out and plate template detailing sample locations were 
recorded in a laboratory record book. Antigen was diluted in coating buffer to the 
correct concentration (as determined by the titration), taking into account the number 
of plates that requiring coating. Then SOIlI of diluted antigen was added to all wells of 
the plates for overnight incubation at 4°C. 
Next morning ElISA plates were washed three times in PBS/Tween wash solution and 
lS01l1 of blocking solution was added to each well. Plates were subsequently incubated 
at room temperature for three hours. After incubation, plates were washed three 
times in PBS/Tween and 40 III of blocking solution was added to each well, followed by 
10 III of sample to each well into duplicate.A serial dilution of a positive control sample 
(pooled hyper-immune serum from Tanzania) was included on each plate along with 4 
wells as blanks, which contained no sample. Plates were then incubated overnight at 
4°C. 
A er overnight incubation plates were washed five times in PBS/Tween and SOIlI of 
conjugate solution (horseradish peroxidase-conjugated rabbit anti-human IgG, Dako 
#P0214) diluted to 1/5000 in PBS/Tween, was added to each well. The plates were 
incubated for three hours at room temperature and then washed five times in 
PBS/Tween. 100".t! per of OPD (SigmaFast OPD tablets, Sigma) substrate solution was 
added to each well and left at room temperature in the dark for 15 minutes for the 
assay to develop. The reaction was stopped by adding 2SIlI of 2M H2S04 per well. 
Plates were read at 492nm in ElISA reader and the raw data was saved. 
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3.4.1.5.1. Calcula ng serial dilu ons for control sera 
Rather than prepare controls separately, a stock of positive controls (a pool of serum 
from adults living in a hyperendemic region) that was enough for all the ELlSA plates 
was made. This reduces the variability between plates Serial dilutions dropping 
fourfold were prepared as follows: 1/10, 1/40, 1/160, 1/640,1/2560, 1/10240. 
3.4.2. Molecular Diagnosis (PCR) 
PCR was used to identify low density parasite infections for the assessment of infection 
and to examine the effect of parasite carriage on seroprevalence. From four camps 
including camp 1, 2, 4 and 5 a sub set of samples(filter paper blood spots), including all 
ROT positives and randomly selected 120 RDT negative samples, were assayed by PCR 
(Snounou et al., 1993a). The selection was carried out by randomly picking a sample 
(filter paper blood spot) from a well-shuffled bag containing all samples of a camp. 
Except for camp3 in which all samples (505) were subjected to PCR analysis. 
3.4.2.1. DNA extrac on from Iter paper blood spots using Chelex 
A 5 mm disc was cut of each FPBS using a hole punch and placed in a deep 96-well 
plate. Three +ve controls were added in the last three wells and to each row one 
negative control was added which was distributed across the deep-well plate. Then 1 
ml of freshly made 0.5% saponin (Sigma) was added in 1X PBS to completely wet the 
filter paper and was incubated at 37·C overnight. Saponin causes haemoglobin to be 
released into the PBS solution and leaves host DNA (including parasite DNA) on the 
filter paper. 
The plate was centrifuged briefly for 2 min at 4000 rpm and saponin solution and 
debris were removed using suction pump (using a new tip for each of the well) leaving 
only filter paper. Then 1ml fresh PBS (lX, autoclaved) was added and centrifuged for 2 
minutes. Liquid and debris were removed again. The washing step was repeated with 
1X PBS untill there was no visible haemoglobin left on the sample. Next 150111 of 6% 
chelex suspension in nuclease-free water was added to each sample followed by 
adding 100111 nuclease-free water. 
The plate was covered with foil, heat sealed and boiled for 30 minutes in water bath 
set at 100·C. The plate was centrifuged for 2 min to spin down chelex and remaining 
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filter paper. 100~1 of DNA supernatant was taken and added into a fresh, sterile PCR 
plate. The PCR plate (DNA) was stored at -20°C. The Chelex beads and filter paper were 
discarded. 
3.4.2.2. Diagnos c peR for iden ca on of Plasmodium species 
An optimised diagnostic nested peR by Snounou and colleagues(Snounou et al., 1993a) 
which targets the small subunit ribosomal RNA gene (ssrRNA) was used to detect P. 
/a/ciprum and P. vivax in samples. 
Species identification was a 3 step process; firstly a set of genus specific primers were 
used in nest! (NI) reaction. The N1 product was used in two separate N2 reactions 
using sets of species-specific primers, one for P. vivaxand the other for P. /a/ciparum. 
The primers are detailed in Table 3.4. Positive and negative controls were used in all 
PCR steps for quality control. 
Table 3.4 Genus and species speci c primers for both P. /alciparumand P. vivax 
Purpose Forward Reverse 
Genussped c 5' TIAAAATIGTIGCAGTIAAAACG 3' 5'CYTGTIGTIGCCTIMACTIC 3' 
5'TIAMCTGGTTIGGGAAAACCAMTA 5' ACACAA TAGACTCM TCA TGACTACCC 
P. vivax sped c TATI3' GTC3' 
P./a/ciprum 5'CGCTICTAGCTIMTCCACATMCTGA 5'ACTICCMGCCGMGCAMGAMGTC 
sped c TAC3' CTIA3' 
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3.4.2.2.1. Nest 1 Reac on 
The Nest 1 PCR mix and cycling conditions were as follows 
PCRMix 
Working concentra on Final concentra on Reac on volume 20 uL 
dH20 - 10.5 
10XNH4S04buffer lX 2 
50mM MgCb 2mM 0.8 
10 mM dNTPs 250~M 0.5 
5j..lM Primer mix (genus specific) 250nM 1 
Taq DNA polymerase 1~1 0.2 
DNA - 5 
Cycling condi ons 
Temp (DC) Time (min.) Cycles 
95 5 1 
58 2 25 cycles 
72 2 
94 1 
58 2 1 
72 5 
25 10 1 
95 
3.4.2.2.2. Nest 2 Reac on 
Same PCR mixes and cycling conditions were used for both the N2 PCRs. 
PCRMix 
Working concentra on Final Quan ty per 20 
concentra on uL 
dH20 - 14.5 
10XNH4S04buffer 1X 2 
50mM MgCb 2mM 0.8 
10mM dNTPs 250 IlM 0.5 
5 IlM Primer mix (P. falciprum or P. vivax specific) 250nM 1 
Taq: 11l' 0.2 
DNA (N1 product) - 1 
Cycling condi ons 
Temp (DC) Time (min., Cycles 
95 5 1 
58 1 30 cycles 
72 1 
94 1 
58 1 1 
72 5 
25 10 1 
96 
8ul of the nest2 product was separated on 2% agarose gel ran at 90v for 60minutes. 
Plasmodium Jalciparum produces 20Sbp PCR product and for Plasmodium vivax the 
PCR product size produced is 120bp (Figure 3.3). 
l Fl F2 F3 l Vi V2 
Figure 3.5Gel photograph showing the nest 2 PCR product of P. !alciparumand P. vivax. 
Key to gure 3.3: L=Hyperladder IV (DNA ladder), Fl-F3=P. falciprum PCR products, Vl-V2=P. 
vivax peR products. 
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3.4.2.3. Iden ca on of muta ons associated with G6PD de ciency 
An optimised PCR RFLP (restriction fragment length polymorphism) assay by (Bushra 
2009) was used for the detection of G6PD 563C-T [type 11]/188 Ser-7Phe mutations in 
Jalala camp. 
3.4.2.3.1. G6PD peR 
DNA obtained through chelex extraction described above was used as a template in a 
PCR reaction. Negative controls were added in each set of PCR for quality control. 
Primers used 
5' ACTCCCCGAAGAGGGGTTCAAGG 3' 
5' CCAGCCTCCCAGGAGAGAGGAAG 3' 
PCR Mix: The total reaction volume was 20ul. 
Working concentra on Quan ty per 25 III 
dH20 10.6/11.1 
10XN H4S04buffer 2.5 
50 mM MgCI2 1 
10 mM dNTPs 2.5 
10 ~M Primer 1.5/1.5 OR 1/1 
Taq 0.4 
DNA 5 
Cycling condi ons 
Temp (DC) Time (min.) Cycles 
95 2 
94 1 38 cycles 
67 30s 
72 40s 
72 5 
The product was run on a 1.5% agarose gel at 100v for 60mins. 
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3.4.2.3.2. Sequencing G6PD peR product 
Prior to restriction of the samples, five G6PD products were sequenced to ensure the 
position of restriction sites for Mboll (restriction site is 563C-T). The sequencing 
protocol was as follows: 
PCR products were treated with Exonuclease I (Exol) and Alkaline Phosphatase (AP) 
(Fermentas) using the following 10ul mix per sample. 
Working concentra on Quan ty per 10 J.l1 
dH20 3.35 
10X Alkaline Phosphatase dilution buffer 0.5 
Exonuclease I (20U/ ~I) 0.15 
Alkaline Phosphatase (lU/ ~I) 1.0 
PCR product 5~1 
The mix was incubated in PCR machine for 60 minutes at 3rc followed by 7rC for 15 
minutes. 
Sequencing reac on 
The BigDye V3.1 manufacturer's protocol (AB) was followed to set up the sequencing 
reactions. Two sequencing reactions were set up per sample; one with the forward 
primer and the other with the reverse primer. The reaction mix comprised of: 
Working concentra on Quan ty per 10 J.l1 
Nuclease free H2O 6.25 
Big Dye V3.1 0.5 
5x sequencing buffer 1.75 
10mM primer 1 
DNA from enzymatic clean up reaction 0.5 
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Cycling conditions were as follows, 
Temp (0C) Time (min.) Cycles 
96 1 
96 30s 25 cycles 
50 30s 
60 4 
4 Hold until purification 
BigOye reac on cleanup 
90ul of Ethanol/Sodium acetate mixture was prepared per sample. The mixture 
composition was as follows. 
Working concentra on Quan ty per 90 J11 
Nuclease free H2O 24.5 
3M NaOAc (pH 5.2) 3 
Absolute ethanol 62.5 
For the final clean-up 90111 of the Ethanol/Sodium acetate mixture was added into each 
lOll I reaction followed by brief vortexing.The tubes were then left at -20°C for 20mins 
for the extension products to precipitate, after which they were centrifuged at 
3000g/4000rpm for 30 minutes. The supernatant was removed by pipetting.150IlI of 
70% ice-cold ethanol was added to each pellet and the tubes were centrifuged again at 
3000g/4000rpm for 10mins. The supernatant was removed again by pipetting. The 
tubes were left to dry in dark for 10-30 mins after which 10111 Hi-Di formamide was 
added to re-suspend the pellet. The tubes were finally submitted for sequencing. 
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3.4.2.3.3. Restric on of the G6PD peR product 
Once the restriction sites and fragment sizes were established through sequencing, the 
G6PD product from rest of the samples were subjected to digestion by restriction 
enzyme Mboll (Fermentas kit) that targeted the 563C-T mutation sites in the 
sequence. 
Mboll 
Cu ng at 
5' ... G A A G A (N)8,J., ... 3' 
3' ... CTTCT(N)71' ... 5' 
The digestion mixture was as follows, 
Reagent Quan ty per 301,11 
G6PD PCR product 14.5 
Nuclease-free H2O 11.3 
Mboll enzyme 1 
BSA 0.2 
10X Buffer B 3 
The mixture was incubated at 37°C for 5 hours. The digested product was then run on 
2.5% agarose gel at 90v for 120mins. 
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3.5. Data management and analysis 
All data from the cross-sectional survey was collected on paper questionnaires, from 
which data was entered into the access sheets. Data was analyzed by using Stata12 
statistical software. As earlier mentioned, only a sub set of samples were selected to 
be assayed by PCR, there were expected to be chances of overestimation of infection 
prevalence or biased results detected by PCR, because all the ROT positive samples 
were included to be assayed by PCR. Therefore to assign measures of accuracy to 
sample estimates and to control and check the stability of the results, Bootstrap 
statistical method was used to estimate the prevalence of infection detected by PCR. 
The basic idea of bootstrapping is to make conclusion about a population from sample 
data (sample -> population) by resampling from the sample data. 
Modelling of seroprevalence in order to derive measures of transmission intensity and 
identify changes in transmission among camps was carried out in Stata12, used within 
the department (Corran et aI., 2007). Principle components analysis to evaluate 
socioeconomic status, logistic regression was used to analyse of risk factors for both P. 
/alciparum andP. vivax. For spatial analysis to detect hot spots of malaria within the 
camps SaTScan and ArcGIS softwares were used. The specific statistical tests used are 
described in detail in the specific chapters where they were used. 
3.S.1. Serological data 
3.S.1.1. Cleaning and interpreta on of ELlSA results/data 
The raw data (ASCII like PRN files) from the ELlSA reader was imported to MS Excel for 
data cleaning and manipulation. Duplicate OD results differing by a factor of 0.2 were 
not used in the analysis. For each ELlSA plate a titration curve was fitted to the OOs 
obtained for the standard plasma dilutions by least squares minimisation using a three 
variable sigmoid model and the solver addin in Excel (Microsoft). Averaged sample OD 
values were converted to units/ml using the fitted curve, assuming an arbitrary value 
of 1000 Units/ml of antibody against each antigen in the standard pool. 
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The concentration (arbitrary units) or magnitude of antibody response is represented 
as a titre using the following formula: 
Titre=dilution/[maximum 00/(00 test serum- minimum OD) -lJ 
Standard curves were plotted and normalised on the same graph to assess the 
difference between them. A plate was repeated if the control curve was considered 
invalid. Conversion of OD to titre occasionally resulted in negtaive titres (e.g. when the 
blank well value was high than the sample OD), these values were adjusted to 0.0001 
and retained in the analysis to allow for a continuous antibody concentration. The titre 
values were skewed and were log transformed. 
3.5.1.2. Cut 0 point calcula on for sera-prevalence determina on 
An important definition in sero-epidemiology is defining a threshold above which a 
sample is considered sero-positive. There are a variety of different methods which can 
result in different interpretation of the same data. The standard way to define cut off 
between sero-positive and sero-negative is to use serum of people who are naive or 
non-exposed to a pathogen as a representation of sera-negative population. Based on 
the normal distribution of their antibodies a cut off for differentiation between sero-
positivity and sero-negativity is calculated. However, in the case of malaria endemic 
areas it will be hard to find directly comparable non-exposed subjects, so naive 
individuals are usually chose from different settings (Le Europeans). However, this 
approach has the disadvantage that these individuals are of different ethnicity and 
exposed to completely different environment and infections which may affect 
generation of immunoglobulin. Also there may be seen nonspecific binding to 
plasmodium antigens due to differential exposure to other infectious agents. Other 
factors that also have an impact on immune responses are host genetics (Farouk et al., 
2005, Modiano et al., 1996), behaviour and culture such as diet and nutritional status 
(Grimble, 2001). 
In this study serological data were fitted to a mixture model to measure appropriate 
cut off to define sero-positivity. This method is already used in different sero-
epidemiological studies of malaria (Bousema et al., 2010c, Cook et al., 2011, Cook et 
al., 2010, Corran et al., 2007). In this model it is assumed that the antibody OD results 
comprise a mixture of two (or more) partially overlapping normal (Gaussian) 
103 
distributions. The samples are assumed to represent both a narrow negative 
distribution and a broader distribution of positive OD's from the population of interest. 
The distribution of sero-negative subjects is used to define cut off for seroprevalence 
negativity. The proportions and the parameters in each group were estimated by 
fitting the model using maximum likelihood methods. 
If there are n measurements from yi ...... yn then the likelihood to be maximised 
L h . L1,ol/~2/o2/p)=n~=1[p<f>(yi/~1,CT1,) + (1- p)<f>(yi/~2/CT2)] 
Where q>(y/~/o/) represent the normal probability function for an outcome y with mean 
Il and standard deviation a. Where Ill, a1 and p are mean, standard deviation and 
proportion respectively in the lower mean normalised aDs group, while 1l2,a2, are the 
mean and standard deviation in the other group. Then the cut off for sero-positivity is 
equal to 1ll+3al(Cook, 2010). The mixture model was run on normalised ODs of each 
antigen in STATA. A separate cutoff value was generated for each antigen (MSP-119 
and AMA-l) for each species (P. vivax and P. fa/ciparum). 
Antigen Cutoff 
PfAMA-l 0.07 
PfMSP-119 0.13 
PvAMA-l 0.43 
PvMSP-119 0.09 
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3.5.1.3. Seroprevalence 
The normalized aDs were used to produce a cut-off value above which samples were 
considered antibody positive (Cook, 2010, Bousema et al., 2010c, Corran et al., 2007). 
Antibody responses were combined by species to determine the presence of any 
reactivity aga inst P. !alciparum orP. vivax to enha nce the assay sensitivity as the overall 
prevalence of antibody was low (Bousema et al., 2010c). Other serological studies 
which used a similar model include (Cook et al., 2011, Cook et al., 2010, Cook, 2010, 
Bousema et al., 2010c, Corran et al., 2007, Drakeley et al., 2005) 
Seroconversion rate and modelling age speci c an body prevalences 
The seroconversion rate (SCR) which is the rate at which a seronegative individual 
becomes seropositive in a year was generated by fitting a simple reversible catalytic 
model to the measured seroprevalence by age in years by using maximum-likelihood 
methods (Corran et al., 2007, Bousema et al., 2010c, Cook, 2010). 
Reversible cataly c prevalence model 
~ ~ : 
A represents SCR and p is the rate of reversion of seropositive individual to 
seronegative in a year. 
The equation for the model is represented by using maximum-likelihood methods 
Pt = A/A+p(1-exp(A+p)t)--equa on 1. 
Where Pt is the proportion of individuals who are seropositive at time t, lambda (A) is 
the annual seroconversion rate which is village specific, and p annual seroreversion 
rate which is area specific. Both sercoversion (A) and seroreversion rates (p) were 
calculated by fitting the model.The value p (seroreversion rate) gives a measure of the 
persistence of the antibody response. Estimates of pwill be more reliable when P is 
large (Le. for older age groups and for higher trans- mission locations), and least easy 
to determine when P is small (i.e. in areas of low transmission)(Corran et al., 2007). 
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The best fit was obtained using a common value of p(Rho) = 0.0173 (0.0135-0.0215) 
(95% confidence interval by likelihood ratio test) for all camps (single constraint Rho 
for all camps). A previous study in Tanzania also used one constrainedp (Rho) for all 
study sites to measure transmission intensity of malaria by using age seroprevalence 
data. The authors found that the quality of fit for a single constrained value of p was 
not significantly improved by the use of individual values of Rho estimated for each 
location, which suggested that p might be mostly independent of transmission 
intensity (Corran et al., 2007). 
106 
Chapter Four 
Assessment of malaria exposure and infec on in Afghan 
refugee camps 
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Chapter 4. Assessment of malaria exposure and 
infec on in Afghan refugee camps 
4.1. Introduc on 
The aim of this chapter was to generate current information on malaria infection 
through parasite prevalence and malaria exposure using antimalarial antibody 
responses in residents of the study area. A secondary objective was to validate the 
usefulness of serology, peR and ROT as tools to monitor malaria endemicity. The study 
also aimed to provide insight into the nature and role of antimalarial immunity in the 
target population. Accurate data on the proportion of malaria cases and population at 
risk are essential for the design and implementation of new interventions. Additional 
information on the population at risk will help malaria control activities and guide 
research, as very little data are available regarding infection and exposure to malaria in 
this particular study area. 
As discussed in the main introduction, malaria in Pakistan is seasonal with the highest 
transmission recorded after monsoon. P. vivax is the predominant species which 
contributes::::: 85% of the malaria cases (Rowland et al., 2001). In KP falciparum malaria 
transmission is particularly unstable, fluctuating markedly from year to year due to 
climatic variations (Bouma et al., 1996a). These have been linked to small outbreaks of 
P. !alciparum in the region reported in the past (Bouma et al., 1996a). 
KP is characterized as low malaria endemic area with unstable and highly seasonal 
transmission (epidemic prone) and reported paraSite prevalence is<10% (Kaleem and 
Jan, 1993, Bano and Mufti, 1980, Bouma et al., 1996a, Rowland et al., 1997a, 
Muhammad and Hussain, 2003, Awan et al., 2012), which may be suitable for malaria 
elimination. However, to achieve this accurate data of malaria transmission intensity 
and burden of the disease of the study area are required. Prior to implementation of 
any control or elimination programme it is essential to assess the previous malaria 
situation and to determine the impact of previous control prevention strategies if any. 
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Entomologic inoculation rate (EIR) is the direct and gold standard measure of 
transmission intensity. However it has limitations: it is difficult to determine when the 
number of infected mosquitoes is expected to be very low in low endemic areas and 
may not re leet thespatial heterogeneity in mosquito densities (Oesterholt et al., 
2006, Smith et al., 1995, Orakeley et al., 2003). EIR can be useful measure of malaria 
transmission intensity in hyper endemic areas but it will be expensive and time 
consuming in low endemic areas and will demand long-term intensive sampling. 
The other most commonly used methods to measure malaria infection are microscopy 
and rapid diagnostic tests (ROT). But both of these measures are less useful at low 
levels of parasitaemia due to lack of sensitivity in low endemic areas (Hay et al., 2008, 
Yekutiel, 1960). They therefore can miss a substantial number samples with low-
density parasitimia, which can play an important role as an infectious reservoir (Okell 
et al., 2009). However, many studies reported that methods based on the Polymerase 
Chain Reaction (PCR) are more sensitive than microscopy or ROT and its use was 
suggested for assessing prevalence of low-density malarial infection (Okell et al., 2012, 
Okell et al., 2009, Roper et al., 1996, Schneider et al., 2007, Snounou et al., 1993a). 
An alternative method to measure malaria transmission intensity and past trends in 
malaria transmission intensity (MTI) is the prevalence of antibodies against malaria 
parasites (Corran et al., 2007, Corran et al., 2008, Orakeley et al., 2005). This method 
was previously used in different regions to compare the level of malaria transmission 
intensity (Orakeley et al., 200S, Corran et al., 2007) and especially useful in areas of 
low endemicity (Bousema et al., 2010c). Serologic markers to measure exposure to 
malaria were suggested to be advantageous, especially when the prevalence of 
infection and infected mosquitoes is low. Because antimalarial antibodies are thought 
to perSist after infections have cleared, antibody seroconversion rates are considered 
to be less vulnerable to seasonal fluctuations on the timescale of thelifespan of vector 
or the half-life of discrete parasite infection (Orakeley et al., 2OOS, Corran et al., 2007). 
Since the malaria endemicity in the study area is recorded as very low, it was expected 
to be difficult to assess malaria transmission intenSity and evaluate burden of the 
disease by using only infection data or exposure data. Therefore all three tools were 
combined to get the maximum information about the prevalence of infection and 
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exposure to malaria in the study area. In this section I used ROT/PCR to determine 
prevalence of infection and serologic markers of exposure to assess exposure to P. 
!alciparum andP. vivaxin different Afghan refugee camps. Parasite positive study 
participants (detected by ROT or PCR) would be expected more likely to be antibody 
positive to either antigen or parasites in general. 
So the current data on the malaria burden at population level will help to accurately 
update malaria situation as routine health facility data (BHU) remain limited due to 
deficiencies in the data collection and variations in the health services utilization as a 
large percentage of possible malaria cases treat malaria at home. This additional 
information on the population at risk will help malaria control activities and guide 
research in the study area. 
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4.2. Material and Methods 
4.2.1. ELlSA to detect an bodies to sped c malaria proteins 
All dried blood spot samples were tested to measure antibody responses (serological 
markers of malaria infection exposure). Blood spots were reconstituted and ElISA was 
carried out as described in detail in Materials and Methods (Chapter 3). Briefly, 
antigens specific for P. !alciparum andP. vivax were coated overnight at 4°C, ElISA 
plates were washed in PBS and blocked with 1% skim milk powder in PBS/Tween for 3 
hours. After further washing, positive controls (a pool of hyper immune plasma) and 
samples were added in duplicate wells on each plate and incubated overnight. The 
following day plates were washed 5 times and incubated with horseradish peroxidase 
conjugated rabbit anti-human immunoglobulin G for 3 hours at room temperature. 
After further washing, SigmaFast o-phenylenediamine dihydrochloride substrate 
solution was used to develop plates for 20 min. 2 mol/L H2S04(S ~I/well) was used to 
stop the reactions and plates were read at 492 nm immediately. Serum was used at 
1:1000 dilutions of original. 
4.2.2. Molecular Diagnosis 
PCR was performed to identify low-density parasite infection for both species on 120 
randomly selected ROT negative samples plus all ROT positive samples in four of the 
five camps including camps 1, 2, 4 and 5 but in camp 3 all the samples(SOS) were 
assayed using a malaria specificPCR (Snounou et al., 1993a). These results were used to 
examine the effect of parasite carriage on seropOSitivity, assess the relative sensitivity 
and specificity of ROT and to see sub-microscopic parasite carriage in this population. 
The method is described in detail in chapter 3. 
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4.2.3. Sta 5 cal analysis 
All analysis was conducted in STATA version 12 (Stata Corp lP, College Station, TX, 
USA) using the survey command (svy) with camp as a stratum and household as the 
primary sampling unit. Maximum-likelihood methods were used to estimate 
seroconversion rates (SCR) from age seroprevalence curves by fitting a reversible 
catalytic model to the measured seroprevalence by age in years. To check for most 
recent changes in transmission, seroprevalence in individuals with age equal to or less 
than five years and titres of antibodies which were suggested to be sensitive than 
seroprevalence were used (Cook, 2010). To test the association between 
seroconversion rate (SCR) and parasite rate (PR) scatter plots were examined 
andcorrelation coefficients were calculated. As mentioned above, only a sub set of 
samples was selected for assay by PCR: because all the ROT positive samples were 
included, there was a risk of overestimation bias of infection prevalence. Therefore to 
assign measures of accuracy to sample estimates and to control and check the stability 
of the results, Bootstrap statistical methods were used to estimate the prevalence of 
infection detected by PCR. The basic idea of bootstrapping is to draw conclusions 
about a population from sample data (sample-> population) by resampling from the 
sample data. 
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4.3. Results 
Cross sectional surveys were successfully completed in 5 camps with a total of 2522 
individuals surveyed. Prior to the surveys demographic data were collected from each 
camp (Table 4.1). Camp population size ranged from 3790 to 12000 approximately and 
there were no major differences in demographic composition. 
The average family size ranged from 7.9-10.3 and 52-60 % of sample collected were 
female in the sample. From each selected household three blood sample collected on 
filter paper from each of the age group mentioned earlier in materials and methods 
chapter, so approximately 33% individuals were sampled from each of the three age 
groups. The questionnaire database was matched with all serology data except for 
10(0.4%} individuals who had no ELlSA data for both P. !alciparum andP. vivax. The 
missing ELlSA results were dropped, as duplicates were not within the specified range 
of each other as mentioned in main Materials and Methods (Chapter 3). 
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Table 4.1 Demographic breakdown of study par cipants by each camp 
Camp 
Adezai Baghicha Jalala Kagan Zangal 
(1) (2) (3) (4) patai (5) 
Total popula on 6011 10879 12000 3790 8178 
(approximate) 
Total number of 411 620 755 401 590 
houses per camp 
(approximate) 
Number of 169 169 169 166 169 
households sampled 
Sample size per 507 507 505 496 507 
camp 
Average family size 8.9 8.4 7.9 8.3 10.3 
Family size range 3-22 1-14 2-17 2-15 3-25 
Sex(%) 
Female 60 60 65 58 52 
Number of individuals selected from each age group/total No. of individuals in each selected 
compound in each age group (%) 
Age group (years) 
1-5 169/1323 169/1111 167/1205 161/957 169/1597 
(13) (15) (14) (17) (11) 
5-20 171/1548 170/1958 170/1343 168/1946 168/1590 
(11) (9) (13) (9) (li) 
>20 167/1632 168/1218 168/1458(12) 167/1232 170/1990 
(10) (14) (14) (9) 
In the table above average family size, range of family size and percentage female in each 
were calculated on the basis of selected number of samples from each camp. 
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4.3.1. Plasmodium vivax 
4.3.1.1. P. vivax infec on prevalence 
4.3.1.1.1. P.vivax prevalence by ROT 
P. vivax prevalence measured by ROT was 4% (96/2522) when data from all camps was 
combined. The camp specific prevalence of P. vivax infection ranged from 0.4-9%, with 
highest prevalence of 9% in camp 3 and lowest of 0.4 in camp1 (Table 4.2). 
4.3.1.1.2. P. vivax prevalence by peR 
As mentioned earlier only a sub-sample of the total set of samples were assayed to 
identify low-density parasite infection. All ROT positive samples and a random 
selection of 120 ROT negative samples (done by randomly picking each sample from a 
bag containing well-shuffled samples of a whole camp) from each camp were assayed 
making a total to 1051 samples altogether. Prevalence of P. vivax infection detected by 
PCR, estimated by bootstrapping was 12% with a range of 5-15%. Again as for ROTs, 
camp 3 had the highest prevalence of infection and camp 1 the lowest. P. vivax 
parasite carriage measured by PCR was approximately 3 times greater than measured 
by ROT (Table 4.2). 
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Table4.2 prevalence of P.vivax infec on and prevalence of an body responses to combined 
an gens in each camp 
P.vivax 
ROT PCR(Bootstrap values) (PvAMA+PvMSP) 
Cam +ve/number %((1) +ve/number %(CI) +ve/number %(CI) 
p tested tested tested 
1 2/507 0.4(0-1) 10/137 7 (4-12)) 88/501 17.5 
(14-21) 
2 14/507 3(1-5) 19/137 10(4-14) 164/504 31.9 
(28-36) 
3 49/505 9(6-12) 79/505 15 (13-18) 240/505 45 
(38-50) 
4 10/496 2(0-4) 8/130 4(0-6) 143/495 26.8 
(23-31) 
5 21/507 3(1-4) 23/142 7(3-11) 97/507 17.2 
(14-21) 
Total 96/2522 4(3-4) 140/1051 12(10-15) 732/2,512 28 
(27-30) 
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4.3.1.1.3. Prevalence of P. vivax infec on by age 
Prevalence of parasite for each camp by age group is shown in figure 4.1. An increase 
in prevalence with age was not seen except in camp 2 when detected by ROT. In camp 
3 and 5 the highest parasite prevalence is seen in middle age group (see appendix 2 for 
detail). 
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Figure 4.1 Prevalence of P. vivaxinfec on by age group in each camp 
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4.3.1.2. Plasmodium vivax serological responses 
Of the 2522 samples collected ELlSA was performed but 10 results were discarded for 
both antigens (AMA+MSP), an additional 11 were not included from AMA-1 and 10 
from MSP-119• This resulted in a final of 2512 total for combined antigen, 2512 results 
for AMA-1 and 2518 data points for MSP-119• Missing ELlSA results were discarded 
because of the discordant duplicate 00 values (see chapter 3 for detail). They are 
unlikely to affect the results, as the discarded samples were few and did not appear to 
be systematically clustered i.e. come from one particular camp or house. 
23% (590) individuals were seropositve to PvAMA-1 (see appendix 4), which was 
approximately double that of responses to PvMSP-119, 6 fold higher than parasite 
detected by ROT and approximately 1.7 times greater than peR data. Seroprevalence 
was 11.5% (301) to PvMSP-119 (see appendix 4), which was 3 fold higher than ROT 
prevalence and similar to peR parasite prevalence (12%). 
To enhance the sensitivity of serological measure of transmission intensity antibody 
responses were combined for each species (AMA-1 and MSP-119), as previously done 
by Bousma et al.(Bousema et al., 2010c). Antibody responses against P. vivax (AMA-
1+MSP-119) were detected in 28% (732/2512) of individuals tested (Table 4.2) which is 
7 fold higher than ROT and approximately double of the peR prevalence. 
Antibodies responses against P. vivax were significantly different among the camps 
(X2=27.2, p<O.Ol).A consistency was observed among the three measures (serology, 
ROT and peR), when heterogeneity in P. vivax infection and exposure among the 
camps was compared, which shows that for all three measures the highest malaria 
prevalence was observed in camp 3 and lowest in camp1. 
4.3.1.2.1. Age seroprevalence of Plasmodium vivax 
Seroprevalence to P. viv,ax antigens by age group in each camp is summarized in Table 
4.3. Seroprevalence to combined antigens (AMA+MSP) increased significantly with age, 
p<O.Ol (using logistic regression). PvAMA-1 seroprevalence shows a clear increase with 
age in all studied sites with p<O.Ol, while the increase of seroprevalence for PvMSP-119 
antibodies with age is not significant with p<O.l (logistic regression) (for detail see 
appendix4). 
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Table 4.3 Seroprevalence to combined P. vivax an gens in each age group in each camp 
Camp Age group P. vivax(AMA+MSP) 
(years) +ve/ Number % (Cl) 
Adezai (1) 1-5 6/169 3(0.5-5.4) 
5-20 25/170 13.5(7.5-19.5) 
>20 57/162 39.9(31.5-48.3) 
Baghicha(2) 1-5 14/168 10.8(5-16.6) 
5-20 39/168 22.8(15.3-30.2) 
>20 111/168 64(56.6-71.6) 
Jalala(3) 1-5 55/167 31.8(24-39) 
5-20 70/170 39.9(31.5-48.3) 
>20 115/168 66.8(59-74.6) 
Kaghan(4) 1-5 15/161 9.1(4.4-14) 
5-20 29/167 15.6(9.5-21.8) 
>20 99/167 59.5(51.5-67.3) 
Zangal patai(S) 1-5 23/169 11.6(6.5-16.7) 
5-20 32/168 17.6(11.2-24) 
>20 42/170 23.9(16.9-30.8) 
Total 1-5 113/834 13.4(10.8-15.8) 
5-20 195/843 22.6(19.4-25.7) 
>20 424/835 52.9(49.4-56.4) 
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4.3.1.2.2. Age sero-prevalence curves ofP/asmodium vivax 
A model was fitted to the seroprevalence data using a reversible catalytic equation. 
The best fit was obtained using a common value of seroreversion rate called Rho (P), 
means one Rho was used which was not allowed to vary for each camp (single 
constraint Rho for all camps). A previous study in Tanzania also used one constraint 
Rho for all study sites to measure transmission intensity of malaria by using 
seroprevalence data and its comparison with EIR. It was assumed that a single 
constrained value of Rho could gave a quality of fit of the model to the observed data 
and that individual values of Rho estimated for each location were also not 
significantly different, which was suggested that Rho is mostly independent of 
transmission intensity (Corran et al., 2007). 
However, another study liThe use of serological markers for evaluation of malaria and 
transmission dynamics" did not constrain Rho but allowed it to vary for each sentinal 
site (Cook, 2010).Therefore in this study seroprevalence curves were fitted with 
maximum liklehood model and 95% confidence intervals around the model across the 
five camps (Figure 4.2). Age seroprevalence curves for individual P. vivax antigen 
PvAMA and PvMSP-119 are given in appendix 7 and 8 respectively. 
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Figure 4.2P.vivax age specific seroprevalence plots for P.vivQX antibodies for each refugee camp 
Graphs represent seroprevalence curves for A) campl B) camp2 C) camp3 D) camp4 E) campS and F) combined data of all five camps, which show the overall 
age seroprevalnce pattern and transmission intensity of the study area. Filled circles represent observed data and the line is the fitted equation 1 in chapter 3 
section 3.5.1.3. The proportion of seropositive individuals is represented by the vertical axis in each age group; the horizontal axis is the midpoint age of each 
age group, while dashed lines indicating 9S% confidence intervals by likelihood ratio test. 
121 
0.7 
-Camp I - Camp2 - Camp3 
0.6 
- Camp4 - Camp S 
Cl) 0.5 
> ;: 
Vi 
0 0.4 Q. 
c: 
0 
'f 0.3 0 Q. 
0 
... 
~ 0.2 
0.1 
0 
0 20 40 60 80 
Age(yrs) 
Figure 4.3 Comparison between ed age seroprevalence curves for an -vivax an bodies 
among camps 
The gure above is showing the ed age seroprevalence curves against combined P. 
vivaxan gens (AMA+MSP) of each camp to compare the heterogeneity in seroprevalence 
among camps. 
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4.3.1.2.3. SCR Vs. EIR 
EIR was estimated previously by using SCR (A) which was derived from age 
seroprevalence data (using single P. /alciparumantigen AMA-1 or MSP-119) obtained 
from different MTI sites in Tanzania (Drakeley et al., 2005). Following are the 
estimated EIR values based on the correspondence SCR values derived from 
seroprevalence to P. /alciaparum antigens from the above mentioned study. 
Es mated EIR values based on SCR values calculated by using age seroprevalence to pfAMA-
1 
SCR (A) 
0.001 0.005 0.01 0.05 0.1 0.15 0.2 
Estimated EIR 
0.002 0.035 0.13 3 11 24 41 
Same approach was used here to estimate EIR values for P. vivax for each camp. The 
resulted EIR values for the camps may not be as accurate as was calculated for 
Tanzanian data but may be indicative of EIR in the study sites. Firstly due to 
unavailability of the model based on P. vivax SCR values to estimate EIR. Secondly as 
mentioned above the estimation of EIR was made on the basis of using single P. 
/alciparumantigen PfMSP-119 and I estimated SCR by combining antibody responses to 
both P. vivax antigens (estimated SCR values for individual P. vivax antigen are given in 
appendix 10). 
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Table 4.4 Seroconversion rates calculated for P. vivax using combined an gens 
(PvAMA+PvMSP) for each camp 
P.vivax 
Camp SCR(Cls) Estimated EIR's based on PfMSP-119 
1 0.016(0.013-0.020) 0.3 
2 0.036(0.031-0.043 ) 1.3 
3 0.063(0.054-0.073 ) 4.4 
4 0.029(0.025-0.035 ) 0.9 
5 0.017(0.014-0.021) 0.3 
Overall 0.030(0.028-0.032) 0.9 
According to the table the es mated EIR (based on PfAMA-1 SCR) in the study area ranged 
between 0.3-4.4 by using seroprevalence data to combined P. vivaxan gens (AMA-1+MSP-
119)' 
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4.3.1.2.4. Plasmodium vivax an body tres by age groups and camps 
Figure 4.4 shows median titre responses to PvAMA-l and PvMSP-119 by age groups in 
each camp. There is a very clear increase of median titre responses with the age group 
using oneway ANOVA test. The results show, camp 1 with F= 61.41, p<O.Ol, camp 2 
with F= 13B.B, p<0.01, camp 3 with F= 53.B4, p<0.01, camp 4 with F= 10B.6, p<O.01 and 
camp 5 with F=31.B1, p< 0.01) in case of PvAMA-l (Figure 4.4. A). Again PvMSP-119 
median titres show no increase with increasing age groups (camp1 with F=3.0B, p< 
0.05; camp 2 with F=0.70, p<0.5; camp 3 with F=3.13, p<0.05; camp 4 with F=1.B4, 
p<0.2 and camp 5 with F=0.B9, p<O.5) (figure 4.4.8). 
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Figure 4.4 MedianPvAMA-l(A) and PvMSPl19 (B) tres by age group over camps 
Box plot is showing the rela onship between an body tres against (A) PvAMA-l (B) 
PvMSP-119 and age. The median tre is shown as middle horizontal line in the box. The 75 th 
and 25 th percen les are represented by the top of box above the median and the bo om of 
the box below the median line respec vely. Maximum and minimum tres values are shown 
by the whiskers of the plot. The PvAMA-l tre shows a clear increase with increasing age, 
while PvMSP-119 also shows increase of tres with age except from camp3. An body tres 
are log transformed. 
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4.3.2. Plasmodium /alciparum 
4.3.2.1. Plasmodium /alciparum prevalence by ROT 
Only one study participant in camp 5 was P. jalciparum positive making 0.2% (1/507) 
prevalence, while in the rest of the four camps the prevalence was zero. The overall P. 
jalciparum infection prevalence detected was 0.04% (1/2522) (Table 4.5). 
4.3.2.2. Plasmodium /alciparum prevalence by peR 
The same samples (n=1051) assayed for P. vivax infection by PCR were also tested for 
P. jalciparum (Snounou et al., 1993a). Prevalence of P. jalciparumwas 0% in three of 
the camps with one positive individual 0.8% (1/130) in camp 4 and eight infection 
positive individuals 1.4% (8/505) in camp 3. Overall prevalence detected by PCR was 
approx. 0.8% (9/1051) when all camps data was combined (Table 4.5). 
4.3.2.3. Plasmodium /alciparum serological responses 
Of the 2522 samples assayed, 2514 samples were included in the analysis and the rest 
were discarded due to discordant aDs as described previously in chapter 3. 
Overall seroprevalence to PfAMA-l observed was 4.34 % (105), while to PfMSP-119was 
2%(48) individuals were seropositive. The seroprevalence data suggests that the 
residents of camp 2 (9.06%) have higher exposure to PfAMA-1 and camp 4 (1.44%) 
have lowest among the camps, while in case of PfMSP-119 the highest prevalence was 
observed in camp 5 and the lowest was in camp 3 (see detail of individualP. jalciparum 
antigensin appendix 3). The data suggests low overall responses to both P. jalciparum 
antigens, with antibody responses to PfAMA-1 (4.3%) were approx. 2 times higher than 
Pf MSP-119 (2.0%), consistent with previous observations (Cook, 2010). 
Table 4.5 shows seroprevalence data of Plasmodium jalciparum to combined PfAMA-1 
and PfMSP-119antigens, where overall 6%(147) individuals were seropositive. By 
comparing seroprevalence among the camps, camp 5 residents show the highest (11%) 
antibody prevalence and camp 4 the lowest (3%) seroprevalence to combined PfAMA-
1 and PfMSP-119. Parasite prevalence detected by peR was 6 fold lower than the 
combined P. jalciparum antigen seroprevalence, which ranges from 0-1.39%, with 
highest prevalence in camp 3 (Table 4.5). 
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Table 4.5 Percentages of study popula on seroposi ve to P./a/ciparum and prevalence 
infec on measured by ROT and peR 
P. /a/ciparum 
ROT peR (AMA+MSP) 
Camp Number %(+ve) Number %(+ve) +ve/Number % (Cl) 
tested tested tested 
1 507 0 137 0 16/501 4 
(2-6) 
2 507 0 137 0 46/504 9 
(7-11) 
3 505 0 505 1.39(7) 23/505 4 
(2-5) 
4 496 0 130 0.77(1) 12/496 3 
(1-4) 
5 507 0.2(1) 142 0 50/507 11 
(7-15) 
Total 2522 0.04(1) 1051 0.76(8) 147/2,513 6 
(5-7) 
128 
4.3.2.3.1. Age seroprevalence of P. !alciparum 
Overall, seroprevalence of antibodies to the two P. !alciparum antigenswas very low. 
The data do not show a clear increase with sero-positivity and age in any camp except 
camp 2 (Table 4.6) where seroprevalence significantly increases with increasing age 
p>0.001 (logistic regression). Estimated SCR values of each P. !alciparum antigen are 
given in appendix 9. 
Table 4.6 Seroprevalence to combinedP. ja/ciparuman gens in each age group in each camp 
Camp Age group P.jalciparum(AMA+MSP) 
(years) +ve/ Number Percent (Cl) 
Adezai(l) 1-5 4/167 2.3(0-5.1) 
5-20 5/168 4.0(0-8) 
>20 7/166 5.5(1-9.3) 
Baghicha(2) 1-5 2/168 1. 7(0.0-4.0) 
5-20 9/168 5.2(1.0-9.4) 
>20 35/168 20.7(14.4-27) 
Jalala(3) 1-5 6/167 2.6(0.4-4.7) 
5-20 9/170 3.9(1-6.5) 
>20 8/168 4.3(1.3-7.5) 
Kaghan(4) 1-5 1/161 0.5(0-1.4) 
5-20 5/168 3.4(0.0-7.0) 
>20 6/167 4.6(0.8-8.0) 
Zangal 1-5 17/169 11.0(5.4-16.0) 
Patai(5) 5-20 17/168 13.0(6.4-19.0) 
>20 16/170 8.5(4.0-12.0) 
Total 1-5 30/832 3.1(1.9-4.3) 
5-20 45/842 5.9(3.9-7.8) 
>20 72/839 8.9(6.9-10.9) 
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Table 4.7 Es mated seroconversion rates (SCR) for P. /olciporumusing combined an gens 
(PfAMA+PfMSP) for each camp 
P·falciparum 
Camp SCR(Cls) Estimated EIR's based on PfMSP-119 
1 0.002(0.002-0.004) 0.003 
2 0.007(0.005-0.009) 0.040 
3 0.003(0.002-0.005 ) 0.007 
4 0.002(0.001-0.003 ) 0.003 
5 0.008(0.006-0.011) 0.060 
Overall 0.005(0.004-0.005 ) 0.030 
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4.3.2.3.2. P. !alciparuman body tres and age groups by camp 
Figure 4.7.A suggest no clear pattern of increase in median values of titres for PfAMA-l 
with increasing age, but except for campl the median titre shows little increase with 
age. According to Figure 4.7.B, a very little increase in median the PfMSP-119 
antibodies titre values with age group in case of camp 1 but again no clear increase of 
titres with age in case of other four camps (2-5) was observed. The detail of oneway 
ANOVA is given below: 
PfAMA-l: Camp 1 with F= 16.3, p<O.Ol; camp2 with F= 13.53, p<0.24; camp 3 with F= 
0.36 p<0.7; camp 4 with F= 6.18, p<0.02 and camp 5 with F= 0.73, p<O.5 (figure 4.4. B). 
PfMSP-ltg : Camp 1 with F= 12.53, p<O.Ol; camp 2 with F= 1.51, p<O.3; camp 3 with F= 
4.46, p<O.Ol; camp 4 with F=3.08, p<O.OS and campS with F= O. 107, p=0.9 (figure 4.4. 
B). 
Camp 5 median antibody titre was very low (about two third of the individuals had 
negative antibody titre) which is not consistent with median antibody titre with other 
four camps. To check the validity of the camp 5 data the EUSA assay and analysis were 
repeated twice but similar results were obtained. These unusual results for camp 5 
may be due to handling of the blood spots during collection and storage or may be due 
to other reasons. 
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4.3.3. Comparison of serological and parasitological measures 
4.3.3.1. Plasmodium vivax 
ROT vs peR 
A comparison of the performance of PCR and ROT in detecting P. vivax infection is 
shown in Table 4.8. As expected the nested PCR test identified more positive infections 
than by ROT and it was used as the gold standard to calculate the sensitivity of ROT. 
The ROT had shown a sensitivity of 81.1% (95% Cl: 71.7%-88.4%) and a specificity of 
93.4% (95% Cl: 91.6%-94.9%). A positive predictive value (PPV) of 55% (95% Cl: 46.4%-
63.4%) and a negative predictive value (NPV) of 98% (95% Cl: 96.9%-98.8%) with 
observed Roe value 0.9. 
Table 4.8 Comparison of the performance of ROT using PCR as a standard 
P. vivQX ROT 
PCR Pas. Neg. Total 
Pas. 77 63 140 
Neg. 18 893 911 
Total 95 956 1,051 
P. vivQX Sensi vity Speci city PPV NPV ROC 
(95% Cl) (95% Cl) (95% Cl) (95% Cl) (95% Cl) 
ROT 81.1 93.4 55 98 0.9 
(71.7 -88.4) (91.6-94.9) (46.4-63.4) (96.9-98.8) (0.8-0.9) 
• Sensi vity is the propor on of diseased pa ents correctly iden ed. Speci city is 
the propor on of healthy pa ents correctly iden ed. 
• ROC (Receiver Opera ng Characteris c curve) area is the average of sensi vity and 
speci city 
• PPV & NPV (posi ve and nega ve predic ve values) show the probability of pa ent 
having the disease with a po si ve test or not having the disease with a nega ve test 
respec viely. 
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4.3.3.1.1. ROT vs. An bodies responses 
P. vivax prevalence measured by ROT was compared with the immune response 
against P. vivax antigens (Table 4.9). 59.4% of ROT positive individuals had antibodies 
to one or other P. vivax antigens (AMA+MSP). 35.4% of the PvAMA-l seropositive 
samples were ROT positive, while 53.9% individuals of ROT positive were PvMSP-119 
positive (see appendix 12). These data suggest that the sensitivity (serological 
detection of parasite positive samples) of PvMSP-119 was higher than PvAMA-l. 23%, 
11% and 28% of the ROT negative individuals were seropositive respectively to AMA-l, 
MSP-119 and combined (AMA+MSP). 
4.3.3.1.2. peR vs. An body responses 
By comparing P. vivax immune responses with parasite prevalence measured by peR, 
32.2 % parasite positive individuals were detected by PvAMA-l. 39.9 % of PvMSP-119 
seropositive individuals were parasite positive. It was evident from the data that 
PvMSP-119 is more sensitive to detect parasite positives individuals than PvAMA-l 
(detailed in appendix 13). In case of PvMSP-119 significantly (p<O.OOI) more parasite 
positive individuals were seropositive than seronegative, while for PvAMA-l more 
parasite positive by both peR and ROT individuals were seronegative. 
By combining both antigens, the sensitivity of the ElISA assay was increased from 
32.2%{PvAMA-1} and 39.9% (PvMSP-119) to 50.0% to detect parasite positive 
individuals (peR), which were more likely seropositive with P<O.OI (chi squared test). 
50% of the parasite positive individuals detected by peR were seropositive against 
both P. vivax antigens (AMA+MSP) and 33.9% individuals seropositive to both antigens 
were parasite negative (Table 4.10). 
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Table 4.9 Number and percentages of ROT posi ve and an -vivax seroposi ve individuals 
Combined ROT nega ye ROT posi ye Pva/ue 
(AMA+MSP) 
Seronegative 72.06 %(1741) 40.62 %(39) <0.01 
Seropositive 27.94 %(675) 59.38%(57) 
Table 4.10 Number and percentages of PCR posi ve and seroposi ve individuals against 
combined P.vivax an gens 
Combined PCR nega ve PCR posi ve Pvalue 
(AMA+MSP) 
Seronegative 66.01%(600) 50%(70) <0.01 
Seropositive 33.99 %(309) 50%(70) 
4.3.3.1.3. Associa on of P. vivaxprevalence measured by ROT and PCR 
and P. vivax seroconversion rate (SCR) in camps 
The data suggest a strong association between SCR (estimated from PvAMA-1 
seroprevalence data) and ROT (R2=0.6) but the association was found to be very week 
for PCR (R2=0.2). While PvMSP-119 prevalence has a strong association with ROT 
(R2=0.9) and moderate with PCR (R2=0.S). The correlation between SCR (estimated 
from combined antibody responses to both antigens, i.e. (PvAMA+PvMSP) and parasite 
prevalence (ROT and PCR) was also moderate (R2=0.5). The scatter plots of relationship 
between infection prevalence and SCR are given in Figure 4.10 and R squared values 
are given in table below. 
RZyalue 
P.vivax ROT PCR 
AMA 0.6 0.2 
MSP 0.9 0.5 
AMA+MSP 0.5 0.5 
136 
A B .. ~ C 
~ ~, ;j 12 C I g • 0- I .. ~ I 4 . ~ 'ii • > 'i ~ > ~ e Q. ~ ! ~ • 0; ! ! 'i It .. :~ I! ! I! :! .. ~ .. Cl. ! 11. ! I I I I I • 0.00 0.01 0.02 0.03 0.04 0.05 0.000 0.005 0.010 O.oHIi 0.020 0.025 0.030 0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 
SCRlAMA) SCR(MSP) SCR(AMA+MSP) 
• ROT \I + ROT 181 • ROT 11 .. I I I 0 E F 15 _ 15 _ 15 
.... ~ .... 0-0-In I 
g 12 h 
:!! 12 
I ! " . " ..'i I ;;; I > 9 ! > I > 9 " ! e a. ... Q. .. ! I ~ ... 6 "ii • .. 6 e I I! I I! I • .. ... .. 11. 11. 
0 0 
0.00 0.01 0.02 0.03 0.04 0.06 0.000 0.005 0.010 0.015 0.020 0.025 0.030 0.00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 
SCR(AM A) SCR(MSP) SCR(AMA+M SP) 
+ PCR 
• peR • peR 
Figure 4.8Relationship between P.vivax infection prevalence (measured by ROT and peR) and seroconversion rate (SCR) in camps 
The above scatter plots show the association between prevalence of P. vivax infection measured by ROT and PCR and SCR estimated from age seroprevalence of PvMSP-119 and 
PvAMA-1. Plot A to C represents relationship between P. vivax infection measured by ROT and SCR of PvAMA-l(A), PvMSP-119 (8), PvAMA-l+PvMSP-119 (e) and plots 0 to F 
represents association between P. vivax infection measured by PCR and SCR of PvAMA-l(O), PvMSP-l19 (E), PvAMA-l+PvMSP-119 (F). 
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4.3.3.1.4. Prevalence of infec on vs. Es mated EIR 
The scatter plots (figure 4.9) show the association between estimated EIR based on 
SCR values and prevalence of P. vivax infection measured by ROT and PCR, the 
relationship was linear (R2=O.7) and (R2=O.6) respectively. 
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Figure 4.9Rela onship between es mated entomologic inocula on rates (EIRs) based on the 
SCRplo ed on linear scale and prevalence of infec on of Plasmodium vivax measured by 
both ROT and PCR. 
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4.3.3.1.5. Comparison between parasite prevalence and an body tres 
against P. vivax in each age group 
The data shows higher PvAMA-1 and PvMSP-119 titres in individuals who were ROT and 
peR positive compared to negative samples (figure 4.10 A and B). 
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Figure 4.10Box plot showing rela onship between an body tres PvAMA-l and (A) ROT, (B) 
PCR prevalence by age group 
The middle horizontal line of the bar represents the median of the log transformed an body 
res, while the top of the box above the median is 75th percen le and below the median the 
bo om of the box is 25th percen le. Both boxes represent 50% of the an body tres. The 
maximum and minimum an body tres are the whiskers of the plot. An body tres are log 
transformed. 
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Again antibody response (log transformed titres) to PvMSP-119in ROT/PCR positive is 
higher than ROT/PCR negative individuals. 
A. ROT and PvMSP-119 
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Figure 4.11Box plot showing rela onship between an body tres of PvMSP and (A) ROT and 
(B) PCR prevalence by age group 
The middle horizontal line of the bar represents the median of the log transformed an body 
res, while the top of the box above the median is 75 th percen le and below the median the 
bo om of the box is 25 th percen le. Both boxes represent 50% of the an body tres. The 
maximum and minimum an body tres are the whiskers of the plot. An body tres are log 
transformed. 
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Figure 4.12Comparison between parasite prevalence measured by ROT and an body tres 
against (A) PvAMA-l and (B) PvMSP-119 bycamp 
The middle horizontal line of the bar represents the median of the log transformed an body 
res, while the top of the box above the median is 75 th percen le and below the median the 
bo om of the box is 25 th percen le. Both boxes represent 50% of the an body tres. The 
maximum and minimum an body tres are the whiskers of the plot. An body tres are log 
transformed. 
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Figure 4.13Comparison between parasite prevalence (measured by ROT /PCR) and an body 
tres (PvAMA and PvMSP) bycamp 
The middle horizontal line of the bar represents the median of the log transformed an body 
res, while the top of the box above the median is 75 th percen le and below the median the 
bo om of the box is 25th percen le. Both boxes represent 50% of the an body tres. The 
maximum and minimum an body tres are the whiskers of the plot. Where an body tres 
are log transformed. 
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4.3.3.2. Associa on between serological and parasitological measures 
for P./a/ciparum in Afghan refugee camps of KP 
Due to low prevalence of P. falciparum clear relationships between parasite 
prevalence and seroprevalence were difficult to observe. The figures show relationship 
of parasite prevalence (measured by ROT and PCR) in all age groups and SCR are given 
in appendix 11. 
4.3.4. Seroprevalence pa erns between P./a/ciparum and P.vivax 
67.9% of the studied population was seronegative to all antigens used and 2.9% were 
seropositive to both P. falciparum andP. vivax antigens (Table 4.11). In case of PfMSP-
119 and PvMSP-119 0.3% individuals were seropositive to both antigens, while 2.2% 
individuals were positive to both AMA-1 antigens (PfAMA-1 and PvAMA-1). 0.2% of 
studied people were seropositive to both antigens of falciparum (Table 4.13), while 
6.3% individuals were seropositive to both vivax antigens (Table 4.12). 
Table 4.11Percentages of the studied popula on seroposi ve to neither, either or both 
species 
N=2,S08 P. vivax (AMA+MSP) 
P./alciparum(AMA+MSP) Seronega ve Seroposi ve 
Seronega ve 67.9(17020) 26.3(659) 
Seroposi ve 3(74) 2.9(73) 
Table 4.12Percentages of the studied popula on seroposi ve to neither, either or both P. 
vivax an gens 
N=2,513 PvMSP-119 
PvAMA-l Seronega ve Seroposi ve 
Seronega ve 70.7(1777) 5.7(142) 
Seroposi ve 17.2(432) 6.3(158) 
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Table 4.13Percentages of the studied popula on seroposi ve to neither, either or both P. 
/alciparuman gens 
N= 2,514 PfMSP 
PfAMA Seronega ve Seroposi ve 
Seronega ve 92.9(2335) 1.7(42) 
Seroposi ve 3.8(95) 0.2(6) 
In this study 6.45%(8) individuals P.vivaxparasite positive detected by RDT (Table 4.14) 
and 9.5%(16) P.vivax peR were seropositive to P'/alciparum antigens (Table 4.15). 
Table 4.14 Number and percentages of P. vivax ROT posi ve and seroposi ve individuals 
against, an ·P. /alciparum 
P./alciparum P.vivax 
(AMA+MSP) ROT nega ve RDTposi ve Pvalue 
Seronega ve 94.3 %(2278) 93.6%(88) 0.7 
Seroposi ve 5.7 %(139) 6.4 %(8) 
Table 4.15 Number and percentages of P. vivax peR posi ve and seroposi ve individuals 
against, an ·P./alciparum 
P./alciparum P.vivax 
(AMA+MSP) PCR nega ve PCR posi ve Pvalue 
Seronega ve 95.6%(866) 90.5%(124) 0.01 
Seroposi ve 4.4%(43) 9.5%(16) 
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4.3.4.1. Cross reac vity between the equivalent an gens of P. vivax and 
P. Jalciparum 
Scatter plots ofPfAMA-1 vs. PvAMA-1 (Figure 4.14) and PfMSP-119 vs. PvMSP-119(Figure 
4.15} were used plot to check the credibility and validity of the data, whether there is 
cross reactivity between the antigens. Antibody responses against equivalent antigens 
of P. vivax and P. /a/ciparum obtained from the dataset of this study do not show any 
evidence of cross reactivity . 
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4.4. Discussion 
Results presented in this chapter are from the malaria epidemiological study 
undertaken in the Afghan refugee camps designed to compare different methods for 
estimating malaria transmission intensity in the different camps. The study included 
measures of parasite infection (ROT and PCR) and serological prevalence of both P. 
falciparum andP. vivaxmalaria in all age groups. The main reason of this study was to 
use serological and parasitological measures to provide up-to-date information on 
exposure to malaria and infection in the study area and compare camps on the basis of 
these measures. Transmission intensity observed in this area is very low making it 
potentially suitable for malaria elimination. However, there are little accurate, current 
data available and any new data will help guide and plan control efforts. 
The field investigations of parasite prevalence included CareStart™ Malaria HRP-
2/pLDH (Pf/pan) Combo Test detecting the Plasmodium falciparum specific antigen 
histidine-rich protein (HRP-2) and the pan-Plasmodium antigen lactate dehydrogenase 
(pLDH). All the ROT used in the field worked according to the information provided by 
the manufecturer except for only three ROT cassettes, which I repeated. A sub set of 
120 ROT negative samples and all ROT positive were tested for parasite infection by 
PCR (Snounou et al., 1993a), to measure submicrosopic infection and to validate ROT 
results. All samples underwent serological analysis for antibody responses to AMA-l 
and MSP-119 against both P. falciaprum and P. vivax. 
4.4.1. Plasmodium vivax 
4.4.1.1. Prevalence of infec on measured by ROT and peR 
The overall prevalence of P. vivax infection detected by ROT was 4% and ranged from 
4.0-9.0%, being highest in camp 3 and lowest in camp1. This difference in the 
prevalence of P. vivaxinfection in different studied camps (when measured by ROT) is 
highly significant with p< 0.0001 (pearson's chi2). While the overall prevalence of P. 
vivax infection measured by PCR observed was 12%, which ranged from 4% (camp 4) 
to 15% (camp3). The difference in the P. vivax prevalence among different camps is 
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weakly significant when measured by PCR (p< 0.05) and highly significant when 
estimated by ROT (p< 0.01). 
One likely explanation for the observed differences in the prevalence of infection 
between the camps might be, the difference in the geographical location of the camps 
(close to rivers and rice fields etc.) and prevalence differences in vector 
abundance(Rowland and Nosten, 2001). Another possible explanation for the detected 
variation in the prevalence of vivax infection among the camps may be due to 
differences in the use of ITN, there prevalenceand/or previous malaria control 
activities and malaria awareness in the camp. For example there were fewer people 
using ITN in the people of camp 3 and 5 as compared to other camps (this will be 
described in more detail in the following chapter). 
Another likely reason for the observed heterogeneity in the prevalence of infection 
among camps may be the historically higher prevalence of malaria in some camps. This 
higher exposure may have led to development of partial immunity in the individuals, 
which is effective at controlling parasite densities. For example in the present study 
the camp (3) in which prevalence of infection was found to be high (9.0% by ROT), had 
lowest Annual Vivax Incidence (AVI) (BHU data) in the past as compared to other 
camps, while the camp (1) which has now lowest prevalence of infection (0.4% by 
ROT), was one of the camps experienced high Annual Vivax Incidence in past (BHU data 
appendix 14). 
Although the surveys were carried out at different months of the year (June 23rd_ 
September 19th, shown in table 1 of chapter 2) in different camps, but comparison of 
infection prevalence at different study sites was possible as the first cases of P. vivax 
malaria were observed to happen much earlier, mainely in April (Rowland et al., 
1997a). However, the prevalence of infection observed for studied camps is consistent 
with the number of cases recorded at the BHU. These results also are in agreement 
with previous studies (Rowland et al., 2001), representing P. vivax the major species of 
malaria as compared to P. falciparumhas been successfully reduced (Rowland et al., 
2002b) after major epidemics seen in early 1990s in Afghan refugee camps. 
PCR detected a higher number of parasite positive individuals than ROT as expected, 
which is consistent with other studies (Harris et al., 2010, Okell et al., 2012, Oke" et al., 
147 
2009). A review on the submicroscopic infections hypothesized that in lower 
transmission areas infections on average are older and more likely developed to 
submicroscopic phase, while in high-transmission areas repeated infections and 
superinfection may results in the increase of average parasite density in an infected 
individuals (Okell et aI., 2012). Another likely explanation for the high prevalence of 
submicroscopic infections could be the frequency of G6PO deficiency in the Afghan 
population, which wouldreduce parasite growth. Finally high rates of infection may be 
due to location of the refugee camps along the rivers, on marshy places or rice fields 
that support vector breeding sites (Leslie et aI., 2010). 
In this study some of the ROT P. vivax positive individuals (18/94) were missed by PCR, 
similar findings are also reported by other studies (Osman et aI., 2010). One of the 
likely reasons for the discordance between ROT and PCR might be the false positive 
results by ROT, as were reported in Sudan (Osman et aI., 2010). According to some 
studies false positive ROT results (poor specificity) were due to cross-reactivity with 
rheumatoid factor in blood and heterophile antibodies, but replacement of IgG with 
IgM (malaria) in recent products are thought to reduce this problem (Wongsrichanalai 
et aI., 2007). While some of the ROT are designed to detect antigen rather than live 
parasites, which means detecting previous exposure (older infection) rather than 
recent infection. 
However, a study conducted in Afghanistan to evaluate the performance of three 
types of malaria ROT, showed 98.6% sensitivity and 0% false positive results (100% 
specificity) for the same type of ROT (CSPfPan) used in this study (Mikhail et aI., 2011). 
Another study for the evaluation of malaria ROT in a reference setting recorded 90.2% 
sensitivity at a parasite densities 500/~1 and 100% specificity for P. vivax{WHO, 2011b). 
According to these studies the malaria ROT used in the present study was sufficiently 
consistent and reliable, to make it appropriate for P. vivax predominant region. 
Another alternative reason for the discordance between PCR and ROT might be the 
limited sensitivity of conventional PCR, which is affected by using small amount of 
blood used for detection and PCR sensitivitymay also be affected by not removing PCR 
inhibitors (e.g. chelex) during DNA extraction. Some studies also reported DNA 
degradation due to enzymatic activities, which will affect PCR sensitivity (Rodulfo et aI., 
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2007). Stratifying by age group prevalence of infection (ROT and PCR) was higher in 
children (1-5) and in individuals with age 5-20, lowest in adults (20+years) as was 
expected (fig.4.1). 
4.4.1.2. Serological Data 
Since this study was to be conducted in a low transmission area the corresponding 
immune responses were expected to be low. Therefore to detect low level of exposure 
to parasite, the blood stage antigens AMA-l and MSP-119 were selected based on 
previous studies (Drakeley et al., 2005, Corran et al., 2007, Bousema et al., 2010c, 
Cook, 2010, Cook et al., 2010). As discussed earlier in Chapter 3 blood stage antigens 
were found to be relatively more suitable for detection of low levels of exposure to 
malaria than pre-erythrocytic stage antigens (CSP and lSA) (Drakeley et al., 2005, 
Orlandi-Pradines et al., 2006, Bousema et al., 2010c, Cook, 2010). 
To enhance the sensitivity of serological measure of MTI responses to both AMA-l 
and MSP-119 (AMA+MSP) were combined as in aprevious sero-epidemiological study 
conducted in Somaliland which is a similar low transmission area (Bousema et al., 
2010c). We needed to measure antibody response to combined antigens so if an 
individual did not react to one antigen, then reaction to another antigen may be 
detected. This was done for both P. vivax and P. !alciparumresponses. 
To minimize chances of cross reactivity between immune responses to malaria and 
other parasites, recombinant proteins (representing single antigens) were used as 
cross reactivity have been reported when whole parasite extract was used (Abramo et 
al., 1995, Naus et al., 2003). In this study no relation in antibody titers between the 
homologous antigens of P. !alciparum andP. vivax was observed (Fig.4.14 and 4.15). 
Additionallyl tested samples at significantly higher dilutions (1/1000), as previous 
studies suggested less chances of cross reactivity at a high dilution (1:80) of sera 
(Bousema et al., 2010c, Abramo et al., 1995). Moreover, a suitable cutoff to 
differentiate seropositive individuals from seropnegative, was drived from within the 
study sample to minimize bias caused by local cross-reactive antigens (Bousema et al., 
2010c). 
Defining cutoff values is critical for interpretation and the modeling approach to 
seroprevalence data used here. Ultimately the splitting of a population into antibody 
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positives and negatives is an arbitrary process, so it is important to make the criteria 
for this partition, as clear as possible, and to define when particular criteria will be 
appropriate. For example a cutoff value calculatedusing a mixture model needs a 
substantial proportion of a seronegative population in the antibody responses, which 
is less likely in high transmission areas as almost all individuals will have high antibody 
levels. In such a high transmission population the cutoff value will be overestimated, 
resulting in underestimation of seroprevalence. Some loss of sensitivity may also occur 
when including parasite positive individuals (some of whom may have developed low 
antibody responses in response to infection and in whom existing basal antibody levels 
will be enhanced). Since OD and titre distributions are usually quite asymmetrical, a 
slight change in cutoff in a population with few clearly positive individuals may result in 
a large change in the proportion of defined positives. The use of sample sets from 
malaria unexposed populations (often Caucasian) to establish parameters for normal 
unexposed distributions in populations from very different environments is also 
problematical as malaria exposed populations often differ markedly in other 
characteristics - totallgG levels in Africa, for instance, or exposure to a range of other 
parasites which may cross-react non-specifically with malaria antigens. Since groups of 
samples from malaria endemic populations which can be guaranteed to be malaria 
unexposed are difficult to identify let alone obtain, one or other of the two alternative 
approaches of mode ling exposed populations or using controls of doubtful validity 
must be employed. Since exposure in Afghan refugee populations is relatively light as 
demonstrated by the parasite data, I have used mixture modeling, in which the 
unexposed population is assumed to have a normally distributed set of ODs 
(admittedly based on information from unexposed Caucasian populations) and the 
exposed population is approximated by a second Gaussian. Cutoffs are based solely on 
the parameters of the Gaussian fitted to the putative non-exposed individuals. 
The cutoff estimation based on mixture model was suggested suitable in low 
transmission areas where majority of the population is supposed to be seronegative 
(Cook, 2010). Therefore this model was used to calculate cutoff in this study as the 
camps are coming under low transmission areas of Pakistan and existing BHU data 
suggests low incidence of clinicle disease too. 
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4.4.1.2.1. Seroprevalence 
Overall seroprevalence to combined P. vivax antigens (AMA+MSP) was 28% 
(732/2517), antibody responses to individual P.vivax antigens. In children with age less 
than or equal to five seroprevalence to combined P. vivax antigens (AMA+MSP) was 
15% (113/732), while in older individuals (>20) it was 58% (424/732). Of all anti-vivax 
seropositive children of under five age group, 49% (55/113) were belonging to camp 3, 
where the lowest seroprevalence i.e., 6% (6/113) in children under five was observed 
in camp1. The seroprevalence data was in line with the infection data (ROT and PCR), 
-which also shows camp 3 with high prevalence of vivax malaria as compared to other 
studied camps. 
In this study the number of children with ~ 5 ages having titres greater than 300 was 
35 and 57 in case of anti-PvMSP and anti-PvAMA respectively, suggesting that these 
children may have had a recent infection or have hypnoloites. The serological data 
presented here provided strong evidence that there is ongoing local P. vivax 
transmission due to seropositive children under age five. As in previous studies 
conducted in low endemic areas, such as Costa Rica and Somaliland, strong antibodies 
responses in children with age less than five (indirect fluorescent antibody titres ~ 20 
in Costa Rica and ElISA antibody titres >200 to falciparum in Somaliland) were used as 
an evidence for active transmission of malaria (Bousema et al., 2010c, Warren et al., 
1976, Warren et al., 1975). The data also suggest that there must have been vivax 
malaria transmission and exposure in the last 5 years due to high antibody responses 
in older age group individuals. This data is in agreement with BHU data of the camps. 
By comparing both antigens, seroprevalence to PvAMA-1 was high than to PvMSP-119, 
which is consistent with other studies (Drakeley et al., 2005, Stowers et al., 2002, 
Polley et al., 2004). 
4.4.1.2.2. Age seroprevalence and seroconversion rates 
The age stratified curves for combined P. vivax antigens (AMA+MSP) showed a clear 
pattern of increased sero-prevalence with age for all camps except camp 5. In camp 5 
there is seen a uniform seropositivity across the population. The high proportion of P. 
vivax seropositive individuals in younger age groups made the data difficult to fit to the 
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conventional seroconversion model in camp 5.This indistinct pattern of age 
serprevalence for camp 5 is because of the PvMSP-119 data. A similar unclear age 
seroprevalence profile was also observed for P. vivax anti-MSP-119 for camp 3(see 
appendix 8). The ELlSA assay was repeated to confirm the reproducibility of the results 
and double check to validate the data but the results were the same as previously 
observed. 
Such unclear age seroprevalence profile, when a" ages of the population are equally 
exposed to malaria for a defined period, are thought to be the result of an epidemic in 
an area (Cook, 2010). An alternative explanation for the observed high seropositivity in 
young children in camp 3 and 5 may be the presence of antibodies cross-reacting with 
antigens from other infectious agents such as leishmaniasis (cases are reported in this 
camp previously) or toxoplasmosis(Naus et al., 2003, Abramo et al., 1995). 
Moreover the prevalence of infection detected by PCR among individuals aged 1-20 
years was higher in camps 3 and 5 as compared to other camps (number of positives in 
1-20 age group out of total positives was 62/79 and 17/23 in camp 3 and 5 
respectively). And prevalence of infection (ROT and ROT) also showed a significant 
association with PvMSP-119 as compared to PvAMA-1(Pearson's chi2=0.9, P=O.4 for 
AMA and for MSP chi2= 47 P<0.001), which means that PvMSP-119 positive individuals 
were more likely to be parasite positive. This is suggesting that PvMSP-119 might be the 
marker of recent infection and PvAMA-l more of a cumulative marker of exposure in 
the study area. 
However, according to previous studies, PfAMA-1 reflects recent exposure and 
antibodies against PfMSP-119 saturate over longer periods of exposure representing 
cumulative risks (Orakeley et al., 2005, Stowers et al., 2002, Po"ey et al., 2004). On the 
contrary, results from this study suggesting that parasite positive individuals are more 
likely to have antibodies to PvMSP-119 in the studied population rather than PvAMA-
1.Although, the influence of hypnoloites in P. vivax infections (i.e. relapses) on 
serological profiles is also unknown (Bockarie and Oagoro, 2006). 
Visual assessment of the age seroprevalence plots of combined antigens against P. 
vivaxfor camp 4 showed a poor fit of the model, for the age groups between 10 and 
20, where seroprevalence was lower than predicted, suggesting a change in 
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transmission at this point. Such outliers in the seroprevalence curves may also be due 
to non-exposure of older people (In malaria free pre-war times in Afghanistan due 
intensive malaria control before Russian invasion in Afghanistan in 1978) and an age-
dependent immune responses may not be primed if exposure is in later life. 
Age seroprevalence curves for combined antibody responses to P. vivax antigens 
(AMA+ MSP) give better fits than looking at individual antibody responses to PvAMA-1 
or PvMSP-119, which are given in appendix 7. PvAMA-1 showed a clear increase of 
seroprevalence with age as compared to PvMSP-119• But when examing the P.vivax 
MSP-119 antibody titres, there is seen a little increases with age, except in camp 3 the 
titre was high in children (age group 1-5) as compared to older age group (>20). 
Age-specific sero-prevalence rates were used to estimate SCR which is an equal 
probability of a seronegative individual to become seropositive in a given interval of 
time at a rate A year-1, with the probability being a function of the immunogenicity of 
the antigen and the likelihood of being infected (Corran et al., 2007). A seroconversion 
rate (SCR) was calculated using a reversible catalytic model for each of the five Afghan 
refugee camps. The combined camps P. vivax seroconversion rate (A) was estimated 
approximately 0.03. Our estimates of age-specific seroprevalence rates (SCR) of P. 
vivax demonstrate that there is heterogeneity in transmission across the studied 
camps, with camp 3 having high and camp1 have lowest SCR value, ranged from 0.01-
0.07. Which are approximately equivalent to less than 0.12 to more than 3 infectious 
bites per person per year (EIR) for individual P. !alciparum antigen. These estimation of 
EIR is based on the previously published survey (Corran et al., 2007), where SCR values 
were used to derive an estimated EIR values. 
4.4.2. Plasmodium jalciparum 
4.4.2.1. Prevalence of infec on measured by ROT and peR 
Overall P. !alciparum parasite prevalence was very low; 0.04 % by RDT with only one P. 
falciparum infection positive individual in camp 5. Infection prevalence was 0% by PCR 
in three camps, with only one positive individual (0.7%) in camp 4 and 1.3% in camp 
3(7 positives). Of the 8 PCR positive individuals, 4 were children under five (Table 4). So 
whilst these results suggest a very low prevalence of P. !alciparum but suggesting 
ongoing transmission. 
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The prevalence of P. !alciparum infection in adults (age>30), suggests carriage of 
submicroscopic infection. As P. !alciparum infections are associated with high 
morbidity but these positive individuals had no historyof fever (fever history was 
collected during survey), these may represent submicroscopic asymptomatic 
infections. 
The infections in children under five are perplexing as dogma suggests that these 
children would have little immunity and any infection would lead to illness with fever 
and/or infection detected by ROT. There are several possible explanations for these 
observations; firstly these results may be false positive due to peR 
contamination. However, the positive samples were not adjacent or on different peR 
plates suggesting no systematic contamination. Secondly, a recent work on 
submicroscopic malaria infections in different settings,suggested that the prevalence 
of submicroscopic infections in children and in low-transmission areas reflected that 
parasite-suppressing immune responses may develop more efficiently and infections 
may be older and more likely attained a submicroscopic phase as compared to 
infections in high transmission areas (Okell et aI., 2012). 
Overall, however the data presented here are consistent with the decline in disease 
burden of falciparum malaria in the last decade documented previously for the studied 
Afghan refugee camps in KP by BHU of the 2004-2009 (see appendix 14). Although 
direct comparison to previous BHU data is considerably limited as the data is passive or 
clinical data (the annual number of cases recorded by Afghan refugee BHU) and the 
present study was active surveillance. Previous studies in Afghan refugee camps in KP 
also has shown that P. !alciparumis more successfully reduced by interventions 
(IRS/ITN) than P. vivax, due to limited effects interventions have on relapses (Rowland 
et aI., 1997a). 
The survey was conducted before the transmission season (June-September) of 
falciparum malaria, so this might be another reason of zero % or extremely low (in two 
camps by peR) parasite prevalence, as falciparum malaria infections peaks later 
(October-November) in the year (Rowland and Nosten, 2001). The first new cases of 
falciparum malaria can be usually seen in late August, although BHU recorded cases in 
May and June. But the number of cases of falciparum malaria in the studied camps by 
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BHU ranged from 0-5 in the last 6 years (2004-2009), which is in agreement with low 
prevalence of falciparum infection observed by this study. 
4.4.2.2. Serological Data 
4.4.2.2.1. Seroprevalence 
P. !alciparumseroprevalence to PfAMA-1 and PfMSP-119 was 4.4% and 2% respectively 
(detailed in appendix 3). Antibody levels for Children under age five seropositive to 
PfAMA-1 where antibody titre ranging from 5-4308 indicates that there is likely to be a 
very low ongoing local falciparum transmission. However no children of age group 1-5 
were found seropositive to PfMSP-119 except in camp 5 (antibody titre ranged from 63-
1325), showing no ongoing transmission (see appendix 3). 
Overall seroprevalence to combined anti-falciparum antigens (PfAMA+PfMSP) 
observed was 6% (147/2513), but none of these individuals had clinincl infection. 
Among the 147 individuals who were seropositive for P. !alciparum antibodies 
(AMA+MSP), 30 (20%) were children under the age of five years suggestive of recent 
malaria exposure. Over 56% (17/30) of these children were from camp 5. Sero-
prevalence in the oldest age (>20) group was 49% out of the total 147 seropositive 
individuals. 
In previous studies conducted in low endemic areas Costa Rica and Somaliland strong 
antibodies responses (indirect fluorescent antibody titres ~ 20 in Costa Rica and ElISA 
antibody titres >200 to falciparum in Somaliland) were used as an evidence for active 
transmission of malaria {Bousema et al., 2010c, Warren et al., 1976, Warren et al., 
1975}. In our study the antibody level (titre) in children under five who were 
seropositive ranges from 6-4308. Seven out of thirty seropositive children of age ~ 5 
had high antibody titres ranges from 550-4308 to P. !alciparum, thus presenting more 
evidence of recent infection. These titres are not directly comparable due to the 
differences in antigen used, different study populations and technique used to 
measure antibody levels (ElISA and IFAT) in the above-mentioned studies. However, 
these high levels of titre in children having age less than five suggesting that kids with 
high antibody titres are likely to be a result of recent infection, especially if positive to 
both antigens used against P. !alciparum. 
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The study revealed extremely low levels of falciparum malaria detected by serology at 
all study sites which are consistent with the parasitological data of the study and 
available basic health unit records of malaria (Iow AFI from 2004-2009 appendix 14). 
low seroprevalence was even observed in adults (>20 years), which suggests that may 
be P. /alciparum transmissionwas never very high in the study area or in the group 
resident here. low overall seroprevalence (6%) and with very little evidence of age 
specific increase in the seropositive individuals or titre is suggesting that there is no 
ongoing transmission. But due to presence of sub-ROT P. /aciparum infection and few 
reported cases by BHU year before the survey (2009), suggesting that there is still very 
low ongoing transmission of P. /aciparum in the camps. 
It is widely considered that antibody responses require repeated exposure to become 
established at detectable level in low transmission areas. On the other hand may be 
due to low transmission intensity in the area, many individuals would be more likely to 
lose their anti-falciparum antibodies that were previously acquired before building up 
to detectable level. Or the IRS campaign that was in placed during 1990s may be one of 
the reasons to reduce exposure to malaria, or may be other malaria control 
programme (ITN) helped to control the level of falciparum malaria. Due to very low 
falciparum malaria transmission intensity in the study site and the presence of malaria 
vectors make it potentially more susceptible to malaria epidemics. For example several 
epidemics were recorded among refugees in the 1990's, over 150 000 cases were 
being diagnosed and treated each year by the combined health services of the UNHCR, 
the government of Pakistan and NGO (Rowland, 1999a, Rowland and Nosten, 2001). 
The number of cases has declined as control measure took effect (Rowland et al., 2002 
b). 
The P. /alciparum seroprevalence showed evidence of heterogeneity with camp 5 
showing the highest seroprevalence (11%) and camp 4 showing the lowest (3%) among 
the five camps. These regional differences were statistically significant with 
p>0.01(using Pearsons chi2 test) for all P. falciparum antigens (PfAMA, PfMSP and 
combined anti-pf antigens). Variability in the AFI among the camps was observed in 
the BHU data and also in serology data from this study. 
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4.4.2.2.2. Age seroprevalence and seroconversion rates 
Because of extremely low overall seroprevalence of P. Jalciparum no clear increased of 
sero-prevalence with age was observed. Therefore age stratified curves for P. 
Jalciparum showed little increase in seroprevalence with age to combined antigens 
(AMA+MSP). Age seroprevalence curves for each of the P. Jalciparum antigen showing 
little increase of seroprevalence with age (AMA-l) to no increase (MSP-119) (see 
appendix 5 and 6 respectively). In areas where transmission has been consistently low 
for many years a loss in seropositivity in older individuals may result in uniform 
seropositivity across the population; masking any change point in transmission. 
Previous sero-epidemiology study conducted in Tana (Vanuatu) also suggested that in 
areas of very low transmission, models use to assess an increase in seropositivity with 
age may be inappropriate (Cook, 2010). In a situation where age seroprevalence 
reveals little information, investigation of antibody titres may be more useful (Cook et 
aI., 2010). But using antibody titres to study an increase in seropositivity with age was 
also uninformative except for camps 1 and 2 using PfMSP-119 data as no clear pattern 
of increase of antibody titres with age for PfAMA-l was observed. 
Estimated transmission intensity based on SCR for P. Jalciparum varied very little from 
camp to camp, where camp 2 and 5 had high SCR values than the rest of the camps. 
The P. Jalciparum seroconversion rate (A) for all the camps combined was estimated to 
be approximately 0.005. There is no obvious evidence of recent changes in 
transmission. In a similar transmission setting in Somaliland Bousema et aI., described 
SCR of 0.005 for PfAMA-l and 0.008 for PfMSP-119.These seroconversion rates were 
considered to be equivalent to an EIR of >0.1 using a validated model to relate age-
specific seroconversion rate to EIR (Corran et aI., 2007). In this study SCR value for 
PfAMA-l is higher compared to PfMSP-119, which are 0.003 and 0.001 respectively. 
4.4.3. P. vivax vs. P. /a/ciparum 
It is widely held in Pakistan that P. Jalciparum constitutes less than 30% of all malaria 
infections, and 70-90 % of malaria infections are caused by P. vivax in this study 
population (Rowland et aI., 1997a). However, these data needed to be confirmed, as P. 
vivax infections are often missed during routine clinical microscopy. The data from this 
study confirmed that P. vivax is the predominant malaria in the area. This is similar to 
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areas of low transmission intensity where P. vivaxprevalence is also found higher than 
P. falciparum (Noor et al., 2011). The possible reasons given for this difference in the 
prevalence of the two mentioned malaria species are: 
Firstly, the presence of infected hypnozoites in liver in case of P. vivax which would not 
be detected by microscopy and difficult to clear these hypnozoites as G6PD deficiency 
makes the P. vivax control challenging. Monthly BHU malaria data from these Afghan 
refugee camps also showed that there is monthly fluctuation of P. vivax over the 
season but not of P. falciparum. The fluctuation of P. vivax seen throughout the year 
may be due to different life cycle of P. vivax in which hypnozoites remain in infected 
liver cells for long time and cause relapses months or years later. Secondly different 
susceptibility of malaria vectors may also be the reason for differences in transmission. 
An increase in P. vivax cases has been also reported in areas where P. falciparum 
transmission appears to be on the decline (Noor et al., 2011, Stewart et al., 2009, 
Stowers et al., 2002). One possible explanation given is that immunity developed to 
one species of plasmodium affect the acquisition of immunity to the other species 
(Gamage-Mendis et al., 1991, Maitland et al., 1996). Some studies suggested that due 
to cross stimulation of immune response falciparum could be suppressed by the 
presence of vivax (Haghdoost and Alexander, 2007, Maitland et al., 1996, Nagao et al., 
2008, Whitehorn et al., 2010). The high P. vivax seroprevalence seen in children under 
five may be due to the fact that clinical immunity is rapidly acquired for P. vivax than 
for P. falciparum(Maitland et al., 1996). 
4.4.4. Associa on of serological, parasitological measuresand EIR 
Estimates of SCR showed a strong relationship with estimates of parasite rate of P. 
vivax (when detected by ROT) for individual antigens i.e. PvMSP-119 or PvAMA-l and 
also when both antigens were combined (PvAMA+PvMSP) for P. vivax (Fig.4.11). The 
relationship was found very weak between PCR detected parasite rate and SCR when 
looking at the individual antigens, for AMA-1 and MSP-119(Fig.4.11). But the 
relationship was observed moderate (R2=0.5) between parasite rate detected by PCR 
and SCR (estimated from seroprevalence to combined antigens (AMA+MSP)) although 
with a greater degree of scatter (Fig.4.11). A strong relationship was also observed 
between SCR and parasite prevalence detected by microscopy (Cook, 2010). This 
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indicates the utility of the serological assay for detecting level of malaria endemicity in 
different study sites. The relationship between P. !alciparum parasite rate and SCR 
could not be determined as the parasite rate was 0% and was extremely low when PCR 
based detection was used. 
The resulted EIR values for the camps may not be as accurate as was calculated for 
Tanzanian data but may be indicative of EIR in the study sites. Firstly due to 
unavailability of the model based on P. vivax SCR values to estimate EIR. Secondly as 
mentioned above the estimation of EIR was made on the basis of using single P. 
!alciparum antigen PfMSP-119 and I estimated SCR by combining antibody responses to 
both P. vivax antigens (estimated SCR values for individual P. vivax antigen are given in 
appendix 10). Moreover,Plasmodium vivax, a species with relapses and as serology do 
not "count" the number of relapses which may also lead to overestimation of EIR using 
seroconversion rates for P. vivax. 
Approximately 59.4% of the P. vivaxantibody positive individuals were parasite positive 
detected by ROT and 50% of individuals were both seropositive and parasite positive 
when detected by PCR. The sensitivity of serological measure to detect parasite 
positive person is higher when ROT is used compared to PCR andmay reflects that ROT 
detects higher density of parasite than PCR. It may be more likely about the fact that 
the PCR positive individuals have lower parasite densities and these may not have 
induced detectable immune response that is detected by PCR. 
The sensitivity of available P. vivaxantigens to detect parasite positive individuals is 
less than the P. !alciparum according to some previous studies. For example a study 
carried out in Cambodia have shown only 42% sensitivity of P. vivax antigens to detect 
currently P. vivaxinfected individual and P. !alciparum showed92% sensitivity (Cook, 
2010). While in Korea when five antigens (circumsporozoite protein (CSP-1), 
merozoite surface protein (MSP-1), apical merozoite antigen (AMA-l), serine repeat 
antigen (SERA), and exported antigen (EXP-1)) were combined sensitivity of P. vivax 
antigens. was increased to 80%, as using one antigen was not sufficient to detect 
infection of P. vivax(Kim et al., 2003). However according to a study conducted in 
Brazil the sensitivity was 90% (Rodrigues et al., 2003). In Iran (bordering Pakistan), 
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which is also P. vivax dominant area, the sensitivity was recorded 81% using PvAMA-
l(Haghi et al., 2012). 
Possible explanations for the lack of reactivity observed in some of the parasite 
positive individuals to the P. vivax antigens in the above mentioned studies are, firstly, 
there may be comparatively more allelic polymorphism in P. vivax strains than there 
are in their P. !alciparum homologues. So possible the antigens used here were not 
suitable for this population. A Brazilian study however, showed that the DNA 
sequences encoding MSP-119 were conserved in P. vivaxisolates as compared to the 
equivalent region of other species of Plasmodium. Amino acid sequences of PvMSP-
119 from Southeast Asian and Latin American strains showed only one amino acid 
substitution (Pasay et al., 1995). However, it is unknown whether this single 
substitution is of immunological significance (Soares et al., 1999). Previous studies 
have also shown that there may be a good response of antibodies to different strains 
of P. vivax, as antibodies are directed mainly to conserve epitopes present in both 
allelic forms of the protein (Soares et al., 1999). The gene coding for AMA-1 is highly 
conserved among Plasmodium spp. of rodents, monkeys, and humans. However, 
intra-species unlinked single base substitutions are observed in some regions of the 
gene (Figtree et al., 2000). Secondly, may be many individuals have few infections of 
P. vivax as compared to P. !alciparum as specific antibodies do not build up to a 
detectable level. Alternatively, the parasite positive individuals who did not respond 
to PvAMA-1 and PvMSP-119may produce antibodies to different antigens of the 
parasite (Cook, 2010). 
Sensitivity of the assay was low to detect parasite positive assay in this study, which 
can be increased further by inclusion more antigens in the future in the study area. 
Both serological and parasitological data revealed low levels of vivax and extremely 
low level of falciparum malaria, therefore carefully planned control programmes can 
further reduce transmission in the these camps. Furthermore, continual surveillance 
and monitoring interventions can finally lead control to elimination. 
On the other hand reduction seen in the antibody levels especially in case of 
falciparum malaria symbolising reduction (loss) in the clinical immunity. Several 
reviews have discussed the possible devastating effects of reducing exposure to 
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transmission in young ages and on population immunity levels (Askjaer et al., 2001, 
Ghani et al., 2009). However, a study on submicroscopic infection challenged the 
common assumption that individuals with little previous exposure to malaria have a 
limited immune response against parasites (Okell et al., 2012). The study suggested 
that prevalence of submicroscopic infections in the individuals with little past exposure 
to malaria develops parasite-suppressing immune response more efficiently than 
commonly assumed (Okell et al., 2012). However, whether these low levels of antibody 
responses will result to reduction in the clinical immunity still remains to be seen in the 
study area. 
On the other hand, low malaria transmission intensity detected by this study and the 
presence of malaria vectors may increase chances of epidemics of malaria, as recorded 
previously in the Afghan refugee camps in Pakistan (Rowland and Nosten, 2001). Such 
epidemics were thought to result in a high mortality rate in resource-poor areas like 
the studied camps (Guthmann et al., 2007), especially when there are no outbreak 
detection systems (Coleman et al., 2008). 
Low levels of parasitimia detectable only by PCR are thought to be able to restart 
transmission in favourable conditions. For example in Sudan, during the long dry 
season prevalence of infection detected by microscopy were reported zero but some 
PeR-positive cases result in resurgence of transmission in the rainy season (Roper et 
al., 1996). Therefore, for successful control, survey of the prevalence of asymptomatic 
cases in the camps is vital in many malaria settings (Karl et al., 2011). It is also assumed 
that the prevalence of submicroscopic infections in an area may reflect recent 
transmission dynamics of malaria, that a high prevalence of submicroscopic infections 
may suggest a recent decrease in transmission(Gatton and Cheng, 2010). 
For effective control and elimination of malaria, determination of its transmission and 
burden is obviously crucial. Although, identification of possible risk factors of malaria 
and assessment of its relationship with infection and exposure can benefit further 
prevention and control strategies in the area. These are discussed in detail in the next 
chapter with spatial analysis of malaria infection and exposure to identify hot spots of 
malaria within the camps for more focal malaria control. 
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Chapter Five 
To iden fy behavioural and residen al risk factors of 
malaria exposure and infec on in the refugee camps 
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Chapter 5. To iden fy behavioural and residen al 
risk factors of malaria exposure and infec on in 
the studied camps 
The results presented in this chapter are from the household survey described in 
previous chapters. This is the first ever malaria prevalence and risk factor survey based 
on individual and household characteristics in this area. The aim of this study was to 
identify possible risk factors of malaria and to assess its relationship with infection and 
exposure to malaria in order to benefit prevention and control strategies in the area. 
The study mainly focused on individual characteristics (fever history, traveling history 
and protection from mosquitoes) and the household characteristics included 
household construction material, roof, floor, eaves, windows, toilet facilities, and socio 
economic status as potential risk factors. Therelationship of individual risk and 
household characteristics to the number of malaria infections and seroprevalence 
were examined. The study also assessed the coverage of interventions such as net 
ownership, ITN use and spraying of the household in last 12 months with insecticide. 
As previously stated KP is charact~rized as a low malaria endemic area (Bouma et al., 
1996a, Rowland et al., 1997a), where malaria is seasonal and the majority of 
transmission occurs after monsoon (July-August). The prevalent malaria vectors are 
Anopheles stephensi and Anopheles culicifacies, which mainly breed in river pools, river 
edges and irrigated fields. Monsoon rainfall offers additional larval habitats, which 
have the potential to increase malaria transmission. The Afghan refugee camps are 
commonly situated on marginal land, many of them are waterlogged or adjacent to 
rice cultivation, rivers andstreams, therefore proximal to mosquito breeding sites 
(Rowland and Nosten, 2001). 
Afghan refugees were provided with tents when they first arrived in Pakistan after the 
Russian invasion in 1978. Soon refugees· constructed their homes and walled 
compounds from mud and stone in the local Pakistani villages style (Christensen, 
1998). Mud houses, thatched roof, non glazed windows and presence of eaves in the 
living rooms are a poor barrier to vector mosquitoes. In the hotter humid summer 
months (transmission season of malaria) most of people prefer to sleep outdoors in 
163 
the courtyard which most likely to increase man-vector contact(Rowland et al., 2002 
b). 
Malaria transmission and prevalence are determined by local ecological conditions, 
which can vary from village to village (Ye et al., 2007, Ramachandran, 2010). Previous 
studies conducted to identify the "local" risk factors for malaria transmission 
investigated travel history (cases can be introduced from other areas), (Moore et al., 
2004, Osorio et al., 2004, Joshi et al., 2006), proximity to water bodies (Bousema et al., 
2010c), forest malaria (Cook, 2010), and socio-economic conditions (Ramachandran, 
2010). 
Malaria has always been most endemic in rural areas and a major challenge to control 
compared with urban areas worldwide. For successful control and elimination of 
malaria at community level, it is important to take into account human behaviour, 
socio cultural and economic context through active partiCipation and changing of risk 
behaviour of the community (Williams and Jones, 2004, Opiyo et al., 2007). This study 
aims to assist control programmes by providing information about socio-economic and 
behavioural risk factors of malaria in the study area. 
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5.1. Material and methods 
5.1.1. Laboratory method 
ELlSA was performed as described in chapter 2 and antibody responses were detected 
against antigens from both P. !alciparum andP. vivax. PCR for malaria parasite species 
detection and for detection of sub-ROT infections was also conducted. 
5.1.2. Sta s cal analysis 
The data analysis for the study was done using STATA version 12 using the survey 
. command (svy) with camps as the strata and household as the primary sampling unit. 
Univariate and multivariate logistic regression model was used, to investigate whether 
socio-economic and demographic factors as a risk factors of malaria prevalence of 
infection and exposure in the studies population. The outcome (response) variable was 
the presence or absence of malaria using the ROT, PCR and combined antibody 
responses to P.!alciparum (response to either PfAMA-l or PfMSP-119) and P. vivax 
(response to either PvAMA-10r PvMSP-119). Potential risk factors tested in the models 
were: age in years, sex, travel history, malaria fever history, house construction 
(roofing material, wall material, floor material, presence of eaves and window glazing), 
recent or regular bed net use, insecticide residual spray, and use of repellents or coils 
and socio-economic status (SES) as an indicator of household wealth. To determine the 
effect of each exposure variable on the outcome variable (prevalence of infection and 
seroprevalence) univariate analysis was performed. Any exposure variable significant 
with ps 0.05 in univariate analysis was used in multivariate analysis (Wald test). The 
final multivariate modal includes only significant exposure variable with pS 0.05. 
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5.1.2.1. Measurement of socio-economic status 
Principle component analysis (PCA) is a multivariate statistical 'data reduction' 
procedure used to reduce a set of correlated variables in a data set into a set of 
uncorrelated smaller 'principal components' which represent unobserved 
characteristics (Vyas and Kumaranayake, 2006, Howe et al., 2008). 
PCA can be represented mathema callyas: 
For example, from a set of variables Xl through to Xn, 
where amn represents the weight for the mth principal component and the nth 
variable(Howe et al., 2008). 
Principal component analysis (PCA) was used on household asset ownership data to 
measure socio-economic status in this study. Used guideline for PCA for wealth indices 
were published elsewhere (Vyas and Kumaranayake, 2006, Armstrong Schellenberg et 
al., 2008, Howe et al., 2008). 
Household assets ownership data was analysed using Stata (version 12, College 
Station, Texas,USA) to create household wealth index. The Socio economic status of 
household was the weighted sum of household characteristics including whether they 
owned the consumer durables such as a television (Tv), fridge, radio, bicycle, mobile, 
animals, poultry and whether they used wood for cooking, whether they had mains 
electricity, the type of house construction, roof (iron roof/thatched roof), floor 
(cemented/mud) and toilet. Principal Components Analysis (PCA) on the correlation 
matrix generated weights for the assets in the index. Households were categorized 
into one of five equal sized groups from the most poor to the least poor (Armstrong 
Schellenberg et al., 2008). Summarized data was presented in Table 5.2. 
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Table 5.1 Assets ownership for households in each socio-economic status quin le 
Wealth quintile 
Percentage(number) l(Most 2(very 3(Poor) 4(less 5(least Total 
of households poor) poor) poor) poor) 
having assets 
Households 22.3%(188) 16.6%(140) 17.8%(150) 20.9%(176) 22.5%(190) 844 
Tv 0.8(2) 0.8(2) 3.8(10) 29.9(78) 64.8(169) 30.9(261) 
Fridge 0 0 2.4(6) 27.3(68) 70.8(175) 29.5(249) 
Radio 2.9(18) 21.4(133) 19.3 (120) 26.5(165) 29.9(186) 73.7(622) 
Bicycle 9.7(69) 19.5(138) 20.5(145) 24.4(173) 26(184) 84(709) 
Mobile 18.4(146) 17.4(138) 18.9(150) 21.8(173) 23.7(188) 94.2(795) 
Electricity 22.2(187) 16.6(140) 17.8(150) 20.9(176) 24.5(892) 99.8(842) 
Chickens 21.6(175) 15.6(126) 18.5(149) 21.3(172) 23.1(187) 95.9(809) 
Animals ownership 17.4(71) 1.2(5) 30.6(125) 23.2(95) 27.6(113) 48.5(409) 
Fuel (electricity/gas) 0 0 33.3(3) 22.2(2) 44.4(4) 1.1(9) 
House construction 3.5(2) 5.7(3) 5.2(3) 10.3(6) 75.9(44) 6.9(58) 
Toilet{flush system) 1(2) 0.5(1) 2.8(6) 24.2(51) 71.6(151) 25(211) 
Floor 3.1(2) 3.1(2) 7.7(5) 15.4(10) 70.7(46) 7.7(65) 
Roof 1.2(3) 0 5.8(14) 22.6(55) 70.4(171) 28.8(243) 
The table is showing the number and percentages of household assets from the most poor to 
the least poorquin le. Household characteris cs/assets including ownership of Television 
(Tv), fridge, radio, bicycle, mobile, animals, poultry and type of fuel used for cooking (wood, 
dung, kerosene oil or electricity/gas) whether they had mains electricity, the type of house 
construe on (brick and stones or mud, roof (iron roof! thatched roof), oor (cemented/mud) 
and having ush toilet system. 
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5.2. Results 
The total number of households surveyed was 845 in 5 camps. Overall 2526 individuals 
were examined for recent malaria infection by ROT and blood samples were taken on 
filter paper for molecular diagnosis of malaria and serological analysis. Data about 
fever history, travelling history, ITN use and personal mosquito protection was 
collected from each study individual, no missing data was found except for the ELlSA 
data, which was due to discordant ODs and applied to a total of 11 samples which 
were discarded. 
Table 5.2Detail and division of poten al risk factors for malaria in the camps 
Individual and Household/residen al risk Vector control 
Behavioral risk factors 
factors 
Age House construction Insecticide residual spray (IRS) 
Sex Roof Insecticide treated bed nets (ITN) 
Travelling history Eaves ITN Used last night before survey 
Fever history Windows glazing Personal Mosquitoes Protection 
Treatment history socio-economic status (SES) 
Animals ownership 
The factors in the Table 5.2 were included in the study to see its effect on the infection 
prevalence and seroprevalence of malaria. Individual or behavioral risk factors 
included age {1-5, 6-20 and above 20 age groups), sex, fever history (fever in last 24 
hours or two weeks prior to survey), treatment history (sought treatment or not, 
treatment centre including BHU/govt.hospital/private clinic/pharmacy/field worker, 
antimalarial taken in last two weeks before survey), travelling history (travelling 
outside of district in last 3 months before the survey, returned from recent trip 
including returned within two or four weeks) or ITN used last night prior to survey. 
Household risk factors were comprised of household construction (house build of 
bricks and stones or mud), roof material (iron rods or thatched grass), Windows 
glazing,socio-economic status by quintile (SES) and Animals ownership. While vector 
control measures included to study were, IRS (IRS within 12 months), ITN ownership 
and personal protection from mosquitoes (use of mosquitoes coil, can spray or 
repellents). 
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Demographic and vector control measures informa on 
All infections of malaria detected by RDT were Plasmodium vivax with 4% prevalence 
(96/2522). peR was done on selected number of samples, which detected 12% of 
infection positive individuals (140/1051). Majority of P. vivax infections were found in 
females 60.7% (85/140) when measured by peR, but there were only marginal 
differences of P.vivax infections between male (49/96) and female (47/96) when 
measured by ROT. Seroprevalence was higher in females than in males to both P. vivax 
(66%) and P. /alciparum (58%). Data collected on the use of malaria vector controls 
measures is shown in Table 5.3, where 48.6% of individuals reported having ITN in the 
camps with 28.6% people having used ITN the night before the survey. 
Table 5.3Vector control measures used in refugee camps 
Camp Adezai Baghicha Jalala Kagan Zangal Total 
(1) % (2)% (3)% (4)% patai (5) % % 
IRS within 12 4.2 2.4 7.8 2.4 10.5 5.4 
months 
ITN Ownership 32 78.7 47.6 65.9 20 48.6 
ITN Used Last 16 63.7 3.2 51.4 9.3 28.6 
Night 
Personal Protec on Measures used against vector 
NO 19.5 47.3 68.9 50.6 56.2 48.S 
Coil 76.3 52 30.5 46.3 39 48.9 
Insec cide spray 2.4 1 0 0.6 2.4 1.2 
(can) 
Repellents 1.8 0 1 2.4 2.4 1.4 
The table is showing percentages of households who plot IRS in the last 12 months prior to 
survey, owned ITN, use of ITN previous night before survey and vector control measures 
used for personal protec on which included mosquitoes coils/spray cans/repellents. 
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5.2.1. Risk factors of malaria in study area 
5.2.1.1. P.vivax infec on and risk factors 
S.2.1.1.1. Univariate Analysis 
A full list of factors investigated for association with the prevalence of P. vivax by ROT 
and peR are shown in Tables 5.4 and 5.5 respectively. 
Individual or behavioral risk factors 
The prevalence of P. vivax infection detected by ROT decreased with increasing age (in 
age group >20 the OR= 0.4, p<O.Ol). Women were less likely to be parasite positive 
than men when infection measured by ROT (ROT, OR= 0.6, p= 0.05) but the difference 
was not significant (p= 0.80) when peR prevalence was used as an outcome variable. 
Individuals with fever history (fever within 2 weeks or 24 hours) were strongly 
associated with parasite prevalence (ROT, OR= 6.4, p<O.Ol; peR OR= 4.6, p<O.Ol for 
fever within 2 weeks and ROT, OR= 13.9, p<O.Ol; peR OR= 6.8, p<O.Ol for fever within 
24 hours). 
Individuals who reported having sought malaria treatment in the past had signifi'cantly 
higher prevalence of infection when detected by ROT but not by peR (ROT, OR= 2.5, p= 
0.024; peR, OR= 2.1 with p=0.067). Administration of antimalarial drugs in the past two 
weeks before the survey was not significantly associated with prevalence of infection 
measured by either ROT or peR. 
Prevalence of P. vivax was lower in individuals who had remained in the camp of 
resident for the last six months (ROT, OR= 0.1, p< 0.02; peR, OR= 0.2, p< 0.01), while 
outside travel within 3 months from the resident camp and returning from recent trip 
were not significantly associated with increased prevalence. 
Risk factors related with household 
Individuals living in a household built of bricks were less likely to be parasite positive 
(peR, OR= 0.3, p<O.OS). Household construction type (mud/brick) was not significantly 
associated with ROT positivity. While roof constructed of iron roof and sheets was a 
significantly associated with lower risk of P. vivax infection when detected by ROT, OR= 
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0.4, p<0.01; but was non-significant when detected by peR (Table 5.4). Individuals 
living in a room with no eaves were most likely P. vivax ROT negative (ROT, OR= 0.4, 
p<0.01; peR OR= 0.5, p<0.01) than the individuals sleeping in room having eaves (Table 
5.4). Window glazing was not significant risk factor of malaria in the studied camps by 
both measures. In univariate regression analysis the prevalence of P. vivax infection by 
both ROT and peR decreased if individuals were from the least poor households SES 
bracket compared to those from the poorer households (ROT, OR= 0.2, p<0.01; peR 
OR= 0.3, p<0.01) (Table 5.4). 
Factors related to limit and control vector 
The use of ITN on the night prior to survey was associated with protection from P. 
vivax infection (ROT, OR= 0.2, p<0.01; peR OR= 0.5, p<0.02). ITN ownership was not 
significantly associated with ROT prevalence of P. vivax infection. ITN in the house 
significantly associated with increased risk of P. vivax infection when detected by peR 
(OR= 1.6, p<0.03) (Table 5.4). Using of mosquitoes coils/spray can or repellents for 
protection from mosquitoes were significantly associated with the decreased 
prevalence of P. vivax when infection was measured by ROT (OR= 0.2, p<0.01) but the 
association was not significant when detected by peR. IRS within 12 months was not 
significant between those with and those without vivax infection. 
5.2.1.1.2. Mul variate variate Analysis 
The details of multivariate logistic regression analysis for risk factors and prevalence of 
vivax infection detected by ROT and peR are given in Tables 5.4 and 5.5 respectively. 
The multivariate regression model showed a significant association ofP. vivax infection 
(detected by both ROT and peR) and stay in the camp of residence since last 6 months 
before the survey, previous and current fever status (fever within 24 hours/fever 
within two weeks) and last night ITN use age of individual. SES of household was a 
significant risk factor of vivax parasite prevalence in the camps only when infection 
detected by peR, while sought malaria treatment and use of mosquito coils/repellents 
were significantly associated with the vivax infection when detected by ROT. 
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Table 5.4 Univariate and mul variate analysis for prevalence of P. vivax in fee on diagnosed 
by ROT 
P.vivax (ROT) Univariate Mul variate 
Risk factors OR p< OR p< 
Age groups 
1-5 1 1 
6-20 0.8(0.5-1.3) 0.35 0.8(0.5-1.2) 0.25 
>20 0.4(0.2-0.7) 0.01 0.3(0.2-0.6) 0.01 
Sex 
Male 1 
Female 0.6(0.4-1.0) 0.05 
Stay last 6 months in the camp 
No 1 
Yes 0.1(0.0-0.7) 0.01 0.2(0.04-0.7) 0.02 
Fever in the previous 24 hours 
No 1 
Yes 13.9(5.7-34.3) 0.01 10.6(3.1-36.8) 0.01 
Fever in the previous 2 weeks 
No 1 0.01 
Yes 6.4(3.61-1.3) 0.01 47.6(15.3-147.9) 
Sought malaria treatment before 
No 1 
Yes 2.5(1.1-5.5) 0.02 0.1(0.02-0.2) 0.01 
Roof 
Thatched grass 1 
Iron sheets and rods 0.4(0.2-0.7) 0.01 
Eaves 
Open 1 
Closed 0.4(0.2-0.7) 0.01 
SES (Most to least poor) 
1 1 
2 0.4(0.2-0.9) 0.03 
3 0.6(0.3-1.3) 0.17 
4 0.5(0.2-1.0) 0.04 
5 0.2(0.1-0.3) 0.01 
ITN last night 
No 1 
Yes 0.2(0.1-0.5) 0.01 0.1(0.1-0.5) 0.01 
Using coil/repellents/spray can 
No 1 
Yes 0.3(0.2-0.5) 0.01 0.3(0.2-0.6) 0.01 
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Table S.S Univariate and mul variate model for prevalence of P. vivax infec on detected by 
PCR 
P.v;vax (PCR) Univariate Mul variate 
Risk factors OR p< OR p< 
Age groups 
1-5 1 
6-20 1.3(0.8-2.2) 0.25 
>20 1.0(0.6-1.7) 0.90 
Stay last 6 months 
No 1 1 
Yes 0.2(0.1-0.6) 0.01 0.4(0.2-0.9) 0.03 
Fever in the previous 2 weeks 
No 1 1 
Yes 4.6(2.5-8.3) 0.01 3.5(1.8-7.0) 0.01 
Fever in the previous 24 hrs 
No 1 1 
Yes 6.8(3.0-15.1) 0.01 4.6(1.8-11.6) 0.01 
Household construe on 
Mud 1 
Bricks/Stones 0.3(0.1-1.0) 0.04 
Eaves 
Open 1 
Closed 0.5(0.3-0.9) 0.01 
SES (Most to least poor) 
1 1 1 
2 0.6(0.3-1.2) 0.16 0.6(0.3-1.3) 0.21 
3 0.5(0.3-1.0) 0.04 0.6(0.3-1.2) 0.23 
4 0.6(0.4-1.1) 0.08 0.5(0.3-1.0) 0.07 
5 0.3(0.2-0.6) 0.01 0.3(0.2-0.7) 0.01 
ITN ownership 
No 1 1 
Yes 1.6 (1-2.3) 0.04 2.4(1.5-3.8) 0.01 
ITN last night 
No 1 1 
Yes 0.5(0.2-0.9) 0.02 0.2(0.1-0.6) 0.01 
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5.2.1.2. Risk factors for P. vivax exposure 
5.2.1.2.1. Univariate Analysis 
Initial univariate analysis (weighted for sampling probability and adjusted for clustering 
by using svy command in Statal identified the following factors associated with 
antibodies responses to vivax malaria (Table 5.6). 
Individual or behavioral risk factors 
Being in an older age group i.e. >20 (OR=7.3, 95% Cl 5.6-9.4, p<O.Ol) and females 
(OR=1.7, 95% Cl 1.3-2.0,p<0.Ol) were strongly associated with the likelihood of being 
seropositive to P. vivax. Individuals who travelled outside of the resident camp within 3 
months (OR=1.9, 95% Cl 1.5-2.5, p<O.Ol) and ones who returned back to camp from 
travelling within 2 or less than 4 weeks were more likely seropositive (OR=2.4, 95% Cl 
1.8-3.3, p<O.Ol and OR=1.8, 95% Cl 1.1-2.9, p<0.02 respectively). Fever within two 
weeks before survey (OR=3.2, 95% Cl 2.2-4.6, p<O.Ol), individuals who sought malaria 
treatment after having malaria infection (OR=3.5, 95% Cl 2.3-5.2, p<O.Ol), and 
individuals who taken antimalarial drugs within last two weeks before survey (OR=2.9, 
95% Cl 1.9-4.5, p<O.Ol) were significantly associated with increased P. vivax 
seroprevalence. 
The analysis showed no association between P. vivax seroprevalence and individuals 
who had remained in the camp of resident from the last six months and fever within 
24 hours prior to survey. 
Risk factors related with household 
In the residents of households; having eaves in living room (OR=3.4, 95% Cl 1.5-7.8, 
p<O.Ol) and non glazed windows (OR=7.3, 95% Cl 5.6-9.4, p<O.Ol) were associated 
with significant increase in seroprevalence. Individuals sleeping with animals in the 
same courtyard (OR=1.6, 95% Cl 1.3-1.9, p<O.Ol) were also found with increased risk of 
P. vivax serolprevalence. The analysis showed no association between P.vivax 
seropositivity and roof material, household construction and SES. 
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Factors related to limit and control vector 
Use of mosquito coils, spray cans or repellents (collectively these are personal 
protective measures against malaria vector) were strongly associated with reduced 
antibody responses toP. vivax (OR=0.6, 95% Cl 0.5-0.8, p<O.Ol) (Table 5.6). There was a 
trend that house spraying within the previous 12 months and sleeping under a net 
previous night was associated with reduced or lower seroprevalence, but this 
relationship was not statistically significant in this study using P. vivaxantibody 
responses as an outcome variable (IRS, OR=.8 with p<0.4 and ITN, OR=O.9 with p<0.23). 
5.2.1.2.2. Mul variate variate Analysis 
The final multivariate model identified increasing age (age group> 20 with OR=7.9, 
p<O.Ol), fever within 2 weeks (OR=1.7, 95% CI= 1.3-2.1, p<O.Ol) and sleeping with 
animals in the same house (OR= 1.6, 95% Cl= 1.3-2.1, p<O.Ol} and Individuals who 
were not using personal protection against mosquitoes (coils, spray cans and 
repellentsO (OR=O.6, 95% CI= 0.5-0.8, p<O.Ol) were associated with increased risk of 
being seropositive against P. vivaxantigens. The detail is given in Table 5.6. 
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Table 5.6 univariate and mul variate analysisP.vivax seroposi vity 
P.v;vox (Seroposi ye) OR Pvalue OR(Mul variate Pvalue 
(Univariate) ) 
Age groups 
1-5 1 1 
6-20 1.9(1.4-2.5) 0.01 1.9(1.4-2.5) 0.01 
>20 7.3(5.6-9.4) 0.01 7.8{5.8-10.5) 0.01 
Sex 
Male 1 
Female 1.7{1.3-2.0) 0.01 
Outside travel within 3 months 
No 1 
Yes 1.9{1.5-2.5) 0.01 
Return recent trip 
No trip 1 
<2 weeks 2.4(1.8-3.3) 0.01 
< 4 weeks 1.8(1.1-2.9) 0.02 
> 4 weeks 1.1(0.7-1.8) 0.7 
Fever in the previous 2 weeks 
No 1 
Yes 3.2{2.2-4.6) 0.01 2.1{1.0-4.7) 0.05 
Sought malaria treatment before 
No 1 
Yes 3.5{2.3-5.2) 0.01 
An malarial drug taken within 
last 2 weeks 
No 1 
Yes 2.9(1.9-4.5) 0.01 
Sleeping in the same courtyard 
with Animals 
No 1 1 
Yes 1.6(1.3-1.9) 0.01 1.6{1.3-2.1) 0.01 
Eaves in living rooms 
Open 1 
Closed 0.8{0.6-1.0) 0.05 
Windows glazed 
No 1 
Yes 0.8{0.6-1.0) 0.03 
Using coil/repellents/spray can 
No 1 1 
Yes 0.6(0.5-0.8) 0.01 0.7(0.5-0.8) 0.01 
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5.2.1.3. P. jalciparum and risk factors 
5.2.1.3.1. Analysis of risk factors and P. jalciparum infec on 
Detailed statistical risk factors analysis for P. !alciparum infection was not performed 
as parasite prevalence by ROT was zero in four of the five the camps except for one 
positive sample in Zangal patai camp (camp 5). Overall prevalence of P. !alciparum 
infection measured by PCR was 0.76% (8/1051) with 7/505 in Jalala camp (camp 4) and 
1/498 in Kagan camp (camp 4) (See Chapter 4 results). 
5.2.1.3.2. Risk factors for P. jalciparum exposure 
Seroprevalence against P. !alciparumcombined antigens (AMA-l+MSP-119) was 6% 
(147/25130). To identify potential risk factors for P. !alciparumseroprevalence a 
regression model was developed using P. !alciparum seroprevalence as the outcome. 
All the detail of significant variables of univariate and multivariate analysis is given in 
Table 5.7. 
5.2.1.3.3. Univariate Analysis 
Individual or behavioral risk factors 
In the univariate logistic regression analysis model, individuals in age group of >20 
were more likely to be P. !alciparum seropositive than the children equal to or less 
than five years age (OR = 3.1, 95% Cl 1.8-4.9, p<O.Ol). Stay in the camp of residence 
from the last six months prior to the survey was significantly associated with reduction 
in seroprevalence to P. !alciparum (OR=O.l, 95% Cl 0.03-0.2, p<O.Ol). Travelling 
outside the camp within 3 months was also associated with increasing P. !alciparum 
seroprevalence (OR=1.9, 95% Cl 1.3-2.9, p<O.Ol). While individuals, returned from trip 
in less than 2 weeks were also found more likely to be P. !alciparum seropositive 
(OR=1.9, 95% Cl 1.1-3.1, p<O.Ol). 
Fever within two weeks before survey (OR=2.0, 95% Cl 1.1-3.8, p<0.02) and individuals 
who sought malaria treatment after having malaria infection (OR=2.0, 95% Cl 1.0-4.2, 
p<O.OS), and individuals who taken antimalarial drugs within last two weeks before 
survey (OR=2.2, 95% Cl 1.1-4.3, p<0.03) were significantly associated with increased P. 
!alciparum seroprevalence. 
177 
Risk factors related with household 
Seroprevalence to P. !alciparum was lower in the residents of households constructed 
of bricks or stone compared to mud (OR= 0.4, 95% Cl 0.2-1.0, p<0.05). Risk of being 
seropositive to P. !alciparum combined antigens was high in individuals sleeping in a 
room with thatched roof made of grasses and palm leaves (OR= 1.7, 95% Cl 0.4-
6.0,p<0.01) and if eaves were present in living room. SES was not a significant risk 
factor for seropositivty to falciparum malaria. 
Factors related with control vector 
The only significant risk factor for P. falciparum seroposi vty (related with vector 
control) was use of repellents/mosquitoes coils or spray cans in the sleeping room, 
which was associated with decreasing likelihood of P. falciparum seroprevalence (OR 
=0.6, 95% Cl 0.5-0.8, p<O.Ol). IRS within last 12 months and use of ITN last night were 
not significantly associated with P. falciparum antibody responses. 
5.2.1.3.4. Mul variate variate Analysis 
In the multivariate model the following exposure variables remained significant (Table 
5.7). 
Individual risk factor: An increase in seropositivity to P. fa/ciparum antigens was seen 
with increasing age (6-20 years: OR =1.8, 95% Cl 1.1-3.1, p<0.03 and >20 years: OR 
=2.8, 95% Cl 1.7-4.5, p<O.Ol). Staying in the camp from last 6 months in camp of 
resident was associated with reduction in seropositivity to P. !alciparum (OR =0.6, 95% 
Cl 0.S-0.8, p<O.Ol). 
Household risk factors: 
Household constructed of bricks or stones was associated with reduce risk to 
P.falciparum seropositivity (OR =0.4, 95% Cl 0.2-0.9, p<0.03). Thatched roofs made of 
grasses and palm leaves were associated with increased risk to P·falciparum 
seroprevalence (OR =1.5, 95% Cl 1.0-2.4, p<O.Ol). Rooms with no eaves were also 
associated with lower risk of being seropositive or negative to P. !alciparum antigens 
(OR =0.6,95% Cl 0.4-1.0, p<O.Ol). 
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Vector control measures: 
Personal protection from mosquito vectors by using repellents or coils or spray cans 
was significantly associated with lower risk of P. !alciparum seropositivity(OR =0.6, 95% 
Cl 0.5-0.8, p<O.Ol). 
Table 5.7 Univariate and mul variate analysis for P./a/ciparum seroposi vity 
P./a/ciparum OR p< OR p< 
Seroposi ve (Univariate) (Mul variate) 
Age groups 
1-5 1 1 
6-20 1.9(1.1-3.2) 0.01 1.8(1.1-3.1) 0.02 
>20 3.1(1.8-4.9) 0.01 2.8(1.7-4.5) 0.01 
Stay last 6 months 
No l(base) 
Yes 0.1(0.03-0.2) 0.01 0.2(0.1-0.5) 0.01 
Outside travel within 3 months 
No l(base) 
Yes 1.9(1.3-2.9) 0.01 
Return recent trip 
No trip 1 
<2 weeks 1.9(1.1-3.1) 0.01 
< 4 weeks 1.7(0.7-4) 0.24 
> 4 weeks 2.1(0.9-4.7) 0.06 
Fever in the previous 2 weeks 
No l(base) 
Yes 2.0(1.1-3.8) 0.02 
An malarial drug taken within 
last 2 weeks 
No 1 
Yes 2.2(1.1-4.3) 0.02 
Sought malaria treatment before 
No l(base) 
Yes 2.0(1.0-4.2) 0.05 
Household construe on 
Mud l(base) 
Bricks/Stones 0.4(0.2-1.0) 0.05 0.4(0.2-0.9) 0.03 
Roof 
Iron sheets and rods l(base) 
Thatched grass 1.5(1.0-2.4) 0.03 1.8(1.2-2.9) 0.01 
Eaves 
Open l(base) 
Closed 0.6(0.4-0.9) 0.02 0.6(0.4-1.0) 0.05 
Windows glazed 
No l(base) 
Yes 0.7(0.6-0.9) 0.03 
Self mosquitoes protec on (coil! repellents! spray 
can) 
No I l(base) 
Yes I 0.6(0.4-0.8) 0.01 0.6(0.4-1.0) 0.03 
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5.2.1.4. P. vivax vs. P. /alciparum seroprevalence and its risk factors 
In the univariate logistic regression model exposure variables, which were statistically 
significant for both P. /a/ciparum andP. vivaxwere included: Age group, outside travel 
within 3 months, return from recent trip (<2week, <4weeks or >4weeks), fever within 
two weeks, antimalarial drug taken within last two weeks prior to survey, sought 
r:nalaria treatment, presence of eaves in sleeping room, presence of glazed windows 
and personal protection from mosquitoes vector (coils/repellents/spraycans). Residing 
for the last 6 months in the camp, households built of bricks or stones and iron sheets 
roof were significantly associated with lower seroprevalence only to P. /a/ciparum (see 
Table 5.7). While sleeping with animals in the same courtyard and being m'ale were 
significantly associated with increased seroprevalence to P. vivax (Tables 5.6). 
In final multivariate logistic regression model, the risk of being seropositive to both P. 
/a/ciparum andP. vivax was increased with increasing age and decreased by using 
mosquitoes coils/ repellents or can spray. However, fever within two weeks prior to 
survey and sleeping with animals in the same courtyard were significantly associated 
with increased seroprevalence to P. vivax but were not statistically significant to P. 
/a/ciparum seroprevalence(Table 5.8). Conversely, the risk factors which were 
significant only in the multivariate logistic regression model of P. /a/ciparum included 
stay last 6 months in the camp of residence, household construction, roof and 
presence of eaves in the sleeping room (Table 5.7). 
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5.3. Discussion 
Results of this chapter are from the population based household malaria survey in five 
Afghan refugee camps of KP, Pakistan which aimed to provide information on the 
potential risk factors involved in exposure and infection of malaria in the study area. It 
is expected that these results will be prove useful in assessing potential malaria risk 
factors and improve the malaria control programs targeting of interventions. 
Logistic regression model was used for the statistical analysis. In this analysis several 
factors relating to demography (age, gender), recent medical history (fever), travel and 
travel history, main material of the room's wall, roof and floor, IRS in the past 12 
months, ownership and use of ITN, use of repellents, animal ownership and SES of 
household were used as a potential risk factors of infection and exposure to both P. 
vivax and P. /alciparum in the study area. Age is well known confounder, was adjusted 
for in all multivariate logistic regression analysis. 
5.3.1. Individual risk factor 
Data from this study show that all age groups were exposed toP. vivax infection, but 
the OR of P. vivax infection when detected by ROT was reduced in age group >20 OR= 
0.4(0.2-0.7), p<O.Ol as compared to children of age of five or less than five years, 
which was consistent with the situation of malaria (mostly P. vivax) in low endemic 
areas (Ramachandran, 2010). The prevalence of P. vivax infection detected by ROT 
amongst children (1-5) was 39.6%, in young age group (5-20) was 43.8% and in 
individuals with age more than 20 years was 16.6%. A previous study in Ethiopia 
suggested that prevalence of malaria infection (mostly P. /alciparum) was highest in 
children and females (Ayele et al., 2012). Another study in Ethiopia also revealed that a 
unit increase in age resulted in 3% reduction in odds of a positive malaria test (Aye le et 
al., 2012). Where in lowland Africa proportion of positive malaria infection (mostly P. 
/alciparum) decreased with increasing age, as immunity thought to build up readily 
due to repeated exposure during childhood (Ramachandran, 2010). 
Serological data for both P.vivax and P./alciparum showed age-dependency in antibody 
responses; an expected result of the acquisition of antibody response with increasing 
age due to repeated exposure (Corran et al., 2007, Bousema et al., 2010c, Cook, 2010), 
which suggests a level of consistency in exposure in the study area. 
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Staying in the camp of resident from the last six prior to survey was associated with 
lower risk of both P. vivax (ROT/peR) and P. /alciparum (antibody responces). 
Travelling history was used to investigate whether movement of local resident to other 
endemic areas was a risk factor of malaria in the camps. Previous studies, in Mexico 
(Oanis-Lozano et al., 2007), Thailand (Sornmani et al., 1983, Fungladda et al., 1987) and 
India (Ramachandran, 2010) also showed the association of malaria and traveling 
history (Oanis-Lozano et al., 2007, Moore et al., 2004, Osorio et al., 2004). Rogelio et al 
suggested the movement of local resident to other neighbouring endemic areas is an 
important risk factor of malaria in low transmission settings (Oanis-Lozano et al., 
2007). These findings of the above mentioned studies from similar low endemic areas 
are similar with results from this study. Similarly, a case-control study conducted in 
Colombia, showed that travelling to an endemic area 8-14 days before disease onset 
was the strongest risk factor for both P. /alciparumand P. vivaxmalaria (Osorio et al., 
2004). 
Survey data showed that risk of being infected with P. vivax (ROT/PCR) was higher in 
the people who had fever within 24 hours or two weeks before the survey was 
conducted as compared to one who had no fever. Individuals with fever were expected 
more likely to be parasite positive. In case of exposure to malaria (antibody responses) 
as an outcome, only fever within 2 weeks prior to survey was associated with P. 
vivaxseroprevalence, as antibody responses represents past exposure to malaria. 
Similarly individuals who were treated against malaria before were also significantly 
associated withP. vivaxinfection detected by both ROT and PCR. 
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5.3.2. Household risk factors 
In the .final multivariate logistic regression household construction (mud), eaves in 
sleeping room and thatched roof made of grasses and palm leaved were significantly 
associated with increased exposure to P. !alciparumexposure (antibody responses), for 
details see Table 5.7. 
Houses built of mud with thatched roof, eaves in the sleeping room, and non glazed 
windows are commonly found to be at significant higher risk for malaria (Ayele et al., 
2012). Because iron roof, houses constructed of bricks are thought to reduce contact 
with the mosquitoes via a reduction in the number of entry points to the house hence 
reduces infection when compared with poorer house structure (Ayele et al., 2012). 
Gamage-Mendis et al. showed that there was significantly (p<O.Ol) higher malaria 
incidence rate (21.2%) in the poorly constructed houses (incomplete, mud, or palm 
walls, and palm thatched roofs) than better constructed houses (bricks/stones) (10.5%) 
(Gamage-Mendis et al., 1991). 
Similarly in Southeast Asian countries, living in poorly built houses (mud, palm walls, 
and palm thatched roofs) were associated with increased risk of malaria that was 
suggested to increase vector-human contact (Arasu, 1992, Oemijati, 1992). For 
example a study in Thailand demonstrated that poor housing conditions (mud, palm 
walls, and palm thatched roofs) increased the risk of malaria 19 fold (Butraporn et al., 
1986). Similarly, in India better housing conditions (bricks walls/cemented or iron 
sheet roof with no eaves) in town was associated with low risk of malaria prevalence 
than ruler areas that were thought to limit access to vector mosquitoes (Dev et al., 
2004). 
Low SES appears was a risk factor for the prevalence of P.vivax infection (PCR). Other 
studies also had shown lower socio-economic factors related to high malaria risk 
(Thang et al., 2008, Cook, 2010, Feachem et al., 2010). SES was also found significant 
risk factor of malaria prevalence in a study conducted in Ethiopia (Ayele et al., 2012). 
This may be due to a variety of factors such as being less able to afford antimalarial 
control measures (IRS, ITN, repellents, fan and poorly built houses as mentioned 
above) to reduce the risk of transmission. Therefore, the risk of malaria might be 
higher for households in a lower socio-economic bracket than higher status, which 
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suggests that the poor are less likely to use these preventative measures mentioned 
above to effectively reduce the spread of malaria. Possible explanation for the 
increased risk of malaria seen in individuals living in a poorly built house and with low 
SES may be a combination effect of both of these risk factors which means may be 
both risk factors are collinear. 
Increased P. vivax sero-prevalence was associated with sleeping of study participants 
with animals in the same courtyard (OR= 1.6, p<O.Ol). However, this association was 
not significant risk factor for P. vivax infection and P. Jalciparum seroprevalence. A 
study carried out in Afghan refugee school children, to examine that cattle might 
protect occupants against malaria through zooprophylaxis, found a significantly 
greater parasite prevalence (15.2%) in children of families that kept domestic cattle in 
house courtyards was observed than among those which did not (9.5%) (Bouma and 
Rowland, 1995). Previous studies conducted in Ethiopiahad also shown that sharing of 
house with livestock increased the risk of fever (Deressa et al., 2007, Graves et al., 
2009). Domestic animals may compound the risk rather than decrease transmission of 
malaria were suggested to support the prediction of Sota-Mogi theoretical model 
(1989), especially, when vectors are zoophilic, rate of infection is low, and a high 
human:cattle ratio (Mathys, 2010, Bouma and Rowland, 1995). 
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5.3.3. Vector control measures 
This cross sectional study collected information only about coverage of Insecticide 
Residual Spray (number of houses with IRS within 12 months) and did not deal with the 
efficacy of IRS. The percentage of houses that reported having had IRS within 12 
months in all the camps data was 5.4%, ranged between 2.4-10.5 % with lowest 
percentage in Baghicha (camp 2) and highest in Zangal patai (camp 5). According to 
this study, IRS within 12 months was not significantly associated with low prevalence 
of infection or exposure to both P. /alciparum andP. vivax. Possible reasons for the non 
significant association between IRS within 12 months and malaria infection and 
exposure may be that the spraying was not conducted by any governmental 
organization or NGO but by a household head who were not trained. As such they may 
be unaware of the careful choice of insecticide as certain vector species are resistant 
to DOT and organophpsphate insecticide (Rowland and Nosten, 2001) or the proper 
time of IRS which might exerts maximum effect before transmission season (Rowland 
and Nosten, 2001). It may also be that at such low coverage no effect was likely to be 
observed. 
However, previous studies to determine the efficacy of IRS showed 50%-60% 
protective efficacy against P./alciparum and 40%-50% against P.vivax, by using 
malathionand lambdacyhalthrin in the Afghan refugee camps (Rowland et al., 1994). 
Another study conducted in nomadic Afghan refugees showed that spraying tents with 
permethrin lowered the risk of P./alciparum malaria by 66% (Bouma et al., 1996). In a 
comparative study of ItN and IRS in refugee camps in Pakistan and Tanzania, both IRS 
and ITN were observed to be effective (Curtis et al., 1999, Rowland, 1999a). 
The study also collected information about the number of household-owned ITN and 
its use on the night before the survey to determine association of both exposure 
variable (ITN ownership and ITN use night prior to survey) with prevalence of infection 
and exposure to malaria: According to results the overall ITN coverage was 48.6%, 
ranged from 78.7% in camp 2 to in 20% camp 5. This study showed that sleeping under 
ITN on previous night before the survey was associated with lower risk of vivax malaria 
infection (both ROT and PCR). The single night before the survey is unlikely to have not 
accurately captured the net use over a longer period, but can reflect the behaviour of 
people towards ITN use. As these results only deal with the ITN coverage in the camps 
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and its use, they therefore cannot be directly compared with previous studies about 
ITN efficacy in these camps that were based on different design. Secondly, these 
studies were also done at the time when parasite rate may be much higher (as was 
reported previously) as compared to the present studywhen the parasite rate is much 
reduced (BHU data). For example, a previous household randomized trial of ITN in 
Afghan refugee camps in KP, Pakistan had shown 61% protection against P.falciparum 
and 45% protection against P. vivax(Rowland et aI., 1996, Rowland et aI., 1997b). 
Another household randomized trial in Afghan refugee camps where, top sheets, 
blankets and Islamic head-body veils were treated with permethrine, which gave 64% 
protection against P. falciparum and 38% against P. vivax, and these were suggested as 
a good means for short term epidemic control of malaria (Rowland, 1999b). 
A study in Thailand to evaluate the effect of irregular and non use of mosquito nets, 
revealed an increased risk of malaria (2.5 fold) in nonusers, in irregular users (1.5-6.4 
fold) than regular users. According to a review on epidemiology and control in refugee 
camps and complex emergencies, there is very little or no tradition of using net for 
protection against mosquitoes in south and central Asian countries (Rowland and 
Nosten, 2001). Similarly a study in Ethiopia also found low risk of malaria for mosquito 
nets users compared to non users (Ayele et aI., 2012). 
The use of mosquitoes repellents/coils or can spray as a personal protective measures 
were also associated with a reduced risk of vivax malaria infection (ROT) and exposure 
to both P. vivax and P. falciparum. Similarly on several traveller sites (including 
Afghanistan and Pakistan) the most commonly malaria prevention measures suggested 
based on the risk assessment included: drugs used in the prophylaxis of malaria, bed 
net, insect repellent, flying insect spray, mosquitoes coils, long-sleeved clothing and 
specific medicines to prevent malaria (COC, 2012b). However a systematic review of 
trials to determine the role of mosquitoes coils in prevention of malaria found no 
evidence that burning mosquito coils may led to prevention of malaria infection, but 
may reduce the chances of being bitten by mosquitoes (lawrance and Croft, 2004). 
All the three measures ROT/PCR and antibody responses against Plasmodium species 
are different. For example, ROT is commonly used to detect recent infection; PCR is 
used for detection of recent and submicroscopic infections; while antibody responses 
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are used to determine exposure to malaria parasite. But all of them are useful to 
measure malaria transmission and to determine its potential risk factors in an area, 
especially at low levels of transmission, where microscopy and ROT may not be 
sensitive measures of infection prevalence. This study site is a low malaria 
transmission intensity area, where P. falciparum infection prevalence was almost zero 
and P. vivax infection prevalence was very low when detected by ROT. Therefore all 
the three measures together may be useful to represent any likely source of exposure 
and infection to identify potential risk factors of malaria in an area. Similarly, in low 
endemic areas of Somaliland antibody responses were used to detect low levels of 
malaria transmission where microscopy detected no malarial infection but antibody 
responses against both P. falciparumand P. vivax were detected to evaluate ongoing 
malaria transmission (Bousema et al., 2010c). The application of these results to advise 
malaria control programmes of the study area to help in the control of malaria are 
discussed in chapter 6. In which heterogeneity in infection and exposure to malaria 
disease was assessed within the camps and to discuss the risk factors as being 
associated to living in a hot spot of malaria transmission. 
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Chapter Six 
Iden fying hot spots of malaria exposure and infec on 
within the refugee camps 
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Chapter 6. Iden fying hot spots of malaria 
exposure and infec on within the refugee camps 
In this chapter, heterogeneity in infection and exposure to malaria disease was 
determined in the residents of five Afghan refugee camps in KP, Pakistan. To achieve 
this objective, household level GIS data was combined with infection data and 
serological responses to map potential foci of infection. Geographic information 
systems (GIS) data integrated with malaria data may provide a quick display/picture of 
malaria transmission to identify areas of intense or lower than average malaria 
exposure. To analyse and visualizeclusters of malaria transmission, GIS programmes, 
SaTScan and ArcGIS were used. 
Malaria mapping has become increasingly common throughout the worldover the past 
decade to provide a spatial overview of the disease which permits spatial patterns of 
the disease. Aid agencies who are assisting malaria control and elimination both 
financially and technically in malaria-prone countries focusing on the mapping of 
malaria to provide specific spatial information of the disease (Map, 2013, EMRO, 2013, 
WHO, 2011a). Mapping of malaria is done on variety of scales but mostly on 
large/global or country level and the utility of spatial analysis on small admin zone is 
beginning to be used (Bousema et al., 2012). 
The distribution of malaria risk and its burden is unequal within the population 
(Greenwood, 1989, Wool house et al., 1997, Carter et al., 2000). The factors which are 
responsible for the heterogeneity in malaria is not fully described or explored yet the 
most commonly observed factors include, environmental and behavioural factors and 
use of interventions (EMRO, 2001). Although there is spatial heterogeneity in the risk 
of infection, but there is also similar heterogeneity for infectiousness. Because a small 
number of infected individuals can most likely increase transmission by infecting a 
huge number of mosquitoes (Smith et al., 2007), which can increases basic 
reproductive number of malaria parasites (RO) 2-4 fold (Woolhouse et al., 1997). 
Therefore, it would be potentially more useful and efficient to control and target 
malaria to the areas that contribute disproportionally to malaria transmission and 
focus efforts on a relatively small proportion of people (Smith et al., 2007). The 
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usefulness of a targeted approach is thought to be more beneficial in areas where 
transmission has decreased but reservoirs of infection exist as hot spots of malaria 
transmission (Bousema et al., 2010a, Bousema et al., 2012). Specially targeting hot 
spot of infection in the malaria endemic areas will most likely reduce transmission and 
also save money and time by targeting control to these areas (Fegan et al., 2007, 
Bhattarai et al., 2007). So, controlling malaria at individual level may not only direct 
benefits for the individuals who are included in the control effort but also at the 
community level by interrupting onward transmission. 
Variation in the risk of malaria within populations can be used for targeted 
interventions to identify hot spots of malaria transmission (Bousema et al., 2010a). 
However, a prerequisite for this is accurate information on the geographical 
distribution of malaria transmission intensities (Gustavo Bretas, 1996, EMRO, 2001, 
Carter et al., 2000). Mosquito abundance (Bousema et al., 2010a), elevations in malaria 
incidence (Clark et al., 2008, Bousema et al., 2010a, Bejon et al., 2010, Ernst et al., 
2006), asymptomatic parasite carriage (Ernst et al., 2006, Bejon et al., 2010) and 
serological responses to malaria specific antigens (Bousema et al., 2010a, Bousema et 
al., 2010c) have been used previously to describe spatial patterns in malaria 
transmission. 
The most direct evidence of hotspots of malaria transmission can be described by 
increased exposure to infectious mosquito bites. But EIR has low sensitivity at low 
transmission intensity and will require huge sampling which is laborious and time 
consuming process which make entomological detection of hots pots logistically 
unattractive (Bousema et al., 2012). Asexual parasite carriage was observed to be a 
more stable indicator of hotspots of malaria transmission (Bejon et al., 2010). 
Similarly, malaria-specific antibody responses were suggested to be the most robust 
indicators of hots pots of malaria transmission and were previously used to show small 
scale variations in malaria exposure (Bousema et al., 2010a, Bousema et al., 2010c, 
Wilson et al., 2007). Because antibody responses are long-lived, accumulate with age 
due to cumulative exposure and hots pots of malaria transmission were observed to be 
unaltered after overall malaria transmission is reduced (Ernst et al., 2006, Bautista et 
al., 2006, Gaudart et al., 2006). Additionally, antibody prevalence was higher than both 
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measures of parasite prevalence (ROT/PCR) and this extra sensitivity may provide more 
detailed examination of the spatial patterns in the study area. ROT, PCR and serology 
were employed together to detect any likely source of ongoing transmission in this low 
transmission intensity area. Although, all the three measures have their own biases, 
each contributes essential information about transmission dynamics especially in low 
malaria endemic areas. 
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6.1. Analysis 
Spatial patterns in malaria transmission at a household level were determined using 
parasite prevalence rates measured by ROT, PCR and seroprevalence. To determine 
the infection status CareStart 3-line Pf (HRPII) Pan (pLDH) combo ROT was done on all 
samples (2526) with observed 98.6% sensitivity previously (Mikhail et al., 2011). Spatial 
analysis to detect hot spots of parasite prevalence (areas whereby infection and 
disease are concentrated in a small proportion of individuals) measured by ROT was 
done for all camps. Spatial analysis to detect hot spots of parasite prevalence 
measured by nested PCR was done for camp 3 only. This was because a subset of 
samples (discussed in chapter 2 in detail) was assayed by PCR in all the four camps 
except for camp 3 from which all samples were assayed. Antibody responses were 
combined to both antigens againstP. vivax (PvAMA+PvMSP) andP. jalciparum 
(PfAMA+PfMSP) antigens to enhance the power for mapping seroprevalence data. 
Before detection spatial clusters of seroprevalence antibody responses to P. vivax and 
P. falciparumwere log transformed and adjusted for age as described previously 
(Wilson et al., 2007, Bousema et al., 2010c, Cook, 2010). This was done to see whether 
antibody responses were higher or lower than expected for any given age. For each 
individual and each antigen, age dependency of antibody responses was determined 
by visual assessment against a lowess lines on age-normalized OD. The age 
dependency of antibody response was confirmed by using linear regression on 
different age blocks to see if the slope or Significance level changed. If the association 
was non-significant then did not fit a line but in case of statistically significant 
association, a linear line was fitted and deviation from this line was determined. 
Spatial analysis software provides greater opportunity to understand disease 
distributions, risk factors, and changes to population health over time and space. To 
assess spatial heterogeneity i.e. the presence of hot/cold spots in P. vivax and P. 
jalciparum infection/seroprevalence within camp SaTScan software version 9.1.1 was 
used. SaTScan is the most commonly used software package for detection of disease 
cluster in a population. However, SaTScan only implements scan statistic methods and 
do not deal with modeling-based approaches (Robertson and Nelson, 2010). 
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The most significant clusters (potential areas with significantly higher or lower 
numbers of exposure than the mean with P value~0.05) were detected by using 999 
Monte Carlo replications to ensure sufficient power to define clusters. The standard 
purely spatial scan statistic used a circular window on the map but an elliptic shaped 
window can also be used, which provides slightly higher power for true clusters than 
circular. In this study for systematic scanning of each studied camp, a circular-shaped 
window was used instead of elliptical because the coordinates collected by GPS were 
in decimal degrees units, while elliptical windows uses coordinates in Cartesian units 
only. 
Maximum spatial cluster size was selected as 50 percent of the population at risk. The 
circular windows were restricted to 1km radius and upper limit was specified as 50% of 
the village population. For each cluster an expected number of cases were calculated 
and was compared to the observed number of cases. To determine high 
seroprevalence (0/1) and parasite prevalence (0/1) clusters a Bernoulli model was 
used, which is used for cases and non-cases (people with or without a disease) 
represented by a 0/1 variable. While for scanning high antibody responses (age 
adjusted normalized ~Os, continues values) clusters, a normal model was used to fit 
the continuous nature data. The same constrains as described above were used for 
this model. 
Integrated maps showing basic features and predicted hotspots were produced in 
ArcGIS version 10 (Environmental Systems Research Institute). Visual display of 
individual level attributes was done using the GPS coordinates for each household and 
displayed using ArcGIS 10 (ESRllnc. USA). Main roads and inland water bodies (canals, 
streams and rivers) longitude and latitudes points were assembled, developed and 
computed using Google earth. 
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6.2. Results 
Total number of P. vivax infections detected by ROT was 96/2526, the number ranged 
between 2-49 with lowest in camp 1 and highest in camp 3. No ROT positive individual 
was observed for P. falciparum in four camps except for a single positive individual in 
camp 5. Therefore spatial analysis of P. vivax infection (ROT) was conducted in all 
camps but not for P. jalciparum infection due to zero prevalence. peR was done on all 
samples only for camp 3 which detected 79/505 positive individuals. In other four 
camps (camp 1,2,4 and 5) 120 plus all ROT positive samples were assayed by peR for 
each of the camps (discussed in detail in chapter 4). Hence, to observe hot or cold 
spots of P. vivax infection detected by PCR was done only for camp 3. Again due to 
limited number of P. jalciparum infections (7) observed by peR in camp3, spatial 
analysis to see significant cluster of infection in the camps was not possible. However, 
spatial analysis was carried out for all the camps and for both P. jalciparum andP. vivax 
using seroprevalence data. 
Parasite prevalence and seroprelence in individuals less than 5 years of age were used 
to represent local and recent transmission. Children in age group 1-5 are most likely to 
represent recent exposure and are less likely to have travelled to other high 
transmission area. Antibody response (log transformed normalized OOs) to both P. 
jalciparumand P. vivax (AMA-1 and MSP-119) were adjusted for age to represent 
whether antibody responses were higher or lower than expected for any age given age 
group. Heterogeneity in prevalence of malaria infection and exposure was also 
assessed considering all ages in the study because certain factors will only be observed 
in adults (e.g, past malaria exposure, movement to other endemic areas) and to 
provide a more comprehensive assessment of transmission. 
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6.2.1. Spa al Pa erns in infec on and seroprevalence in Campl 
6.2.1.1. Children under or equal to ve years of age 
No significant cluster of infection and seroprevalence were observed in camp 1 this is 
likely due to the fact that as infection detected by both ROT and seroprevalence were 
very low among individuals equal to or less than five years age. 
6.2.1.2. Clusters of age adjusted an body responses 
No significant cluster of age adjusted antibody responses against P. vivax were 
detected in camp1. While one significant hot spot of age adjusted P. !alciparum OD 
was observed in this camp (Radius 0.24 km, Number of households in the hot spot=63, 
p<O.Ol) (Figure 6.2.A). 
6.2.1.3. Seroprevalence and infec on cluster in individuals of all ages 
In camp1 the SaTScan analysis carried out for detection of high or low P. vivaxantibody 
prevalence clusters considering individuals from all ages, showed one hot (Hot spot: 
Radius 0.12 km, Number of cases=31, Expected cases=13.17, p<0.01) and one cold spot 
(Radius 0.22 km, Number of cases=16, Expected cases=36.53, p<0.01) (Figure 6.2B). 
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Figure 6.1Aerial view of camp 1 
This bird's eye view of the camp was captured from Google earth with eye al tude 1.25 Km. 
The gure is showing the households posi on rela ve to their distance from water bodies, 
eld, roads and BHU. The small pink dots represent selected households for the study. 
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Figure 6.2(A) Hot and cold spot of age adjusted op cal density values against P. /alciparum 
and (B) seroprevalence in all ages against P.vivax 
In gure A colored dots indicate mean age-adjusted op cal densi es per household for 
combined seroreac vity to P. /alciparum (MSP-119 and AMA-l). The red circular window 
indicates a sta s cally signi cant cluster of higher P. /alciparum andP. vivaxseroreac vity, 
while the green circular window represents cold spot. In gure B, Colored dots indicate 
mean seroprevalence in each household for combined an gensof P. vivax (PvMSP+PvAMA). 
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6.2.2. Spa al Pa erns in infec on and seroprevalence in Camp 2 
6.2.2.1. Children under or equal to ve years of age 
No significant foci of infection and seroprevalenec to both P. jalciparum andP. vivax, 
either cold or hot was found for camp 2. 
6.2.2.2. Clusters of age adjusted an body responses 
In camp2 age adjusted P. vivax seroreactivity was significantly increased in a cluster of 
49 households with P=O.OOl (Figure6.4.A). One significant hot spot of age adjusted P. 
jalciparum OD was observed in camp 2 (Radius 0.22 km, Number of households in the 
hot spot=55, p<0.01)(Figure6.4.B). 
6.2.2.3. Seroprevalence and infec on cluster in individuals of all ages 
Only one P. jalciparumhighly significant hot spot with radius 0.21 km, number of cases 
44, expected cases15.9, p<O.Ol and one cold spot was detected with radius 0.41 km, 
number of cases 2, expected cases 23, p<O.Ol in camp 2(Figure6.4.C). This hot spot is 
in similar geographical location as was detected when age adjusted ODs data was 
used. 
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Figure 6.3Aerial view of camp 2 
This bird's eye view of the camp was captured from Google earth with eye al tude 1.25 Km. 
The gure is showing the households posi on rela ve to their distance from water bodies, 
eld, roads, tobacco factory and BHU. The small pink dots represent selected households for 
the study. 
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Figure 6.4(A) Spa al distribu on of P. vivax age adjusted ODs (A) age adjusted ODs of P. 
/alcipatrum and (C) P. /alciparumseropositves in all ages 
In gures A and B colored dots indicate age-adjusted op cal densi es per household for 
combined seroreac vity to P. /alciparumand P. vivaxMSP-l19 and AMA-l. The red circular 
window indicates a sta s cally signi cant cluster of higher P. /alciparumandP. 
vivaxseroreac vity, while the green circular window represents cold spot. In gure C, 
Colored dots indicate mean seroprevalence in each household for combined an gensofP. 
/o/ciparum(PfMSP+PfAMA). 
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6.2.3. Spa al Pa erns in infec on and seroprevalence in Camp 3 
6.2.3.1. Children under or equal to ve years of age 
In camp 3 one cluster of high parasite prevalence (with 0.33 km radius, number of 
observed cases 19, expected cases 7.5 and p<O.Ol using Likelihood Ratio Test) and one 
of low prevalence (with radius 0.56 km, observed number of cases 0, expected number 
of cases 10 and with p<O.Ol) was detected when using ROT data (Figure 6.6.A). The 
same hot spot of infection was also detected by using peR data, where the number of 
cases observed was 16 and the number of expected cases was 6.16 (radius 0.34 
km,p<O.Ol) (Figure 6.6.8). 
The analysis of cold/hot spots of sero-prevalence against P. vivaxin individual of age 
equal or less than five years showed only one significant hots pot in camp3. This 
comprised of similar households and was geographically congruous with those 
detected for peR and ROT, with radius 0.41 km, 46 cases, and 26 expected cases with a 
p<O.Ol(Figure 6.6.C}. 
6.2.3.2. Clusters of age-adjusted an body responses 
In camp3 one cluster of higher than expected age-adjusted P. vivaxOO values was 
detected, consisted of 25 households with p<O.Ol(Figure 6.7.A). One significant hot 
spot of age adjusted P. Jalciparum 00 was also observed in camp 3 (Radius 0.16 km, 
Number of households in the hot spot=ll,p<O.Ol) (Figure6.7.B). 
6.2.3.3. Seroprevalence and infec on clusters in individuals of all ages 
In camp 3 one hot spot of infection prevalence (ROT) in individuals of all ages, with 
radius 0.33 km, number of cases 39, expected cases 16. 6, p<O.Ol and one cold spot 
with radius 0.47 km, number of cases 0, expected cases 17.3and p<O.Ol(Figure 6.8.A). 
One hot (radius 0.40 km, number of cases 2, expected cases 18.3) and one low P.vivax 
prevalence cluster p<O.Ol and (radius 0.56 km, number of cases 59, expected cases 37, 
p<O.Ol) was detected when peR based infection prevalence was used. This was similar 
in geographical position with hot and cold spots detected when ROT data was used 
(Figure 6.6.8). No significant hot or cold spots were found in the other four camps 
using parasite infection prevalence data. One hot spot (Radius 0.18 km, Number of 
cases=82, Expected cases=48.58, p<O.Ol) and one clod spot {Radius 0.92 km, Number 
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of cases=8, Expected cases=118.59, p<O.Ol) of P. vivax antibody prevalence was also 
detected at common geographical position as hot spots detected when RDT/peR data 
was used(Figure 6.6.C} . 
Figure 6.5Aerial view of camp 3 
This bird's eye view of the camp was captured from Google earth with eye al tude 1.25 Km. 
The gure is showing the households posi on rela ve to their distance from water bodies, 
eld, roads and BHU. The small pink dots represent selected households for the study. 
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A. ROT (in children ~S) B. PCR (in children ~S) 
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Figure6.6 (A) Hot and cold spots of P. vivax infec on using ROT data (B) PCR spa al 
distribu on of parasite posi ve people (C) seropositve individuals against P.vivax, in 
individuals equal to or less than ve years. 
Household with nega ve infec on individuals are represented by hollow circle and 
household with parasite posi ve individuals are represented by a red circle. The red circular 
window indicates a sta s cally signi cant cluster of higher P. vivaxinfec on, while the green 
circular window represents cold spot. 
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Figure 6.7Hot and cold spot of age adjusted op cal density values against (A) P.vivax and (B) 
P. !alciparum 
Colored dots indicate age-adjusted op cal densi es per household for combined 
seroreac vity to P. !alciparum andP. vivaxMSP-119 and AMA-l. The red circular window 
indicates a sta s cally signi cant cluster of higher P. !alciparum andP. vivaxseroreac vity, 
while the green circular window represents cold spot. 
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Figure 6.8Spa al distribu on of infec on prevalence using (A) ROT (B) PCR) and (C) 
seropositve individuals against P.vivax all ages 
In gures A and B, Household with nega ve infec on individuals are represented by hollow 
circle and household with parasite posi ve individuals are represented by a red circle. While 
in gure C colored dots indicate mean seroprevalence in each household for combined 
an gensof P. vivax (PvMSP+PvAMA). The red circular window indicates a sta s cally 
signi cant cluster of higherP. vivaxinfec on andseroreac vity, while the green circular 
window represents cold spot. 
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6.2.4. Spa al Pa erns in infec on and seroprevalence in Camp 4 
A single significant (p<O.Ol) small hot spot of P. vivax age adjusted aDs with 20 
households was detected in camp 4 (Figure 6.10). 
Figure 6.9Aerial view of the camp 4 
This is bird's eye view of the camp was captured from Google earth with eve al tude 1.25 
Km. The gure is showing the households posi on rela ve to their distance from water 
bodies, eld, roads and BHU. The small pink dots represent selected households for the 
study. 
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Figure 6.10Hot spot of P. vivax exposure using age adjusted aDs in camp 4 
Colored dots indicate age-adjusted op cal densi es per household for combined 
seroreac vity to P. vivaxMSP-119 and AMA-l. The red circular window indicates a sta s cally 
signi cant cluster of higher P. vivaxseroreac vity, while the green circular window 
represents cold spot. 
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6.2.5. Spa al Pa erns in infec on and seroprevalence in Camp 5 
In camp 5 one significant hot spot of age adjusted P. /a/ciparumOOs were observed 
(Radius 0.08 km, Number of households in the hot spot=14,p<0.01)(Figure 6.12.8). 
Two significant cold spot of age adjusted P. vivax 00 (p<O.Ol) was also observed 
(Figure 6.12.A). 
Figure 6.l1Aerial view of the camp 5 
This is bird's eye view of the camp was captured from Google earth with eye al tude 1.25 
Km. The gure is showing the households posi on rela ve to their distance from water 
bodies, eld, roads and BHU. The small pink dots represent selected households for the 
study. 
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against P./alciparum 
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6.3. Discussion 
In this chapter the spatial variation in malaria infection and exposure was examined in 
the five Afghan refugee camps by integrating survey data described in chapter 4 and 
chapter 5 with household level GPS in KP, Pakistan. Spatial statistics were generated 
using SaTScan software to detect areas of higher and lower than expected malaria 
transmission. Areas that had higher or lower number of individuals who were parasite 
positive and having positive antibody responses than expected were defined as hot or 
cold spot respectively. 
Evidence of heterogeneity was observed in prevalence of P. vivax infection and 
antibody responses to both P. /alciparum andP. vivax within the camps. In campi one 
cluster of high age adjusted ODs against P. /alciparum and high seroprevalence against 
P. vivax considering individuals from all ages was detected. In camp 1 the hot spot of 
antibody prevalence to P. vivaxin all age groups was detected and is probably due to 
the fact that these households were found very close to water logged rice fields, and 
far from BHU. In camp 2 one hot spot for each malaria species (P. /alciparum andP. 
vivax) was detected by using age adjusted OOs data. For P. /alciparum another hot 
spot was detected when seroprevalence data of all age groups was used in camp 2. All 
the three hot spots observed in camp 2 (one P. vivax and two of P. /alciaprum) were 
detected in similar geographical position. The hot spots were comprised of households 
that were scattered along a small irrigation water canal and near tobacco factory that 
may be one of the reasons for hot spot as several studies previously mentioned the 
proximity to water bodies a risk for a hot spots (Clark et al., 2008, Oesterholt et al., 
2006). 
In camp 3 a P.vivax hot spot was detected in the same area by using all the three 
measures (ROT, PCR and serology). The hot spot comprised of households most of 
which were under the bracket of lower SES, and reported both limited number of ITN 
ownership and its use the night prior to the survey (data is not Shown). These 
household were also located in between two river branches, which may associated 
with the high levels of vivax malaria. Only one hot spot was detected for P. /a/ciparum 
by using age adjusted OOs data, which is located near to P. vivax hot spot but at 
different pOSition. In camp 4 one hot spot of age adjusted antibody responses against 
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P. vivaxwas found. In camp 5 only one hot spot of age adjusted OD against P. 
!alciparum was detected, while two cold spots P. v;vaxseroprevalence were detected, 
consisted of households located close to BHU and away from the rainwater runoff. 
Variation in a disease risk (geographical clusters of disease incidence) within a 
village/area, which is genetically homogeneous, may be because of variation in 
exposure to malaria-infected mosquitoes (Bousema et al., 2010a), which is consistent 
with the finding of this study as all camps were situated nearby mosquitoes breeding 
sites. Households were scattered along water bodies in three camps (Camp 1 and 
camp 3 along rivers and camp 5 along canal) and camp 2 and 4 are surrounded by rice 
and sugarcane fields which have standing water most of the year (Aria I views of camps 
captured from Google earth). 
In several studies carried out in areas of higher endemicity, distance to water bodies 
was associated with malaria incidence and immune responses (Clark et al., 2008, 
Oesterholt et al., 2006, Staedke et al., 2003, Kreuels et al., 2008, Wilson et al., 2007, 
Creasey et al., 2004). Another study also described that proximity to the mosquito 
breeding sites is not the only predictor of malaria risk, due to variation in the breeding 
sites productivity and longevity (Fillinger et al., 2009). However, this is not always true 
as one study conducted by Bousema et al. (Bousema et al., 2010a) in Somaliland found 
no association of malaria incidence and distance to water body. Detectable water 
bodies may also be misleading as mosquitoes breeding sites may be quite small and 
transitory and likely to be missed during surveys. For example small burrow pits made 
by horse or cattle or any other animal tracks, dirt road or dirt tracks, tyres, buckets and 
open water tanks which may be a potential breeding habitat for mosquitoes. This 
survey did not identify or collect information about mosquitoes breeding sites in the 
camps, which may be one of the reasons of these households to be in the hot spot. 
Therefore it will be useful for control programmes to check for potential mosquitoes 
breeding sites and might apply vector control measures to target outdoor biting 
vectors. 
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Household factors (Greenwood, 1989, Clark et al., 2008, Oesterholt et al., 2006, 
Kreuels et al., 2008, Gamage-Mendis et al., 1991) and the vicinity of alternative hosts 
(cattle) have also be associated with hot spots of malaria incidence (Bousema et al., 
2010a). Which is what was found in this study, where high risk of infection and 
seroprevalence to P. vivaxwere associated with low SES and poorly built houses (mud 
houses with Thatched roofs and living rooms with open eaves), sleeping with animals 
in the same courtyard and traveling of individuals to other malaria endemic areas 
(discussed in chapter 5). 
Other factors which were identified as being associated to living in a hot spot of 
malaria transmission included, distance to the nearest breeding site (Clark et al., 2008, 
Oesterholt et al., 2006, Kreuels et al., 2008), bed net coverage (Clark et al., 2008) and 
walling material (Somi et al., 2007), which are considered as a key factors in 
determining the risk of malaria at individuals level. It is important for malaria 
elimination to identify hot spots of malaria transmission within or among the areas and 
the risk factors associated with these hot spots. Emigration of asymptomatic parasite 
carriers or transportation of infectious mosquitoes can lead to spread of parasites 
beyond the borders of a focus. Therefore it may be useful to improve the housing 
condition, to create malaria awareness about the risks involved with increase in 
malaria burden and to screen individuals before leaving or entering in to the hot spot. 
To reduce high exposure to mosquitoes and high prevalence of parasite carriage 
(asymptomatic) in the hot spot both human and vector hosts control interventions will 
be required as previously suggested (Bousema et al., 2012). Scaling up conventional 
vector control tools such as LLlNs and IRS may be useful for controlling malaria in these 
hots pots. In addition to these indoor biting and resting malaria vectors control 
measures it will be potentially useful to target outdoor biting vectors (Reddy et al., 
2011, Russell et al., 2011) for example larviciding of mosquito breeding sites and adult 
vector (Fillinger et al., 2008). However, widespread adoption of such operational 
constraints has not been encouraged, but they are suggested to be utilized as a 
targeting strategy. 
For reduction of malaria transmission in hotspots it is equally important to control the 
human infectious reservoir (symptomatic and asymptomatic parasite carriers) 
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(Stresman et al., 2010). Therefore, it may be useful to treat households and neighbours 
of individuals who are diagnosed with malaria at health facilities (Moonen et al., 2010) 
and screen people in the hots pots for parasitaemia at regular intervals (Moonen et al., 
2010). Moreover to clear infections in symptomatic and asymptomatic parasite carriers 
(Okell et al., 2009) mass drug administration (MDA) was suggested where a full 
therapeutic antimalarial drug dose are administered to a population without prior 
screening (Okell et al., 2011, Bousema and Drakeley, 2011). 
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Chapter Seven 
Prevalence and molecular characteriza on of G6PD 
de ciency in Afghan refugees, KP, Pakistan 
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Chapter 7. Prevalence and molecular characteriza on of 
G6PD de ciency in Afghan refugees, KP, Pakistan 
7.1. Introduc on 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common red 
blood cell inherited enzymopathy which affects about 400 million people worldwide 
(Cappellini and Fiorelli, 2008) and its global prevalence is approximately 4.9%. It is an 
X-linked recessive hereditary defect caused by G6PDgene mutations, resulting in 
abnormally low levels of the enzyme Glucose-6-phosphate dehydrogenase (Beutler, 
1992). The enzymes plays an important role in the pentose phosphate pathway, to 
provide reducing power to all cells in the form of NADPH (reduced form of 
nicotinamide' adenine dinucleotide phosphate), which help cells to compensate 
oxidative stress that can be generated by several oxidant agents (Cappellini and 
Fiorelli, 2008). RBCs lack mitochondria and so NADPH from the pentose phosphate 
pathway is their only means to generate NADPHand thus to prevent any oxidative 
damage resulting in hemolysis (Luzzatto et aI., 2001, Williams, 2006). Thus hemolysis 
occurs in hemizygotes (heterozygous females) and homozygotes on oxidative 
challenge such as drugs, fava beans and infections. Heterozygous females may be 
completely asymptomatic or at-risk of hemolysi~ depending on their Iyonization (X-
inactivation). In neonates, G6PD deficiency may cause hyperbilirubinemia. 
Clinically, G6PD deficiency is characterized on the basis of residual activity of Glucose-
6-phosphate dehydrogenase enzyme. Enzyme activity ranges from its complete 
absence (classified as Class I) to abnormally high levels (classified as Class V with 
enzyme activity of >150%) (Beutler, 1994). Several studies have shown that G6PD 
deficiency has a protective action against malaria (Frank, 2005, WHO, 1989, Ruwende 
and Hill, 1998). The global distribution of G6PD deficiency is very similar to that of 
malaria with a high prevalence of both in the tropics and subtropics. In malaria 
patients however, severe G6PD deficiency can complicate the infection ~md treatment 
with some antimalarials like Primaquine or Dapsone can lead to fatal intravascular 
hemolysis leading to acute renal failure (Wickramasinghe and Abdalla, 2000). 
Frank et aI., (200S) asserted on prescription of G6PD deficiency tests for patients that 
experience acute hemolytic reaction on exposure to oxidative drugs or when they 
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have a family history other underlying systemic disorders for example of jaundice, 
splenomegaly, or gallstone disease (Frank, 2005). These conditions should be 
particularly considered among populations of African, Mediterranean, or Asian origin 
(Minucci et al., 2008). 
The accurate diagnosis, however, is variable depending on the stage of the diagnosis 
or whether the patient is a male or female (Minucci et al., 2008). Some commonly 
used semi-quantitative assays such as the fluorescent spot tests can be used in 
countries where the deficiency is both frequent and is endemic to malaria. Since the 
test is inexpensive, rapid and sensitive, it can be used in screening large scale 
populations. Other similar tests include the Heinz body examination and GSH stability 
test (Tantular and Kawamoto, 2003). However, in cases of definitive biochemical 
identification (levels of enzyme concentrations) a quantitative assay may be required. 
The commonly used spectrophotometric assay measures the rate of NADPH 
generation at wavelength of 340 nm by adding a precise amount of hemolysate to the 
substrate of glucose-6-phosphate and its cofactor NADP (Beutler, 1984). However, the 
test is reportedly prone to producing false negatives when performed soon after a 
hemolytic episode (Ringelhahn, 1972). 
The genetiC variation in the heterozygous females (especially due to X-inactivation) 
affects the clinical outcome of the deficiency, such that these females might show 
enzyme activity varying from hemizygote-like phenotype to being normal (Minucci et 
al., 2008). In such cases quantitative and qualitative testing described above can give 
counterfeiting results (Peters and Van Noorden, 2009). 
Varieties of molecular techniques have been described that detect G6PD deficiency 
causing mutations even in HF (Du et al., 1999, Zhang et al., 2005, Farez-Vidal et al., 
2008, Minucci et al., 2008). About 140 mutations have been reported in the coding 
regions of G6PD gene resulting in over 450 G6PD variants of which 300 have been 
acknowledged by WHO. (Town et al., 1992, Hirono et al., 2002, Chen et al., 1991, 
WHO, 1991). PCR followed by sequencing of the whole or fragment of gene can 
provide a definite diagnosis and also help in identification of novel and less frequent 
mutations (Minucci et al., 2008). The technique, however, is expensive and thus not 
practical for prompt diagnosis especially in field settings. RFlP of the gene with 
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respect to the known mutations reported in the study population is a rapid and cheap 
PCR screening approach. 
One of the most widely distributed variant of G6PD deficiency is the Mediterranean 
type (G6PD 563C-T) that causes class 11 syndrome (1-10% enzyme activity). This type is 
prevalent in the Mediterranean countries Middle Eastern, and South Asian countries 
including Pakistan (luzzatto et al., 2001, Kurdi-Haidar et al., 1990, Karimi et al., 2003, 
Oppenheim et al., 1993, Bayoumi et al., 1996). In Pakistan comparatively higher 
prevalence of Mediterranean type has been reported in Pathans with respect to other 
ethnicities (Punjabi). Some molecular level work in Pakistan has reported 563C-T, 
silent mutation of 1311 C-T, while l003A-G and 131C-G was found less-frequent and a 
novel 973 G-A variant(Moiz et al., 2009, Moiz et al., 2011, Saha et al., 1994). Studies 
focusing on G6PD deficiency screening before administering anti-malarials [such as 
Primaquin] have reported 2% to 10% (Brooker et al., 2006) prevalence in Afghanistan. 
Plasmodium vivax is the dominant species in the study area, responsible for 70-90% of 
cases and the remainder of cases are caused by P. !alciparum (Rowland and Nosten, 
2001, Rowland, 1999a, Rowland et al., 1994). P. vivax infections cause majority of 
malaria episodes, which is the most stable species due to its ability of formation of 
hypnozoites in the liver. For example previous studies conducted in Afghan refugees 
has shown that one initial infection can cause up to 10 or more subsequent episodes 
even after effective treatment for acute episodes (Leslie et al., 2008, leslie et al., 
2004). The liver stage hypnoloites act as a reservoir of the disease that may help the 
disease to continue its transmission cycle. Furthermore, infected individuals with the 
latent liver stage may reduce the protective efficacy of commonly used preventative 
measures (insecticide treated bred nets) due to its ability to develop further episodes 
even if they regularly use an ITN (leslie et al., 2010, leslie et al., 2008). 
However it is found difficult to control vivax malaria because of the occurrence of 
relapse episodes. The radical cure for latent stage vivax malaria, is primaquine or 
other anti-hynozoite drugs but the high prevalence of G6PD deficiency and the lack of 
G6PD testing facilities among the studied population (AIi et al., 2005, Bouma, 
1995)prevents its use(Bouma, 1995). 
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For an immediate reduction of vivax malaria morbidity and to drop its transmission 
levels it is essential to make G6PD testing readily available. The aim of this chapter 
was to measure the molecular prevalence of SNP's associated with G6PD deficiency in 
five Afghan refugee camps to provide information to aid decisions related to the 
prescribing of anti-malarial therapy with drugs like primaquine. 
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7.2. Materials and Methods 
505samples from camp3 were assayed using RFlP PCR (Moiz et al., 2011), to identify 
G6PDmutations in the study population. The same DNA template was used as that 
extracted for the identification of low-density parasite infection. The method for 
extraction is described in detail in chapter 2 section 3. 
Initially three mutations [{1003A-G/335 Ala-7Thr, Class Ill}, (563C-T/188 Ser-7Phe, 
Class II) and (1311 C-G /44 Ala-7Gly, Class Ill)] (Table 6.1) were selected. However, due 
to time and financial constraints, only G6PD 563C-Tvariant was studied. G6PD 563C-T 
was selected because there is evidence that suggests that it is the most prevalent 
mutation among Pathans, due to their ancestral origin from the Mediterranean basin 
(Bouma, 1995, Dupree, 1973). Furthermore G6PD 563C-T belongs to class 11 mutations, 
which is associated with severe enzyme deficiency (with less than 10% enzyme 
activity) as compared to 1003A-G and 131C-G mutations which are class III 
(Moderately deficient, 10-60% residual activity) (Beutler, 1992). 
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Table 7.1 Primers and restriction enzymes for various G6PD variants 
G6PD variant REF Primers Enzymes Digested products 
/aminoacid (Base pairs) 
substitution 
563C-T [type 11] (Saha et al., 5' ACTCCCCGAAGAGGGGITCAAGG 3' MboII 377,119 (wild) 
/188 Ser-Phe 1994, Moiz et 5' CCAGCCTCCCAGGAGAGAGGAAG 3' (Fermentas) 277,l19,110(homozygous 
aI., 2011) mutant) 
377,277,119,110 (heterozygous 
mutant) 
1003A-G [type Ill] (Noori- 5' CAAGAAGCCCA TICTCTCCCT 3' BstXI 130,78 (wild) 
/335 Ala-Thr Daloii MR, 5'TICTCCACATAGAGGAGGACGGCTGCCAAAGT 3' 100,78,30(homozygous mutant) 
2006) 130,100,78,30 (heterozygous 
mutant) 
131 C-G [ type Ill] (Kaeda et al., 5' CAGCCACTTCT AACCACACACCT 3' HaeIII 107,75,66,48,45,11(wild) 
/44 Ala-Gly 1995) 5' CCGAAGTIGGCCATGCTGGG 3' 123,107,66,45,ll(homozygous 
mutant) 
123,107,66, 75, 48, 45,11 
(heterozygous mutant) 
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7.3. Results 
7.3.1. Wild and mutant types of 563C-T 
Sequencing of 5 samples from camp3 showed digestion product sizes that were 
comparable to those previously reported {Table 7.1 and 7.2}. 
Table 7.2 G6PD wild and mutant type RFLP products a er diges on by Mboll of G6PD 
sequence from this study. Extractor version 1.1.(Stothard, 2006). 
Phenotype Digested products (size in Base pairs) 
Wild type 374, 120 
Homozygous mutant 276, 120,98 
Heterozygous mutant 98, 120,276,374 
7.3.2. G6PD de ciency in camp3 
The X-chromosomes of 505 subjects belonging to camp 3 for Afghan refugees were 
analyzed for 563C-T polymorphism of G6PD gene. Of them 563 C-T mutation was 
observed in only 2 unrelated individuals making {0.4% prevalence}. One was male 
{hemizygous} and another female {Heterozygous}. Their ages were 5 and 4 years 
respectively at the t ime of diagnosis. The female was negative for malaria by ROT, PCR 
and serological tests, whereas the male was positive for all the 3 tests. 
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A. 
B. 
Figure 7.1G6PD peR and RFlP products. 
Key to gures 7.1 A and B: UD=Undigested PCR product, 0= digested product wild 
type, Vl=S63 C-T variant in male, V2=S63 C-T variant in heterozygous female. 
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7.4. Discussion 
The present study originally aimed at identifying 3 mutations (Table 6.1). However, due 
to time constraints only one (Mediterranean type 563C-T which is WHO class 11 with 
<5% enzyme activity) was selected based on its higher reported prevalence in Asian 
and Middle Eastern populations(Cappellini and Fiorelli, 2008). Secondly, G6PD-Med 
(belong to the class 11) was previously suggested the most likely type prevalent in 
Pathans, due to origin of Pathans from the Mediterranean basin (Bouma, 1995, 
Dupree, 1973). Historically, Pathans are suggested to be the descendants of European 
soldiers who accompanied Alexander the Great (Firasat et al., 2007, Papiha SS, 1999) 
and are also considered to be the lost tribe of Jews (Papiha SS, 1999), who have high 
prevalence of G6PD deficiency (Moiz et al., 2009). 
A prevalence of 0.4% was observed camp 3 of Afghan refugees in the present study. A 
comparatively higher frequency of G6PD deficiency has been previously noted in 
Afghani is ranging from 2% to 10% (Brooker et al., 2006). Bournal et al determined the 
prevalence of G6PD deficiency in Afghan Safi tribe to be 15.8% as compared 7% in 
Mohmands (a native Pathan tirbe in Pakistan). This difference in prevalence might be 
a result of lower sensitivity and limitations of RFlP for this specific mutation (563C-T) 
in the present study. In addition, the present study only typed a single mutation, 
whereas other studies that report higher figures of G6PD deficiency among Afghans 
are based on the disease's clinical diagnosis which may encompass a much wider range 
of mutations. 
A few molecular level studies in Pakistan have reported 563C-T, silent mutation of 
1311 C-T, 1003A-G, 131C-G and a novel 973 G-A mutations. These studies showed that 
563C-T mutation was more common in Pathan patients as compared to other 
ethnicities (Moiz et al., 2009, Moiz et al., 2011, Saha et al., 1994). These RFlP based 
studies in Pakistan to detect a specific mutation require prior knowledge regarding the 
mutation's prevalence in the study area. This limits these studies from identifying 
novel mutations which might confer phenotypic effects. Sequencing G6PD targets can 
elaborate the knowledge of genetic variants in the region. 
Following reports of G6PD deficiency found in Pathans, the use of primaquine for the 
treatment of P. vivax was suggested no longer to be recommended (Bouma M.J. et al., 
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1995). Another study conducted in Afghan refugees had also shown that 8 week 
regimen of primaquine could not be readily used in this population (leslie et al., 2008, 
leslie et al., 2004). However, despite reports of CQ resistance from other parts of Asia, 
leslie et al., reported that CQ was still a highly effective drug against vivax 
malaria,when given as the standard 14-day course (leslie et al., 2008, leslie et al., 
2004, leslie et al., 2007). 
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Chapter Eight 
General Discussion 
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Chapter 8. General Discussion 
The aim of this PhD study was to generate current information on malaria infection 
through parasite prevalence and malaria exposure using antimalarial antibody 
responses and to compare the level of malaria transmission intensity among the study 
camps. ROT, PCR and serology were employed together to detect any likely source of 
ongoing transmission in this low transmission area and to validate usefulness of 
serology, PCR and ROT as a tool to monitor malaria endemicity. Since all the three 
measures have their own advantages and disadvantages and contribute essential 
information about transmission dynamics especially in low malaria endemic areas. The 
study will provide additional insight into nature and role of anti-malarial immunity in 
residents of the study a rea. 
The study also aimed to characterize the risk factors for exposure and infection to both 
P. !alciparumand P. vivax malaria and to assess its relationship with infection and 
exposure to malaria in refugee camps in KP to assist decision-makers in better 
targeting malaria intervention and control efforts in the area. These individual and 
household risk factors were associated with the increase or decrease of the number of 
malaria infections and seroprevalence. Additionally GIS data was combined with 
measures of exposure and infection to map potential foci of malaria infection and 
exposure to aid malaria control. Variation in the risk of malaria within camps can be 
used for targeted interventions to identify hot spots of malaria transmission. Specific 
targeting foci of infection in the malaria endemic areas most likely to hinder 
transmitting but also save money and time by only uses control in these areas (Fegan 
et al., 2007, Bhattarai et al., 2007). 
Complete and accurate data of the previous malaria situation, a good record of malaria 
transmission and its burden are key elements of a successful programme. The decision 
to change to the next phase of the malaria control or elimination programme is made 
on the basis of progress made in epidemiological indicators. Monitoring changes in 
transmission intensity and identification of residual malaria foci is therefore very 
essential for successful malaria control programme and to concentrate intervention 
efforts. 
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Entomological monitoringactivities (abundance of vector species, mapping of risk 
areas and monitoring resistance of vectors to insecticides) and specific parasitological 
surveys (blood slides or rapid diagnostic tests) are commonly used as direct 
measurements of potential local transmission. WHO also recommended sero-
epidemiological measures which can help in validation of the interruption of local 
transmission using along with parasitological and entomological surveys (WHO., 
2oo7b). Previous study also used serological measures (SCR and seroprevalence) in 
combination with parasite prevalence (ROT) to monitor the progress of malaria control 
interventions on Bioko Island and a reduction in transmission was detected (Cook et 
al., 2011). Similarly to evaluate transmission dynamic before and after malaria 
elimination in Vanuatu, serological measure in combination with PR data (ROT and 
PCR) were used and confirm its progress towards malaria elimination. 
Several national malaria programmes acquired elimination strategies in the past 15 
years and some of them have succeeded in achieving or nearing that goal. For 
example, Maldives, Tunisia, and the United Arab Emirates (UAE) most recently 
eliminated malaria. This successes was made possible due to intense national 
commitment to achieving zero incidence of infection, together with coordinated 
efforts by partners and keeping a good record of malaria situation (strengthening the 
malaria surveillance system) (WHO., 2oo7a). Iran also adopted national malaria 
elimination programme in 2005, where a significant change in malaria situation has 
been observed (the number of malaria cases dropped to 2700 (2011) from 16,000 
cases in 2006) by implementing focused interventions and strengthening the malaria 
surveillance system and applying a participatory approach to include the local 
communities (UNOP., 2013). 
In general, transmission of malaria is limited in KP but since the province is bordering 
Afghanistan from the west, it has become the host of millions of Afghan refugees from 
the endemic malarial areas of Afghanistan. Malaria was widespread in refugee camps 
in 1990s but nowadays as a result of the anti-malaria campaign started in late 1990s 
after epidemic in refugee camps, malaria transmission was interrupted. Previous 
published (Rowland et al., 2002 b) and BHU data from the camps showed that the rate 
of malaria was steadily declined since past decades after epidemic in the refugee 
camps in late 1990s. The decline observed in malaria transmission in most of the 
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Afghan refugee camps are suggested to be due to the introduction of intensive malaria 
control measures. But other factors such as sodo-economic development are likely to 
be involved in the decline. Therefore this study was designed to facilitate the control 
programmes to assess the presence of the parasite carriers and to evaluate the 
reservoir of infections by using RDT and nested-PeR, where transmission is perceived 
to be reduced in the last decade. The low prevalence of malaria parasites in the 
studied area show malaria can be control and ultimately eliminate in the near future if 
to establish a proper surveillance and follow up system and the level of transmission 
needs to be continually monitored. Very limited and old published data is available on 
malaria situation in the study area and accurate data on the proportion of malaria 
cases and population at risk are essential for the design and implementation of new 
interventions. So the current data on the malaria burden at population level will help 
to accurately update malaria situation and will provide additional information on the 
population at risk, which can help malaria control activities and guide research in the 
study area. 
8.1. Malaria infec on through parasite prevalence 
In the study no Plasmodium /alciparum paraSites were detected by RDT but using peR 
7/506 (1.8%) in camp3 and 1/132 (0.8%) in camp 4 positive individuals were detected. 
Low levels of P. /alciparum prevalence detected by the study are in agreement with 
BHU and previous published data that also reported decline and extremely low P. 
/alcjparum infection prevalence in the studied camps. Other countries who also 
reported reducing asymptomatic falciparum malaria includes Iran (Zoghi et al., 2012), 
Sri Lanka (Fernando et al., 2009) and Kenya (John et al., 2009). The reduction observed 
in theP. /alciparuminfection prevalence and asymptomatic individuals in these refugee 
camps in the past and in the above mentioned countries was thought to be due to 
applying malaria control interventions firmly (Rowland et al., 2002 b). 
Data from the surveys showed overall 4% (96/2522) P. vivaxparasite prevalence 
detected by RDT at all study sites with the highest 9% prevalence in camp 3 and lowest 
in camp 1 (0.4%). This low parasite prevalence corresponds with data from the BHU 
collected in the past decade. Overall prevalence of P.vivax infection detected by peR 
was 12% with a range of 5-15%. Camp 3 with high prevalence of infection detected by 
ROT and camp 1 the lowest among the camps. P. vivax parasite carriage measured by 
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PCR is approximately 4 times greater than measured by ROT, which suggest the 
presence of asymptomatic carriers (carriage of low levels of parasites without 
symptoms) or sub-ROT (infection below the sensitivity of ROT but picked up by PCR) in 
the study area . In endemic areas asymptomatic carriers of malaria are a result of 
continuous exposure, which may lead to partial immunity (Staalsoe and Hviid, 1998, 
Shekalaghe et al., 2007, Sutherland et al., 2007, Roper et al., 1996). A review on the 
submicroscopic infections hypothesized that in lower transmission areas infections on 
average are older and more likely developed to submicroscopic phase, while in high-
transmission areas repeated infections and superinfection may results in the increase 
of average parasite density in an infected individuals (Okell et al., 2012). 
Other low endemic areas that also reported submicroscopic infections of malaria have 
included, Yemen (Bin Mohanna et al., 2007), Solomon Island (Harris et al., 2010), 
Colombia (Cucunuba et al., 2008), Amazon region of Brazil (Suarez-Mutis et al., 2007) 
and Peru (Roper et al., 2000) and Principe (lee et al., 2010). High transmission areas 
including Nigeria (Eke RA, 2006, Achidi et al., 1995), Uganda (Njama-Meya et al., 2004), 
Ghana (Crookston et al., 2010, Owusu-Agyei et al., 2001), Kenya (Bousema et al., 
2004), Senegal (Males et al., 2008, le Port A, 2008), Gabon (Klein Klouwenberg et al., 
2005, Nkoghe et al., 2011) and intermediate transmission areas India, Burma (Richards 
et al., 2007), Thailand (Coleman et al., 2002) also reported the presence of 
asymptomatic carriers in the population. It has been observed that when assessed by 
Pfs25 QT-NASBA, gametocyte prevalence amongst parasite carriers may be as high as 
90% (Bousema et al., 2006). Similarly, studies previously published comparing PCR and 
microscopv for P. Jalciparumhave shown the high sensitivity of PCR as compared to 
microscopy (Okell et al., 2009, Okell et al., 2012). 
All these studies mentioned above have shown that microscopy and ROT can miss 
considerable number of individuals with low-density parasitaemia and is considered as 
a great challenge for malaria control and elimination programmes. Because individuals 
with submicroscopic infections can act as carriers of malaria transmission through 
gametocytes thus can hinder with elimination and control strategies (Shekalaghe et al., 
2007, Sutherland et al., 2007, Roper et al., 1996). Schneider et al. have also suggested 
that submicroscopic infections of malaria can contribute in a similar way as 
microscopic gametocytes do (Schneider et al., 2007). Therefore, survey on the 
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prevalence of asymptomatic individuals in diverse malaria settings has been suggested 
for the successful elimination and final eradication of malaria, is recommended. 
8.2. Malaria exposure using ani malarial an body responses 
In chapter 4 serological markers were used to assess malaria exposure and to examine 
heterogeneity in malaria transmission in the five Afghan refugee camps. Several 
studies used serological data to assess changes in transmission intensity (Stewart et al., 
2009). As previously serological markers were used to detect heterogeneity in malaria 
transmission in low endemic district of Somalia (where non of the slide microscopy or 
ROT showed parasite carriage in the population) (Bousema et al., 2010c). 
Antibody responses against P. vivaxand P. falciparum were seen in 28% and 6% of 
respectively the total examined individuals. Overall seroprevalence of antibody against 
P. falciparum antigens was low with no ROT positive and with extremely low overall 
PCR prevalence (0.4%). Possible explanation for the detection of a very low 
seroprevalence of P. falciparumamong examined subjects may be the extensive use of 
malaria control interventions in the camps since late 1990s after epidemics observed 
in the refugee camps (Rowland et al., 2002 b). 
Statistically significant (p<0.05) seroprevalence (to both P. falciparum andP. vivax) 
differences were observed among the camps, which is evidence of heterogeneity in 
malaria exposure among the camps. Seroprevalence of P. vivax increased with age, 
which suggested exposure-driven age acquisition of antibody response. SCR estimates 
also demonstrate that there is significant heterogeneity in transmission across the 
study site and the current upper 95% confidence limit (upper estimates of 
transmission) for P. vivax ranges from 0.02-0.07 and for P. falciparum ranges from 
0.001-0.01. These results suggest that, despite of reduction in malaria transmission in 
the studied camps in the past two decades (Rowland et al., 2002 b) the impact of 
malaria control is uneven, demonstrated by differences in the current force of 
infection of the camps. 
This is the first study to determine asymptomatic infections and exposure to malaria in 
five Afghan refugee camps in KP, Pakistan. There is no available data for prevalence of 
asymptomatic infections and exposure to malaria from this area with comparable 
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epidemiology. Since this is the first sero-prevalence survey in the study area using 
recombinant MSP-119 and AMA-1, therefore direct comparison to previous studies is 
not possible. 
Although seroprevalence is a cumulative measure of exposure over time and less 
prone to brief fluctuations in transmission, therefore the differences in the 
seroprevalence among the camps described here may indeed replicate a relatively 
stable pattern of malaria transmission. As in the study area malaria transmission is 
highly seasonal and serology will be valuable tool to assess transmission, as it is less 
dependent on the timing of the survey than direct assessment of parasite burden by 
PCR or microscopy that can only provide a snapshot of transmission. 
Cross reactivity between immune responses to malaria and other parasites have been 
reported previously (Abramo et al., 1995, Naus et al., 2oo3) but these were suggested 
less pronounced when recombinant proteins were used instead of whole parasite 
extract. An alternative approach to reduce the likelihood of cross-reactive antibody 
responses speculated was to use sera at a minimum dilution of 1:80 (Abramo et al., 
1995). Serum dilution used (to test the samples) for this study was 1:1000 samples 
(considerably higher dilutions) and no relation in antibody titers between the 
homologous antigens of P. /alciparum andP. vivax observed (detailed in chapter 4). 
Furthermore, to calculate cutoff value to decide seropositivity, seronegative 
population was derived from within the same samples, in order to elimination false-
positive results and to reliably detect low-level local malaria transmission. 
Moreover, seropositivty to malarial antigens may not necessarily represent recent 
exposure in the study area (Corran et al., 2007, Warren et al., 1976), due to longevity 
of antibody responses. For example in adults, previous exposure to parasites in life or 
travel to malaria-endemic areas in the past can make immune responses doubtful 
resulting from recent local transmission (Warren et al., 1975). Once acquired, antibody 
responses against MSP-119 and AMA-1 are suggested to persist for several years 
(Drakeley et al., 2oo5). For this seroprevalence in younger age groups was used to 
investigate current malaria transmission. Low seroprevalence against P. /alciparm are 
also in line with the drop in falciparum' parasite prevalence and a reduction in P. 
falciparum prevalence reported by BHU. 
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SCR estimates were examined for associations with prevalence of infection measured 
by PCR and ROT on camp level. These results show a good association between SCR 
and prevalence of infection by both ROT and PCR. These data is in line with the results 
from a study, where an association was also found between SCR and parasite rates 
(Cook, 2010). SCR rates were also related to EIR, to estimate P. /alciparum transmission 
intensity and good correlation was between the two mentioned measures (Corran et 
al., 2007, Bousema et al., 2010c). 
8.3. Risk factors of malaria in study area 
Results of chapter 5 aimed to provide information on the potential risk factors involved 
in exposure and infection of malaria in the study area. It is expected that these results 
will prove useful in assessing potential malaria risk factors and improve the malaria 
control programs targeting of interventions. 
In these surveys I found that all age groups were exposed to P. vivax infections 
evidenced by antibody responses, but a high proportion of parasite positive individuals 
were observed amongst the young (1-5) and middle age (6-20) groups, which was in 
line with the situation of malaria in a low endemic areas in India (Ramachandran, 
2010). 
Serological data for both P. vivax and P. /alciparum showed age-dependency in 
antibody responses; an expected result of the acquisition of antibody response with 
increasing age due to repeated exposure (Corran et al., 2007, Bousema et al., 2010c, 
Cook, 2010). Where in similar low endemic area in Somaliland malarial antibody 
responses has been reported high in older age groups, which build up with repeated 
exposure during childhood. 
Travelling history was used to investigate whether movement of local resident to other 
endemic areas was a risk factor of malaria in the camps. Staying in the camp of 
resident from the last six months prior to survey was associated with lower risk of both 
P. vivax (ROT/PCR) and P. /alciparum (antibody responces). Number of other studies 
also suggested the movement of local resident to other neighboring endemic areas is 
an important risk factor of malaria in low transmission settings {Oanis-Lozano et al., 
2007, Osorio et al., 2004, Sornmani et al., 1983, Fungladda et al., 1987, Ramachandran, 
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2010, Moore et al., 2004). 
There is evidence according to the study that the people who had fever within 24 
hours and within two weeks were being parasite positive (P. vivax) detected by both 
ROT and PCR as compared to one that had no fever. It validates that parasite positive 
individuals have fever because fever is one of the symptoms of malaria. 
Low SES was associated with high prevalence of P. vivax infection (PCR). There are a 
number of studies which support the evidence of lower socio-economic factors related 
to high malaria risk (Thang et al., 2008, Cook, 2010, Feachem et al., 2010, Arasu, 1992, 
Oemijati, 1992, Butraporn et al., 1986, Oev et al., 2004, Gamage-Mendis et al., 1991, 
Ayele et al., 2012). A study conducted in Amhara, Oromiya and Southern Nation 
Nationalities and People (SNNP) regions of Ethiopia also reported open eaves and SES 
as a significant risk factor of malaria (Ayele et al., 2012). Possible explanation for low 
SES as a risk factor for the prevalence of P. vivax infection is living in a house which are 
more likely to increase contact with the mosquitoes on the contrary households in 
high SES a bracket (a cement floor, iron roof, houses constructed of bricks) to limit 
contact with mosquitoes. Moreover individuals with low SES may be less likely to use 
antimalarial control measures (to reduce favored access of the mosquito vector to 
man) due to costs. These results shows thatched roof and non glazed windows non 
significant which were commonly found significant risk factor in previous studies 
(Ayele et al., 2012). 
To examine that cattle might protect occupants against malaria through 
zooprophylaxis P. vivax sero-prevalence was associated with the animals sleeping in 
the" same house as the study participants. Increased seroprevalence against P. vivax in 
the residents of a household was observed who were sleeping in the same courtyard 
with the cattle. This is in line with previous studies conducted in Afghan refugees 
(Bouma and Rowland, 1995) and Ethiopia (Oeressa et al., 2007, Graves et al., 2009) had 
also shown that sharing of house with livestock increased the risk of malaria 
prevalence. Simple explanation for observing high P. vivax seroprevalence among 
residents of households sleeping with animals in the same place is the increased 
amount of CO2 and cattle odours that attracts malaria vectors. 
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Sleeping under ITN previous night before the survey was associated with lower risk of 
vivax malaria infection (ROT/peR). Although the single night usage of ITN before the 
survey is unlikely to accurately capture the ITN usage over a longer period, but still it 
may represent the behavior of people towards use of ITN. A household randomized 
trial of ITN in Afghan refugee camps in KP, Pakistan had reported protection against 
malaria(Rowland et al., 1996, Rowland et al., 1997b) and top sheets, blankets and 
Islamic head-body veils treated with permethrine, were considered as a protection 
against both P./alciparum and P.vivax(Rowland, 1999b). Similarly, a study in Ethiopia 
also reported lower malaria Prevalence in mosquito nets users compared to non users 
(Ayele et al., 2012). 
Insecticide residual spraying was associated with reduces malaria infection and 
exposure but these show no significant association. Possible reasons for IRS being non-
significant in this study may be that the spraying was done by a household head that 
were not a trained spraymen and without supervision. As such they maybe not careful 
about the choice and quality of insecticide certain vector species are resistant to DOT 
and organophpsphate insecticideor the proper time of IRS which may maximize the 
effect (Rowland and Nosten, 2001). It may also be due to the fact that at such low 
coverage no effect on the prevalence of infection and exposure was likely to be 
observed. This study collected information only about IRS within last 12 months in the 
household and did not deal with efficacy of it. Therefore this study cannot be directly 
compared with other studies in these refugee camps in the last decade based on 
different study design. However, IRS was found significant in previous studies 
conducted by Rowland et al (Bouma et al., 1995, Rowland et al., 1997a) showed 
protective efficacy against both P./alciparum and P.vivax in the Afghan refugee camps. 
Spraying tents with permethrin was found to lower the risk of P./alciparum malaria 
nomadic Afghan refugees (Bouma et al., 1996). 
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8.4. Hot spots of malaria exposure and infec on within the 
camps 
Heterogeniety in malaria has long been observed between the villages or areas where 
a small group of people is most heavily or frequently infected as compared to majority 
of locals with no or very few infections majorty (Snow et al., 1988, Greenwood et al., 
1987). Such variation in a disease risk within a genetically homogeneous (individuals) 
area may be due to difference in exposure to malaria-infected mosquitoes (Bousema 
et al., 2010a). To identify such hot spots (geographically distinct unit where infection 
and disease are concentrated in a small proportion of individuals) of malaria 
transmission in an area and the risk factors associated with these hot spots will be 
useful for an area which is close to attaining malaria elimination and where malaria 
transmission is likely to be sustained in and by a few focal points. In such areas 
transmission can be reduced effectively by targeting such hot spots with carefully 
planned interventions (Bousema et al., 2012). 
An examination of the spatial variation in malaria infection and exposure in the five 
Afghan refugee camps is described in chapter 6. Heterogeneity in infection and 
seroreactivity for both P. !alciparum andP. vivax was observed within the camps. Four 
of the camps out of five (except for camp 4 which is situated besides rice fields) are 
located near to water bodies (rivers, streams and canals). Hotspot of antibody 
prevalences to P. vivaxin all age groups in camp1 comprised of households located 
very close to water logged rice fields, and away from the BHU. As previous studies had 
also mentioned that distance to water body is associated to malaria incidence and 
immune responses (Wilson et al., 2007, Creasey et al., 2004, Clark et al., 2008, 
Oesterholt et al., 2006, Staedke et al., 2003, Kreuels et al., 2008). 
However Bousma et al. found no association of malaria incidence and distance to the 
near water body (Bousema et al., 2010a). As proximity to the mosquito breeding sites 
is not the only predictor of malaria risk, due to variation in the breeding sites 
productivity and longevity (Fillinger et al., 2009), moreover detectable water bodies 
may be misleading, as mosqutioe-breeding sites can be quite small (Greenwood, 1989, 
Clark et al., 2008, Oesterholt et al., 2006, Kreuels et al., 2008, Gamage-Mendis et al., 
1991). Other factors which were identified as indicators of living in a hotspot of malaria 
235 
transmission included less bed net coverage (Clark et al., 2008), walling material (mud 
and palm walls) (Somi et al., 2007), and the vicinity of alternative hosts (cattle) (Bouma 
and Rowland, 1995), which are considered as a key factors in determining the risk of 
malaria at individuals level. 
Hotspots are likely to persist as a source of residual malaria transmission, if not 
targeted (Bautista et al., 2006, Ernst et al., 2006, Gaudart et al., 2006) and are most 
likely to play a catalysing role in areas of stable transmission and can make a problem 
in malaria eliminateion efforts (Moonen et al., 2010). Therefore interventions targeted 
at transmission hotspots are relevant and important for malaria control (Moonen et 
al., 2010, Wool house et al., 1997, Smith et al., 2007, Bousema et al., 2012). It has been 
observed that targeting hots pots with long-lasting insecticide-treated nets (lllNs) and 
indoor residual spraying (IRS) could lead to malaria elimination (Bousema et al., 2012). 
8.5. Prevalence and molecular characteriza on of G6PD 
Plasmodium vivax is the dominant species in the study area(Rowland et al., 1994, 
Rowland, 1999a, Rowland and Nosten, 2001), which is the most stable due to its ability 
of formation of hypnozoites in the liver. The hypnozoites act as a reservoir and help to 
continue P. vivax transmission cycle. Therefore the control of P. vivax has been 
suggested difficult as compared to P. !alciparum due to formation of latent liver 
stages. The radical cure for latent stage vivax malaria is primaquine but the high 
prevalence of G6PD deficiency among the studied population as compared to other 
Pakistani population and the lack of G6PD testing facilities(Bouma, 1995, AIi et al., 
2005) prevents its use. (Bouma, 1995). As the X-linked G6PD disorder causes hemolysis 
in hemizygotes and homozygotes on administration of primaquine. 
The prevalence of G6PD deficiency in Afghans has been observed in several studies 
ranging from 2 to 10%, which had focused only on the testing for G6PD deficiency 
before administering anti-malarials (e.g. primaquin) in Afghanis. For an immediate 
reduction of vivax malaria morbidity and to drop its transmission levels it is essential to 
make G6PD testing readily available. So the present study aimed to measure the 
prevalence and to evaluate the molecular characterization of G6PD deficiency. 
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Initially three mutations [{1003A-G/335 Ala-7Thr, Class Ill), (563C-T/188 Ser-7Phe, 
Class 11) and (1311 C-G /44 Ala-7Gly, Class Ill)) were selected for the study but due to 
time and financial constraints, only G6PO 563C-T variant was studied. Because G6PO-
Med (belong to the class 11) was suggested the most likely type prevalent in Pathans, 
due to origination of Pathans from the Mediterranean basin (Bouma et al., 1995, 
Oupree, 1973). 
505 subjects from camp 3 of Afghan refugees were analyzed for 563C-T polymorphism 
of G6PO gene. 563 C-T mutation was observed in only 2 unrelated individuals with 
0.4% prevalence (one was male of age 5 and one female of age 4). Saha et al. and Moiz 
et ale also described prevalence of G6PO 563C-T (G6PO Mediterranean) in Afghans 
(Saha et al., 1994, Moiz et al., 2009, Moiz et al., 2011). 
The frequency of G6PO deficiency previously noted in Afghani is ranging from 2% 
(Bouma, 1995) to 10% (Srooker et al., 2006). Living in an area where P. vivax was 
prevalent for millennia, intermarriage, Pashthuns are thought to be the descendants of 
European soldiers who accompanied Alexander the Great (Firasat et al., 2007) and are 
also considered to be the lost tribe of Jews (Papiha SS, 1999) (who have high 
prevalence of G6PO deficiency) (Moiz et al., 2009), were given as the possible reasons 
of their higher prevalence of G6PO deficiency as compared to other races in the region. 
8.6. Conclusion 
To detect small-scale differences in transmission intensity serologic markers could be 
valuable at levels of malaria transmission that are too low for detection by microscopy, 
ROT, or entomologic tools. This will be helpful for evaluating malaria control programs 
in low malaria endemic areas. A correlation was observed by this study between 
serological markers of exposure to malaria and malaria infection prevalence measured 
by ROT and peR, which suggest that serological markers of exposure could guide, 
targeted malaria control efforts. Both parasitological and serological measures were 
able to detect spatial variation in infection and exposure to malaria at the micro 
epidemiological level within the camp, which will be useful for spatial targeting of 
malaria control efforts. Therefore for more robust interpretation of serological data 
from low transmission areas (where parasite prevalence indicators are less sensitive), 
congruence between parasitological and serological measures of exposure is needed 
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(Satoguina et al., 2009). Despite of the low sensitivity as compared to peR, microscopy 
should remain a routine diagnostic tool for malaria due to its high specificity as 
previously observed (Musalika, 2010) and cost and time effectiveness. However for 
malaria epidemiological studies in this low endemic area a more sensitive diagnostic 
tool such peR is recommended. 
In summary, the data presented here suggest that efficient and continued surveillance 
is needed to sufficiently capture the current situation on a population level, to reliably 
assess submicroscopic levels of parasitaemia, and to provide information on 
transmission variation over time. Malaria indicators surveys to measure the prevalence 
and burden of the disease should be initially population and health facility-based, then 
narrow down to foci and ultimately to individual cases as malaria control programme 
gradually shift to elimination programme, as recommended by WHO(WHO., 2007b). 
The absence of P. /alciparum infection prevalence detected by ROT, very few 
asymptomatic carriers detected by peR and extremely low seroprevalence to both P. 
/alciparum antigensamong examined individuals support the observations of the 
limited recent P. /alciparum transmission in the study area. The data suggest that in 
these studied refugee camps there is the potential to eliminate falciparum malaria. 
Malaria control effectiveness may be improved by identifying foci of ongoing 
transmission, which can be targeted for more frequent and intensive care. Hot spots of 
malaria were detected in four of the camps. This survey did not collect information 
about mosquitoes breeding sites, which may be one of the reasons of these 
households to be in the hot spot. Therefore it will be useful for control programmes to 
check for potential mosquitoes breeding sites and might apply vector control measures 
to target outdoor biting vectors for example larviciding of mosquito breeding sites and 
adult vector (Fillinger et al., 2008). Scaling up conventional vector control tools such as 
LlINs and IRS may be useful for controlling malaria in these hots pots (Reddy et al., 
2011, Russell et al., 2011) and to treat everyone 3 or 4 times a year individuals living in 
the hot spots observed by this study. Moreover malaria exposure and infection was 
associated with poor housing condition, travelling outside of the camp and behavior of 
ITN use. Therefore it may be useful to improve the housing condition, to create malaria 
awareness about the risks involved with increase in malaria burden and to screen 
individuals before leaving or entering in to the hot spot. 
238 
MI5 or other community based survey should be conducted (to see the actual burden 
and transmission) in other parts of Pakistan especially Baluchistan province and tribal 
areas of KP, where malaria prevalence has been reported high previously as compared 
to other provinces or areas of Pakistan. Because this high reported prevalence of 
malaria is based on hospital records or passive case detection which may be unreliable 
(discussed in detail in the Introduction chapter) and the data is also outdated. The 
study area (KP), which has the high illiteracy rate as compared to other provinces 
(especially Punjab and 5indh) of the country, therefore by awareness about protection 
from malaria, health seeking behavior, prompt diagnosis and treatment can lead to 
significantly improvement in malaria control and ultimately elimination. 
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Appendix 1 Ques onnaire and Consent form administered in the studied Afghan 
refugee camps 
Title: Assessment of exposure, infec on and risk for malaria in refugee camps in 
Khyber Pakhtun Khawa (KP), Pakistan 
PI: Sobia Wahid 
1.1 District: (l=Mardan, 2=Peshawar, 3=Malakand) 
1.2 Camp name? l=Adezai 2=Baghicha 3=Kagan 
4=Jalala 5=Za 
1.3 No. of households in the compound? 
1.4 Household ID 
1.5 Who is the respondent? l=Household head, 
resentative 
1.6 Does the respondent agree? 
1=Yes,2=No 
1.7 Family size ( 
No. of le in each rou: 0-5 
1.8 What is the highest level of education completed by 
Household head? 
l=None 
3=Seconda 
2=Primary 
4=H heir 
1.81 Is there anyone who owns?houshold asset 
ownership? 
1.85 Bicycle 
0= no 1= 
1.9 Mobile 
1.10 Is the house connected to electricity? 
0= no 1= 
1.11 What is the main type of fuel used by your family 
for cooking? 
l=Electicity/gas 2=charcoal 
3=kerosene4=dung 
5=Wood 6=other 
1.12 Are there ducks or chickens? 
0= no 1= s 
1.13 Do have animals in this household like 
Date: / /2010 
district I_I 
Cname I_I 
No.hh I_I 
hhid _11_1_1 
whoresp I_I 
respagreel_1 
I_I 
electricl_1 
fuell_1 
otfuel 
1_1_1_1 
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sheep or cattle-how many? 
0= no 1= 
1.14 What type of wall was used for the construction of 
this house? 
I_I 
housecons 
l=clay/mud 2=bricks/stones 
3=cem inted 4=other 
1.15 What kind of toilet facilities does your household 
have? 
I_I 
toilet 
1 = Flush toilet 
2 = Pit toilet/latrine 3 = No 
facil d 
1.16 What is the main material of the roof? 
1= Iron sheets or tiles 
roofl_I 
otroof 
2= Thatch/grass or leaves 3= Other 
1.17 What is the main material of the floor? 
l=eath/sand 2=cement 
3= d 5=other 
1.18 How many windows are glazed? 
0= no 1= 
1.19 Are the eaves open or closed? 
O=open l=cIosed 
-"'" 
0= no 1= yes 
2.4 Were these nets hanging last night? 
0= no 1=yes 
2.8 Is the net observed? 
0= no 1= yes 
2.9 In the past 12 months, has anyone sprayed the 
interior walls hhold? 
0= no 1= 
2.1 Who sprayed the house? 
1 
2.1 Have any of these been used in your house over 
2 the last week? 
roofl_I 
otfloor 
windglazel_1 
eavesl_1 
ITN hanging I 
netseenl_1 
1=Govt.prog,2=NGO,3=hh 
oldmember, 
4=other(explain) 99=don't 
know 
l=Mosquito coils 
2=lnsecticide spray 
3=Repe"ents 
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3.l Has you lived here for at least last 6 months' 
live here? 
0= no 1= yes 
3.5 Did you stay here last night? 
0= no 1= yes 
3.~ Have you always lived in this district? 
0= no 1= yes 
3.~ If NO, which other district have did you live in 
most recently? 
3. Have you travelled outside this camp in the 
last 3 months? 
0= no 1= yes 
3.1 When did you come back from your most 
recent trip? 
1= <tow weeks 2= <four weeks 3= >4 weeks 
3. Have you been ill with a fever at any time in 
the last 2 weeks? 0= no 1= yes2=not sure 
3. Did you seek advice or treatment for the fever 
from any source? 0= no 1= yes 
3.~ Did you have a fever in the last 24 hours? 
0= no 1= yes 2=don't know 
3,2 Did you take any drugs in the last 2 weeks? 
0= no 1= yes 
3.4 Did you use an ITN last night? 
0= no 1= yes 
Malaria/Record the ROT result: 0= Nega vel= POSI 
GPS. Longitude L.I--1--1I--1--1--1--1--1--1 Latitude 1--1-' 1--1-'-'-'_1_1 
Informa on and Consent Form 
Title of Study: Assessment of exposure, infec on and risk for malaria in refugee 
camps In Khyber Pakhtun Khawa (KP), Pakistan 
Ins tu on: London School of Hygiene and Tropical Medicine 
Principle Inves gator: Sobia Wahid Tel No: 
Locallnves gator: Tel No: 
The London School of Hygiene and Tropical Medicine, and Peshawar University are 
doing a survey. The present study is designed to use seroprevalence to identify 
exposure and the risk factors to both P. !alciparum andP. vivax malaria in KP to guide 
researchers and decision-makers in targeting intervention efforts. Moreover, the study 
may provide insight into the nature and role of antimlarial immunity in the targeted 
population. Additionally by combining GIS data with infection and serological 
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responses we hope to map potential foci of infection to aid malaria control. 
Approximately 2500 people will be in the survey. 
If you agree to take part in the survey, we will ask you questions about your house. 
We will ask about what you do to prevent malaria, whether you or your child has had a 
recent fever and about your recent trips outside of the camps. We will also take a few 
drops of blood by pricking the finger or heel of three members of your family. We will 
take approximately 1/10 teaspoon (about Yz ml) of blood: The amount of blood we will 
take is very small and so no harm will come to anyone who agrees to be in the survey. 
We will test the blood sample for malaria. There may be a small bruise or temporary 
mild pain on the finger or heal where the blood is taken. There is also a small chance of 
infection when blood is drawn. However, our careful procedures make this very 
unlikely. The ROT is free of charge and after positive infection confirmation by ROT e 
will refer to basic health unit so they can be checked completely where treatment is 
free. 
You are free to choose for you and your child to be part of this survey. The facts we 
collect in the survey and the results of the lab tests will be kept private to the extent 
allowed by law. Your name and your child's name will not be used on any of the survey 
reports or survey samples. 
Today's survey: The consent form has been If you agree, circle "YES" 
explained to me and I agree to take part in the 
survey. I understand that I am free to choose for 
me and my child to be in this survey and that saying YES 
"NO" will have no effect on me or my child. 
Adult/mature 
minor/Parent/guardian Name: .................... Signature: ...•.•.... ~ateOO/OO/OO 
If unable to write, please indicate consent with fingerprint 
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Appendix 2 Prevalence of P. vivax infec on across the age group in each camp 
P. vivax Age group peR ROT 
Camp (years) Numbr Number Percent+ve Numer Number Percent+ve 
Tested +ve Tested +ve 
(N) (N) 
Adezal 1-5 47 5 10.6 169 1 0.6 
5-20 49 1 2.0 171 1 0.6 
>20 41 4 9.8 167 0 0.0 
Total 137 10 7.3 507 2 0.4 
Baghicha 1-5 45 4 8.9 169 5 3.0 
5-20 49 7 14.3 170 5 2.9 
>20 43 8 18.6 168 4 2.4 
Total 137 19 13.9 507 14 2.8 
Jalala 1-5 167 21 12.6 167 23 13.8 
5-20 170 41 24.1 170 23 13.5 
>20 168 17 10.1 168 3 1.8 
Total 505 79 15.6 505 49 9.7 
Kaghan 1-5 44 3 6.8 161 3 1.9 
5-20 44 2 4.6 168 3 1.8 
>20 42 4 9.5 167 4 2.4 
Total 130 9 6.9 496 10 2.0 
Zangal 1-5 46 7 15.2 169 6 3.6 
patal 5-20 51 10 19.6 168 10 6.0 
>20 45 6 13.3 170 5 2.9 
Total 142 23 16.2 507 21 4.1 
Combined 1,051 140 13.32 2,522 96 3.81 
data 
245 
Appendix 3Seroprevalence to P. /a/ciparuman gens across the age group in each 
camp 
camp Age pfAMA-1 pfMSP119 
group 
Numbr Number Percent+ve Numer Number Percent+ve 
(years) Tested +ve Tested +ve 
Adezal 1-5 167 4 2.3(0.5-5.1) 169 0 0 
5-20 168 3 2.3(0.7-5.3) 168 2 1.6(1.1-4.3) 
>20 166 6 4.6(1.0-8.3) 166 1 0.8(0.7-2.3) 
Total 501 13 3.0(1.2-4.8) 506 3 0.8(0.3-1.8) 
8aghicha 1-5 168 2 1.6(0.7-4.0) 167 0 0 
5-20 168 9 5.2(1.0-9.4) 168 0 0 
>20 168 35 20.7(14.4-27.1) 161 3 1.6(0.3-3.5) 
Total 504 46 9.0(6.3-11.7) 499 3 0.6(0.1-1.1) 
Jalala 1-5 167 6 2.5(0.4-4.7) 166 0 0 
5-20 170 5 2.3(0.2-4.5) 166 4 1.5(0.09-3) 
>20 168 8 4.3(1.2-7.5) 168 0 0 
Total 505 19 3.0(1.5-4.5) 504 4 0.5(0.03-1) 
Kaghan 1-5 161 1 0.4(0.4-1.4) 161 0 0 
5-20 168 1 1.5( 1.5-4.7) 164 4 1.8(0.1-3.7) 
>20 167 4 2.5(0.1-5.1) 165 2 1.9(0.8-4.7) 
Total 496 6 1.4(0.2-2.6) 496 6 1(0.05-2) 
Zangal 1-5 169 6 5.7(0.8- 10.6) 151 11 5.4(2.0-8.0) 
patal 5-20 168 6 5.4(0.4-10.5) 146 12 9.6(3.8-15) 
>20 170 9 5.3(1.7-8.9) 148 9 4.5(1.2-7.6) 
Total 507 21 5.5(2.1-8.8) 507 32 7(3.6-9.8) 
Combined 2513 105 4.3(3.3-5.3) 2518 48 2(1.0-2.2) 
data 
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Appendix 4 Seroprevalence to P. vivax an gens across the age group 
Camp Age PvAMA-l PvMSP-119 
group 
years N.tested N.+ve Percent +ve N.tested N.+ve %((1) 
Adezal 1-5 169 5 2.5(0.2-4.9) 169 1 0.4(0.4-1.2) 
5-20 170 18 10.4(4.7-16.2) 170 8 3.2(0.9-5.6) 
>20 162 55 38.2(29.9-46.6) 167 7 4.9(1.3-8.5) 
Total 501 78 15.7(12.1-19.3) 506 16 2.7(1.3-4.0) 
8aghicha 1-5 168 7 5.1(1.0-9.1) 167 12 9.4(3.9-14.8) 
5-20 168 28 17.6(10.6-24.6) 168 24 13(7.5-18.5) 
>20 168 111 64.0(56.5-71.6) 168 15 8.6(4.2-12.9) 
Total 504 146 28.3(24.5-32.1) 504 51 10(6.7-13.3) 
Jalala 1-5 167 35 17.4(11.4-23.4) 167 51 30(22.3-38.1) 
5-20 170 48 28.6(20.8-36.4) 169 50 27.5(19.8-35) 
>20 168 108 62.9(54.8-71.0) 168 41 24.5(17-31) 
Total 505 191 34.8(30.2-39.4) 505 142 27.6(22.4-32.8) 
Kaghan 1-5 161 11 6.7(2.5-11.0) 160 5 2.9(0.23-5.6) 
5-20 167 23 11.5(6.1-17.0) 168 12 6.6(2.6-9.9) 
>20 167 95 57.3(49.4-65.3) 167 12 6.4(2.6-9.9) 
Total 495 129 24.0(20.2-27.9) 496 29 5(3-7) 
Zangal 1-5 169 4 2.9(0.4-6.3) 169 20 9.1(4.9-13.3) 
patal 5-20 168 11 6.60(2.2-10.9) 167 23 13.2{7.3-19) 
>20 170 31 16.8(10.8-22.8) 170 20 11.4(6.2-16.5) 
Total 507 46 8.2(5.4-11.0) 506 63 11.3(8-14.5) 
Combined 2512 590 23.0(21.3-24.7) 2518 301 11.5(10.0-13.0) 
data 
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Appendix 6PfMSP-119 age speci c seroprevalence plots in each studied camp of KP A) 
campl 8) camp2 C) camp3 D) camp4 E) campS F) all camps combined data. 
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Appendix 7PvAMA-I age sped c seroprevalence plots in each studied camp of KP A) 
campI 8) camp2 C) camp3 D) camp4 E) campS F) all camps combined data. 
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Appendix 8PvMSP-119 age sped c seroprevalence plots in each studied camp of KP 
A) campl B) camp2 C) camp3 D) camp4 E) campS F) all camps combined data. 
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Appendix gP./alciparumAMA, MSP and combined an gens seroconversion rates for 
each camp 
PfAMA-l PfMSP-119 Combined 
Camp SCR Cls SCR Cls SCR Cls 
1 0.002 (0.0011-0.0034) 0.0004 (0.0001-0.0014) 0.0024 (0.0015-0.0040) 
2 0.0073 (0.0054-0.0098) 0.0004 (0.0001-0.0014) 0.0073 (0.0054-0.0098) 
3 0.0028 (0.0017 -0.0043) 0.0006 (0.0002-0.0015) 0.0034 (0.0022-0.0051) 
4 0.0009 (0.0004-0.0019) 0.0009 (0.0004-0.0019) 0.0017 (0.0010-0.0031) 
5 0.0031 (90.0020-.0048) 0.0053 (0.0037-0.0075) 0.0078 (0.0059-0.0104) 
All Camps 0.0031 (0.0026-0.0038) 0.0014 (0.0011-0.00190 0.0045 (0.0038-0.0052) 
Appendix 10 Seroconversion rates calculated for P. vivQxAMA, MSP and combined 
an gens for each camp 
PvAMA-l PvMSP-119 Combined 
Camp SCR Cls SCR Cls SCR Cls 
1 0.0140 (0.0111-0.0176) 0.0024 (0.0015-0.0040) 0.0161 (0.0129-0.0200) 
2 0.0308 (0.0258-0.0368) 0.0080 (0.0060-0.0106) 0.0362 (0.0305-0.0430) 
3 0.0429 (0.0365-0.0504) 0.0262 (0.0219-0.0314) 0.0627 (0.0537-0.0732) 
4 0.0256 (0.0212-0.0308) 0.0043 (0.0030-0.0063 ) 0.0293 (0.0245-0.0351) 
5 0.0073 (0.0054-0.0098) 0.0101 (0.0078-0.0130) 0.0168 (0.0136-0.0207) 
All Camps 0.0225 (0.0206-0.0245) 0.0096 (0.0085-0.0108) 0.0297 (0.0275-0.0322) 
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Appendix 11 Comparison of P. /alciparumprevalence (measured by ROT and PCR) and 
SCR 
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Appendix 12 Number and percentages of ROT posi yes and seroposi ve individuals 
against PvAMA-1 and PvMSP-119 
P. vivax PvMSP-119 PvAMA-l 
RDT -ye %(n) +ve %(n) -ye %(n) +ve %(n) 
-ye 89.6(2169) 10.4(251) 77(1860) 23(556) 
+ve 46.8(44) 53.9 (50) 64.6(62) 35.4(34) 
Appendix 13 Number and percentages of peR posi yes and seroposi ve individuals 
against PvAMA-l and PvMSP-119 
P. vivax PvMSP-119 PvAMA-1 
peR -ye %(n) +ve %(n) -ye %(n) +ve %(n) 
-ye 84.5 (770) 15.5(141) 71.7 (652) 28.3(257) 
+ve 60.1(83) 39.9(55) 67.9(95) 32.2(45) 
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Appendix l4Previous malaria data showing AVI and AFI trend in the studied camps 
recorded by BHUs of the studied camps from 2004-2005 
10 Annual falciparum incidence (AFI) 
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Appendix 15 Reagents used in Production of MSP119·GST using E.coli 
Reagents 
LB Broth 
Added 2Sg of LB Broth powder to 1 litre de ionised water, mixed, autoclaved, and 
stored at 4°C. 
LB Agar 
20g LB Agar powder was weighed transferred to a Sooml media bottle, which was filled 
up to SOOml mark with deionised water. The bottle was mixed well, autoclaved and 
stored at 4°C. 
Terrl c Broth (Sigma catalogue p.1S30) 
The following were weighed out and added to a 11 autoclavable bottle: 
Tryptone 12g 
Yeast extract 24g 
K2HP04 9.4g 
KH2P04 2.2 g 
Suspended in 992 miDI water and added 8 ml glycerol, mixed and autoclaved. 
Ampicillin 
2.50 g Ampicillin sodium was dissolved in deionised water (25 ml) to give a 100 mg/ml 
solution. Sterile filtered through a 0.22 Il filter and dispensed as 1 ml aliquots. Frozen 
at -200 e. 
IPTG 100 mM 
238 mg IPTG was dissolved in 10 ml deionised water. Sterile filtered through 0.22 Il 
filter and dispensed as 1 ml aliquots. Frozen at -20°C. 
Trlton X-lOO 20% (v/v) 
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In a 50 ml conical-bottomed centrifuge tube 10 ml Triton X-lOO was added to 40 ml 
water and mixed on roller mixer. 
Glutathione Elu on Bu er 
10 mM reduced glutathione in 50 mM Tris-HCI (pH 8.0), was dispensed in 1-10 ml 
aliquots and stored at -20°C until needed. 
LB-Amp plates 
An aliquot of ampicillin from the freezer was removed and set out the appropriate 
number of Petri dishes. A 500 ml of LB-Agar was melted and allowed to cool until 
hand-hot. 0.25 ml of 100mg/ml ampiCillin were added and mixed well. The plates were 
quickly poured,removing and replacing the dish lids so as to give the minimum chance 
of contamination. The plates were allowed to cool completely and when set were 
inverted, labeled and stored at 4°C. 
LB-Amp medium 
A tube of ampicillin (100 mg/ml) was thawed and 0.5 ml ampicillin was added 
aseptically to a 1 litre bottle of LB Broth,before mixing well by swirling. 
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Appendix l6Reagents and prepara on of bu ers for EUSA 
Reagents 
a) Controls (standard dilutions): Pooled positive serum from high transmission 
area in Tanzania 
b) SigmaFast OPO tablets (Sigma) 
c) Tween 20 (Sigma) 
d) Skimmed mifk powder 
e) Horseradish peroxidase-conjugated rabbit anti-human IgG (Oako #P0214) 
f) NaH2P04 (Sodium dihydrogen orthophosphate) VWR Internationalltd 
g) Na2HP04 (di-sodium hydrogen orthophosphate) VWR Internationalltd 
hI NaCI (Sodium chloride) Fisher scientific 
i) H2S04 (Sulphuric acid) BOH 
Bu er solu ons prepara on 
a) Phosphate buffered saline (PBS) x10 pH 7.2 
S.7g NaH2P04 
16.7g Na2HP04 
8Sg NaCI in 11itre distiffed water at pH of 7.2 
Stored at room temperature and disposed of after one month. 
b) Coating buffer pH 9.4-9.6 
1.S9g Na2C03 and 2.93g NaHC03 was dissolve in 1fite distiffed water at pH 9.5 and 
stored at 4°C, disposed of after one month. 
c) OPO substrate solution. A pair of Sigmafast OPO Buffer tablet was dissolved in 20ml 
distilled water and was used immediately and remaining solution was disposed of after 
use. 
d) PBS/Tween wash solution (PBST) 
SOOml 10x PBS was dilutedwith 4.Sfitre distilled H20, 2.SmlTween (0.05% Tween in 
PBS) was added and the unused solution was disposed of at the end of each day. 
e) Blocking solution (1% skimmed milk powder in PBST) 
109 of skimmed mifk powder was mixed with 11itre PBST at ambient temperature 
f) 2M H2S04 
107 ml conc. H2S04 was slowly added to BOOml distilled water. 
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Appendix 17Computer-randomized list used for the selec on of a household from a 
compound comprised of more than one households 
Random numbers Household head's Name 
815 
238 
16 
458 
394 
437 
728 
576 
242 
780 
The names were recorded as given below and was wri en in the order they were 
given. 
Random numbers Name 
815 Afzal 
238 Ahmad 
16 Bilal 
458 Jaweed 
378 Amir 
437 
728 
576 
242 
780 
Next, household head with the lowest number were selected. If they refused, the 
next lowest number was selected. 
Random numbers Name 
815 Afzal 
238 Ahmad 
16 BUal 
458 Jaweed 
394 Amir 
437 
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Appendix 18Computer-randomized list used for the se lee on of studied samples 
<5 years 6-20 years >20 years 
Random Name Random Name Random Name 
815 573 474 
238 21 343 
16 263 835 
458 4 72 
394 117 111 
437 81 795 
728 766 940 
576 903 763 
242 965 25 
780 935 241 
The head of the selected household was asked to give all the ( rst) names of the children 
under or equal to 5 years, then all the names of those 6-20 years and then all the names of 
those above 20 years. The names were recorded as given below and was wri en in the order 
they were given by the head of the family. 
<5 years 6-20 >20 
years years 
Rand+om Name Random Name Random Name 
815 AfshQ.-Io 573 uUQ 474 OS~.-Io 
238 'StLow.y 21 FQti.~ 343 PArwu.-lo 
16 'BoU.AL 263 At(. 835 FQ~ 
458 ~QWUc( 4 M&.tYQ 72 
378 A~Y 117 111 
437 81 795 
728 766 940 
576 903 763 
242 965 25 
780 935 241 
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Next, individuals with the lowest number were selected. If they refused, the next 
lowest number was selected. 
<5 years 6-20 >20 
years years 
Random Name Random Name Random Name 
A{snClII\. wUa OSVlA.QII\. 
815 573 474 
Uu,l.{r FClHVIA.Q PClI'WU1I\. 
238 21 343 
16 'SUal 263 ALL 835 FClt{.1'\.I..a 
JClwu,d MItYCI 
458 4 72 
AmLr 
394 117 111 
437 81 795 
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Appendix 19Peshawar university ethics commi ee approval 
Ref 
DEPARTMENT OF PHARMACY 
University of Peshawar, N W.F.P, Pakistan 
Date .2& _ as"_ .,,10 
E THICA L A PPROVAL FORM 
Applica tion number 0" ECIPharm 
Dale 20.05.20 10 
~amc or Principallnvcsligator Ms. obia Wahid 
Depllrtment Inlectious and Tropical Disca~cs. London ,)~ho" l llf 
Hygiene lmd Tropicall\lt'dicine. Keppcl Su·,·.:t. London 
WCIE7HT,UK 
lIead of the Dcpu r tmcnt Prof. Dr. Simon Croft 
~:llnc of 'upen isol' Or. Chris Drnkeley ( 'r. Lecturer) 
!'lame ofCo-in-e tiga tor Prof. Dr. Akram hah 
ritle: 
Department Of Zoology. {Ini\ersit) of Pt',h:!\\ ar 
., ssessmcnt orE posure & Risk ~a tors for I\lalana In 
Afghan Refugees WFP '(KPK) PakisliUl". 
I hi ~pphcat ion" approved by the committee 
Prol. Dr. lazal Subhall ((onwner) 
Prof. Dr lafar Iqb.ll ( !kmber) 
I'ro t' Dr laho<.1r Ahmad S\\uti 
ProI'. Dr. ,\krnm Shah 
Dr luhmnnl.\d I muil 
Dr aeed-ur-Ralunan (Member) I 
!ember) ~ IJr luham ll1ad Sae.:d eCrelar) ) 
Peshawar. 25120 Pakistan, Tel: +92-91·9216750. Fax: +92-91-9218131 
PBX. +92·91-9216701-20 Ext: (3051) E_mall·pharrnacy@upesh.edu.pk 
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Appendix 20London School of Hygiene and Tropical Medicine ethics commi ee 
approval 
LONDON SCHOOL OF HYGIENE 
& TROPICAL MEDICINE 
ETHICS COMMITTEE 
APPROVAL FORM 
ApplicOItion number: 5715 
Name of Pnncipal Investigator Sobi3 WOIhid 
Department Infectious OInd TropiCOlI Dise3ses 
Head of Department Professor Simon Croft 
TItle: Assessment of exposure OInd risk for mOll3ri3 in Afgh3n refugee 
COImps In North West Frontier Province (NWFP). P3kiSt3n. 
This application IS approved by the Committee. 
Ch;]lr of the Ethics Committee .. ... . 
DOIte .... ................................. .... ... .... . 24 June 2010 .... .... ....... . ... ... .... ... ..... .. . 
Approvill ls dependent on IOC31 ethlcOII 3pprovOII h3ving been received. 
Any SUbsequent ch.lnges to the ilpplicOItion must be submitted to the Committee 
Vl3 3n E2 ;]mendment form. 
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